0001116463-26-000016 | 10-K | XBRL Viewer

Print Document

Income Taxes - Income Taxes Paid (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2025	Dec. 31, 2024	Dec. 31, 2023
Income Tax Contingency [Line Items]
Federal	$ 0
State	(26)
Foreign	1,867
Cash paid for income taxes	1,841	$ 1,800
Proceeds from income tax refunds			$ 4,900
Utah
Income Tax Contingency [Line Items]
State	(100)
Other
Income Tax Contingency [Line Items]
State	74
Canada
Income Tax Contingency [Line Items]
Foreign	2,539
United Kingdom
Income Tax Contingency [Line Items]
Foreign	$ (672)

Summary of Significant Accounting Policies - Summary of Total Net Revenues by Product Line (Detail) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2025	Dec. 31, 2024	Dec. 31, 2023
Disaggregation Of Revenue [Line Items]
Net revenues	$ 115,021	$ 185,827	$ 405,472
Product and Services Revenues
Disaggregation Of Revenue [Line Items]
Net revenues	109,055	184,611	402,222
Product and Services Revenues \| HIV
Disaggregation Of Revenue [Line Items]
Net revenues	49,802	60,804	60,823
Product and Services Revenues \| Sample Management Solutions
Disaggregation Of Revenue [Line Items]
Net revenues	38,356	51,046	54,274
Product and Services Revenues \| COVID-19
Disaggregation Of Revenue [Line Items]
Net revenues	13,759	14,024	12,871
Product and Services Revenues \| HCV
Disaggregation Of Revenue [Line Items]
Net revenues	4,648	3,506	2,265
Product and Services Revenues \| Risk Assessment Testing
Disaggregation Of Revenue [Line Items]
Net revenues	1,866	8,354	9,736
Product and Services Revenues \| Other Product And Services Revenues
Disaggregation Of Revenue [Line Items]
Net revenues	624	45,172	257,779
Product and Services Revenues \| Molecular Services
Disaggregation Of Revenue [Line Items]
Net revenues	0	1,705	4,474
Other
Disaggregation Of Revenue [Line Items]
Net revenues	115,021	185,827	405,472
Other \| Non-product and services revenues
Disaggregation Of Revenue [Line Items]
Net revenues	$ 5,966	$ 1,216	$ 3,250

The Company	12 Months Ended
The Company	Dec. 31, 2025
Organization, Consolidation and Presentation of Financial Statements [Abstract]
The Company	THE COMPANY: OraSure Technologies transforms health through actionable insight and decentralizes diagnostics to connect people to healthcare wherever they are. In February 2023, the Company announced a corporate restructuring to combine the commercial and innovation teams across two segments, being the “Diagnostics” segment and the “Molecular Solutions” segment, into one business unit with sales, marketing, product development, and research teams covering multiple product lines. This change is intended to accelerate innovation, enhance customer experience and result in operational synergies. As a result, all products and services reside under one reporting hierarchy. The Company's product portfolio is broadly divided into diagnostics products and sample management solutions. The Company's business consists of the development, manufacture, marketing and sale of simple, easy to use specimen collection devices and diagnostic products designed to detect certain infectious diseases including HIV, Hepatitis C, Syphilis and Sickle Cell that are performed on a rapid basis at the point of care. The Company's business also includes sample management solutions and molecular services that are used by clinical laboratories, direct-to-consumer laboratories, researchers, pharmaceutical companies, and animal health service and product providers. During 2024, the Company exited the molecular services business. In October 2024, the Company announced the discontinuance of the sales of its risk assessment product line which was completed in the first half of 2025.

Consolidated Statements of Cash Flows - USD ($) $ in Thousands	12 Months Ended			21 Months Ended
	Dec. 31, 2025	Dec. 31, 2024	Dec. 31, 2023	Sep. 30, 2025
OPERATING ACTIVITIES:
Net (loss) income	$ (68,731)	$ (19,500)	$ 53,655
Adjustments to reconcile net (loss) income to net cash (used in) provided by operating activities
Stock-based compensation	10,147	11,920	10,729
Depreciation and amortization	10,192	10,872	20,936
Loss on impairments	0	4,392	10,829
Other non-cash amortization	(222)	(564)	3
Provision for credit losses	(65)	71	(462)
Unrealized foreign currency loss (gain)	365	(263)	103
Interest expense on finance leases	8	22	51
Loss on equity investment	2,344	1,700	0
Deferred income taxes	1,853	(657)	102
(Gain) loss on sale of fixed assets	(725)	563	0
Change in the estimated fair value of acquisition-related contingent consideration	4,570	0	(99)
Payment of acquisition-related contingent consideration	0	0	(19)
Changes in assets and liabilities:
Accounts receivable	1,949	15,872	31,116
Inventories	3,562	13,096	48,228
Prepaid expenses and other assets	(2,368)	4,089	(2,499)
Accounts payable	(1,720)	(7,577)	(26,976)
Deferred revenue	(1,519)	(219)	(730)
Accrued expenses and other liabilities	(8,663)	(6,443)	(3,384)
Net cash (used in) provided by operating activities	(49,023)	27,374	141,583
INVESTING ACTIVITIES:
Purchases of short-term investments	0	(53,244)	(74,652)
Proceeds from maturities and redemptions of investments	0	53,052	102,440
Purchase of equity method investee	0	(30,000)	0	$ (30,000)
Acquisition of business, net of cash acquired	(3,613)	(5,037)	0
Proceeds from sale of assets	1,000	0	0
Purchases of property and equipment	(4,197)	(3,797)	(5,802)
Purchase of property and equipment under government contracts	0	0	(4,501)
Proceeds from funding under government contracts	0	0	48,669
Net cash (used in) provided by investing activities	(6,810)	(39,026)	66,154
FINANCING ACTIVITIES:
Cash payments for lease liabilities	(61)	(842)	(1,345)
Proceeds from exercise of stock options	0	214	269
Repurchase of common stock	(15,040)	0	0
Payment of acquisition-related contingent consideration	0	0	46
Payment of taxes related to net share settlement of equity awards	(1,843)	(3,548)	(1,901)
Net cash used in financing activities	(16,944)	(4,176)	(3,023)
EFFECT OF FOREIGN EXCHANGE RATE CHANGES ON CASH	4,292	(6,816)	1,713
NET (DECREASE) INCREASE IN CASH AND CASH EQUIVALENTS	(68,485)	(22,644)	206,427
CASH AND CASH EQUIVALENTS, BEGINNING OF PERIOD	267,763	290,407	83,980	$ 290,407
CASH AND CASH EQUIVALENTS, END OF PERIOD	$ 199,278	$ 267,763	$ 290,407

Stockholders' Equity - Summary of Restricted Stock Award and Restricted Stock Units Activity Under Stock Plan (Detail) - Restricted Stock Award and Restricted Stock Units shares in Thousands	12 Months Ended
	Dec. 31, 2025 $ / shares shares
Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]
Beginning balance (in shares) \| shares	1,694
Granted (in shares) \| shares	2,226
Vested (in shares) \| shares	(1,128)
Forfeited (in shares) \| shares	(182)
Ending balance (in shares) \| shares	2,610
Issued and expected to vest (in shares) \| shares	2,610
Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value
Beginning balance (in US dollars per share) \| $ / shares	$ 6.60
Granted (in US dollars per share) \| $ / shares	3.25
Vested (in US dollars per share) \| $ / shares	6.05
Forfeited (in US dollars per share) \| $ / shares	4.55
Ending balance (in US dollars per share) \| $ / shares	4.13
Issued and expected to vest (in US dollars per share) \| $ / shares	$ 4.13

Termination Benefits - Additional Information (Details) $ in Millions	Dec. 31, 2025 USD ($)
2023 Reduction in Workforce
Termination Benefits [Line Items]
Payment of reduction in workforce	$ 3.3
Q1 2024 Reduction in Workforce
Termination Benefits [Line Items]
Payment of reduction in workforce	0.4
Q2 2024 Reduction In Workforce
Termination Benefits [Line Items]
Payment of reduction in workforce	1.5
Accrued reduction in workforce	0.1
Q3 2024 Reduction In Workforce
Termination Benefits [Line Items]
Payment of reduction in workforce	1.1
Accrued reduction in workforce	$ 0.1

Income Taxes - Schedule of Income (Loss) Before Income Tax Expense (Benefit) (Detail) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2025	Dec. 31, 2024	Dec. 31, 2023
Income Tax Disclosure [Abstract]
United States	$ (62,742)	$ (21,523)	$ 61,671
Foreign	(1,844)	5,522	(5,413)
(Loss) income before income taxes and equity investment	$ (64,586)	$ (16,001)	$ 56,258

- Definition

Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.

+ References

Reference 1: http://www.xbrl.org/2003/role/exampleRef
-Topic 220
-SubTopic 40
-Name Accounting Standards Codification
-Section 55
-Paragraph 4
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147476153/220-40-55-4

Reference 2: http://www.xbrl.org/2003/role/exampleRef
-Topic 220
-SubTopic 40
-Name Accounting Standards Codification
-Section 55
-Paragraph 21
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147476153/220-40-55-21

Reference 3: http://www.xbrl.org/2003/role/exampleRef
-Topic 220
-SubTopic 40
-Name Accounting Standards Codification
-Section 55
-Paragraph 14
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147476153/220-40-55-14

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Topic 942
-SubTopic 235
-Name Accounting Standards Codification
-Section S50
-Paragraph 1
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147478671/942-235-S50-1

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Topic 942
-SubTopic 235
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-05(b)(2))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147477314/942-235-S99-1

Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 22
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-22

Reference 7: http://www.xbrl.org/2003/role/exampleRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 55
-Paragraph 48
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482785/280-10-55-48

Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 32
-Subparagraph (f)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-32

Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 30
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-30

Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 270
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (i)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482964/270-10-50-1

Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 32
-Subparagraph (ee)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-32

Reference 12: http://fasb.org/us-gaap/role/ref/otherTransitionRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 32
-Subparagraph (c)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-32

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Topic 944
-SubTopic 220
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-04(11))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1

Reference 14: http://www.xbrl.org/2003/role/exampleRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 31
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-31

Reference 15: http://fasb.org/us-gaap/role/ref/legacyRef
-Topic 220
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03(10))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2

Reference 16: http://fasb.org/us-gaap/role/ref/legacyRef
-Topic 942
-SubTopic 220
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-04(15))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1

+ Details

Business Segment Information - Summary of Operating Segment and Asset Information (Detail) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2025	Dec. 31, 2024	Dec. 31, 2023
Segment Reporting [Abstract]
Net revenues	$ 115,021	$ 185,827	$ 405,472
COST OF PRODUCTS AND SERVICES SOLD	66,823	106,437	233,820
Gross profit	48,198	79,390	171,652
Research and development	42,528	26,047	33,728
Sales and marketing	26,117	30,986	36,319
General and administrative	47,677	46,215	58,191
Loss on impairments	0	4,392	10,829
Change in the estimated fair value of acquisition-related contingent consideration	4,570	0	(99)
Gain on sale of assets	(725)	0	0
Operating (loss) income	(71,969)	(28,250)	32,684
Other income (expense) (1)	229	(380)	17,836
Interest revenue	8,078	11,469	5,862
Other segment items	(924)	1,160	(124)
(Loss) income before income taxes and equity investment	(64,586)	(16,001)	56,258
INCOME TAX EXPENSE	1,801	1,799	2,603
LOSS ON EQUITY INVESTMENT	(2,344)	(1,700)	0
NET (LOSS) INCOME	$ (68,731)	$ (19,500)	$ 53,655

Income Taxes - Components of Total Deferred Tax Assets (Liabilities) (Detail) - USD ($) $ in Thousands	Dec. 31, 2025	Dec. 31, 2024
Deferred tax assets:
Net operating loss carryforwards	$ 54,859	$ 55,583
Inventories	2,108	2,344
Capitalized research and development costs	10,889	12,946
Accruals and reserves currently not deductible	1,805	2,754
Depreciation and amortization	114	0
Lease liabilities	2,254	2,497
Stock-based compensation	3,244	3,303
Tax credit carryforwards	6,628	4,184
Net deferred tax asset	81,901	83,611
Valuation allowance	(77,006)	(75,191)
Total deferred tax assets	4,895	8,420
Acquired intangible assets	(2,220)	(3,981)
Depreciation and amortization	0	(2,017)
Right-of-use assets	(2,073)	(2,266)
Deferred compensation	(331)	0
Total deferred tax liabilities	(4,624)	(8,264)
Total deferred tax assets	$ 271	$ 156

Summary of Significant Accounting Policies - Summary of Earnings by Geographic Region (Detail) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2025	Dec. 31, 2024	Dec. 31, 2023
Disaggregation Of Revenue [Line Items]
Net revenues	$ 115,021	$ 185,827	$ 405,472
United States
Disaggregation Of Revenue [Line Items]
Net revenues	78,252	139,161	361,660
Europe
Disaggregation Of Revenue [Line Items]
Net revenues	7,393	8,424	8,111
Africa
Disaggregation Of Revenue [Line Items]
Net revenues	23,993	32,745	29,254
Other regions
Disaggregation Of Revenue [Line Items]
Net revenues	$ 5,383	$ 5,497	$ 6,447

- Definition

Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 606
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 7
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479806/606-10-50-7

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Topic 606
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 5
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479806/606-10-50-5

Reference 3: http://www.xbrl.org/2003/role/exampleRef
-Topic 606
-SubTopic 10
-Name Accounting Standards Codification
-Section 55
-Paragraph 91
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479777/606-10-55-91

Reference 4: http://www.xbrl.org/2003/role/exampleRef
-Topic 606
-SubTopic 10
-Name Accounting Standards Codification
-Section 55
-Paragraph 91
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479777/606-10-55-91

Reference 5: http://www.xbrl.org/2003/role/exampleRef
-Topic 606
-SubTopic 10
-Name Accounting Standards Codification
-Section 55
-Paragraph 91
-Subparagraph (c)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479777/606-10-55-91

Reference 6: http://www.xbrl.org/2003/role/exampleRef
-Topic 606
-SubTopic 10
-Name Accounting Standards Codification
-Section 55
-Paragraph 91
-Subparagraph (d)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479777/606-10-55-91

Reference 7: http://www.xbrl.org/2003/role/exampleRef
-Topic 606
-SubTopic 10
-Name Accounting Standards Codification
-Section 55
-Paragraph 91
-Subparagraph (e)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479777/606-10-55-91

Reference 8: http://www.xbrl.org/2003/role/exampleRef
-Topic 606
-SubTopic 10
-Name Accounting Standards Codification
-Section 55
-Paragraph 91
-Subparagraph (f)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479777/606-10-55-91

Reference 9: http://www.xbrl.org/2003/role/exampleRef
-Topic 606
-SubTopic 10
-Name Accounting Standards Codification
-Section 55
-Paragraph 91
-Subparagraph (g)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479777/606-10-55-91

+ Details

- Definition

Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.

+ References

Reference 1: http://www.xbrl.org/2003/role/exampleRef
-Topic 220
-SubTopic 40
-Name Accounting Standards Codification
-Section 55
-Paragraph 4
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147476153/220-40-55-4

Reference 2: http://www.xbrl.org/2003/role/exampleRef
-Topic 220
-SubTopic 40
-Name Accounting Standards Codification
-Section 55
-Paragraph 14
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147476153/220-40-55-14

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 41
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-41

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 42
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-42

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Topic 606
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 7
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479806/606-10-50-7

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Topic 270
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (i)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482964/270-10-50-1

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 32
-Subparagraph (ee)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-32

Reference 8: http://fasb.org/us-gaap/role/ref/otherTransitionRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 32
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-32

Reference 9: http://fasb.org/us-gaap/role/ref/otherTransitionRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 32
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-32

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Topic 924
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SAB Topic 11.L)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479941/924-10-S99-1

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Topic 606
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 5
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479806/606-10-50-5

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 30
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-30

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 22
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-22

Reference 14: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 40
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-40

Reference 15: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 22
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-22

Reference 16: http://www.xbrl.org/2003/role/disclosureRef
-Topic 606
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 4
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479806/606-10-50-4

+ Details

Goodwill and Other Intangible Assets

12 Months Ended

Dec. 31, 2025

Goodwill and Intangible Assets Disclosure [Abstract]

Goodwill and Other Intangible Assets

GOODWILL AND OTHER INTANGIBLE ASSETS:

Changes in goodwill are as follows:


	Reporting Unit
	Diagnostics		Collection Devices		Total
Balance at January 1, 2024	$	—	$	35,696	$	35,696
Acquisition	6,388		—		6,388
Change related to foreign currency translation	—		(1,754)		(1,754)
Balance at December 31, 2024	6,388		33,942		40,330
Acquisition	1,775		—		1,775
Change related to foreign currency translation	—		1,258		1,258
Balance at December 31, 2025	$	8,163	$	35,200	$	43,363

On November 30, 2025, the Company performed its quantitative annual goodwill impairment test. The Company utilizes a combination of the income approach and market approach in determining the fair value of its two reporting units. The test concluded that the carrying value of the Company's reporting units was below fair value indicating there was no impairment of goodwill.

Intangible assets consist of the following:


		December 31, 2025
	Amortization Period (Years)	Gross		Accumulated Amortization		Net
Definite Life Intangible Assets
Customer relationships	10	$	9,134	$	(9,134)	$	—
Patents and product rights	5	7,596		(7,596)		—
Developed technology	7-15	8,995		(7,095)		1,900
Trade names	5-15	3,501		(3,355)		146
		29,226		(27,180)		2,046
Indefinite Life Intangible Assets
IPR&D technology (Note 13)	N/A	17,000		—		17,000
		$	46,226	(27,180)		19,046


		December 31, 2024
	Amortization Period (Years)	Gross		Accumulated Amortization		Net
Definite Life Intangible Assets
Customer relationships	10	$	10,858	$	(10,858)	$	—
Patents and product rights	5	7,495		(7,399)		96
Developed technology	7-10	10,169		(10,169)		—
Trade names	5-15	4,327		(3,988)		339
		32,848		(32,413)		435
Indefinite Life Intangible Assets
IPR&D technology (Note 13)	N/A	17,000		—		17,000
		$	49,848	$	(32,413)	$	17,435

During 2023, the Company identified a triggering event to test for the recoverability of intangible assets given the decline in the Company's market capitalization leading up to and as of its annual goodwill impairment testing date. The Company performed an undiscounted cash flow analysis and determined the carrying value of the developed technology, trade names, and customer relationships intangible assets could not be recovered through the sum of the undiscounted future

cash flows. The Company used an income approach to determine the fair value of the developed technology and customer relationships intangible assets and the relief from royalty method for the trade names. As a result of this analysis, the Company determined the intangible assets associated with Diversigen and Novosanis were impaired as the fair value of the developed technology, trade names, and customer relationships did not exceed their carrying value. The Company recognized a pre-tax impairment charge of $6.2 million during the year ended December 31, 2023, which is reported in loss on impairments in the Company's consolidated statement of operations.

Also in 2023, the Company determined that its remaining developed technology intangible asset was fully impaired. As a result of failed stability studies, the Company decided to no longer pursue the technology. The Company recognized a pre-tax impairment charge of $2.4 million during the year ended December 31, 2023 which is reported in loss on impairments in the Company's consolidated statement of operations.

Amortization expense for 2025, 2024, and 2023 was $0.3 million, $0.7 million, and $2.0 million, respectively.

Amortization expense for each of the five succeeding fiscal years and beyond is estimated as follows:


2026	$	336
2027	190
2028	190
2029	190
2030	190
Beyond	950
	$	2,046

Insider Trading Arrangements	3 Months Ended
Insider Trading Arrangements	Dec. 31, 2025
Trading Arrangements, by Individual
Rule 10b5-1 Arrangement Adopted	false
Non-Rule 10b5-1 Arrangement Adopted	false
Rule 10b5-1 Arrangement Terminated	false
Non-Rule 10b5-1 Arrangement Terminated	false

Government Capital Contracts (Tables)

12 Months Ended

Dec. 31, 2025

Organization, Consolidation and Presentation of Financial Statements [Abstract]

Summary of Government Contracts Balances Included In Consolidated Statements Of Cashflows

The activity corresponding to the government contracts included in the Company's consolidated statements of cash flows is as follows:


	December 31,
	2023
Cost of assets, cumulative	$	86,993
Reduction for funding earned to date, not yet received	—
Reduction for funding received to date	(86,993)
Total property, plant and equipment, net	$	—

Summary of Significant Accounting Policies - Schedule of Fair Value (Details) - USD ($) $ in Thousands	Dec. 31, 2025	Dec. 31, 2024
Fair Value, Measured on Recurring Basis, Gain (Loss) Included in Earnings [Line Items]
Guaranteed investment certificates	$ 199,278	$ 267,763
Current portion	18,380	0
Long-term portion	9,333	22,910
Level I Instruments
Fair Value, Measured on Recurring Basis, Gain (Loss) Included in Earnings [Line Items]
Guaranteed investment certificates	13,114	66,584
Trading securities	543	724
Level III Instruments
Fair Value, Measured on Recurring Basis, Gain (Loss) Included in Earnings [Line Items]
Current portion	18,380	0
Long-term portion	9,333	22,910
Contingent consideration:	$ 27,713	$ 22,910

- Definition

Amount of investment in debt security measured at fair value with change in fair value recognized in net income (trading).

+ References

Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 820
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (bbb)(2)(i)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482106/820-10-50-2

Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 820
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (bbb)(2)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482106/820-10-50-2

Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 820
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (bbb)(1)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482106/820-10-50-2

Reference 4: http://www.xbrl.org/2003/role/exampleRef
-Name Accounting Standards Codification
-Section 55
-Paragraph 10
-SubTopic 10
-Topic 825
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482881/825-10-55-10

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Topic 825
-SubTopic 10
-Name Accounting Standards Codification
-Section 45
-Paragraph 1A
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482736/825-10-45-1A

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Topic 825
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 11
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482907/825-10-50-11

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Topic 825
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 11
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482907/825-10-50-11

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Topic 825
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 10
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482907/825-10-50-10

Reference 9: http://www.xbrl.org/2003/role/exampleRef
-Topic 825
-SubTopic 10
-Name Accounting Standards Codification
-Section 55
-Paragraph 12
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482881/825-10-55-12

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Topic 820
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482106/820-10-50-2

Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 320
-SubTopic 10
-Name Accounting Standards Codification
-Section 45
-Paragraph 1
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481830/320-10-45-1

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Topic 210
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(2))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1

Reference 13: http://www.xbrl.org/2003/role/exampleRef
-Topic 210
-SubTopic 10
-Name Accounting Standards Codification
-Section 45
-Paragraph 1
-Subparagraph (f)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483467/210-10-45-1

+ Details

Termination Benefits (Tables)

12 Months Ended

Dec. 31, 2025

Termination Benefits [Abstract]

Summary Of One-Time Termination Benefits

The charges for termination benefits included in the Company's consolidated statements of operations are as follows:


	For the Year Ended December 31,
	2023
Cost of products and services sold	$	369
Research and development	566
Sales and marketing	1,543
General and administrative	787
	$	3,265

The charges for termination benefits included in the Company's consolidated statement of operations are as follows:


	For the Year Ended December 31,
	2024
Cost of products and services sold	$	231
Research and development	87
Sales and marketing	69
General and administrative	17
	$	404

The charges for termination benefits included in the Company's consolidated statements of operations are as follows:


	For the Year Ended December 31,
	2024
Cost of products and services sold	$	889
Research and development	478
Sales and marketing	125
General and administrative	160
	$	1,652

The charges for termination benefits included in the Company's consolidated statements of operations are as follows:


	For the Year Ended December 31,
	2024
Cost of products and services sold	$	246
Research and development	33
Sales and marketing	782
General and administrative	141
	$	1,202

Business Combinations (Tables)

12 Months Ended

Dec. 31, 2025

Business Combination [Abstract]

Business Combination

The initial aggregate purchase price of this transaction was funded with cash on hand as shown in the table below:


Cash paid to BioMedomics	$	2,865
Transaction expenses	403
Debt paid off	330
Earnout contingent consideration	325
Expense fund	40
Initial aggregate purchase price	$	3,963

The initial aggregate purchase price of this transaction was funded with cash on hand as shown in the table below:


Milestone contingent consideration	$	15,910
Royalty based contingent consideration	7,000
Cash paid to Sherlock	5,000
Legal expenses	389
Insurance policy expense	50
Initial aggregate purchase price	$	28,349

Summary of Preliminary Estimated Fair Values of Assets Acquired and Liabilities Assumed

The following table summarizes the estimated fair values of the assets acquired and liabilities assumed as of the acquisition date:


Assets Acquired


Other current and non current assets	$	10
Inventory	284
Operating right-of-use assets	120


Developed technology intangible asset	1,900
Goodwill	1,775
Total assets acquired	4,089
Liabilities Assumed
Accounts payable	34
Current liabilities	17
Deferred revenue	72
Operating lease liability	120
Total liabilities assumed	243
Net Assets Acquired	3,846
Estimated fair value of contingent consideration	(233)
Net Cash Paid (net of cash acquired of $25)	$	3,613

The following table summarizes the estimated fair values of the assets acquired and liabilities assumed as of the acquisition date:


Assets Acquired


Other current assets	$	2,570
Property, plant, and equipment, net	9,244
Other noncurrent assets	462
Operating right-of-use assets	4,080
In-process research and development technology intangible asset	17,000
Goodwill	6,382
Total assets acquired	39,738
Liabilities Assumed
Accounts payable	2,449
Current liabilities	3,621
Deferred revenue	1,641
Operating lease liability	4,080
Total liabilities assumed	11,791
Net Assets Acquired	27,947
Estimated fair value of contingent consideration	(22,910)
Net Cash Paid (net of cash acquired of $402)	$	5,037

Business Combination, Pro Forma Information

The unaudited pro forma results presented below include the results of the BioMedomics acquisition as if it had been consummated as of January 1, 2024. The unaudited pro forma results include, amortization of the acquired intangible assets, stock compensation, and lease expense adjustments to income before income taxes but do not include changes in the fair value of the Company's contingent consideration obligations. Material nonrecurring charges, directly attributable to the transactions, including direct acquisition costs, are also excluded. In addition, the unaudited pro forma results do not include any expected benefits of the acquisitions. Accordingly, the unaudited pro forma results are not necessarily indicative of either future results of operations or results that might have been achieved had the acquisitions been consummated as of January 1, 2024.


	For the Years Ended December 31,
	2025		2024
Net revenues	$	115,797	$	187,041
Net loss	$	(68,964)	$	(20,889)


	For the Years Ended December 31,
	2024		2023
Net revenues	$	188,126	$	406,381
Net income loss	$	(41,459)	$	7,992

- Definition

Tabular disclosure of business combination. Includes, but is not limited to, recognized asset and liability.

+ References + Details

Income Taxes (Tables)

12 Months Ended

Dec. 31, 2025

Income Tax Disclosure [Abstract]

Schedule of Income (Loss) Before Income Tax Expense (Benefit)

Income (loss) before income tax expense consists of the following:


	For the Years Ended December 31,
	2025		2024		2023
United States	$	(62,742)	$	(21,523)	$	61,671
Foreign	(1,844)		5,522		(5,413)
	$	(64,586)	$	(16,001)	$	56,258

Components of Income Tax Expense (Benefit)

The components of income tax expense (benefit) are as follows:


	For the Years Ended December 31,
	2025		2024		2023
Current
Federal	$	—	$	229	$	—
State	124		111		1,896
Foreign	(176)		2,116		605
	(52)		2,456		2,501
Deferred
Federal	(11,186)		(2,962)		13,570
State	870		1,368		(382)
Foreign	10,355		4,365		(1,867)
	39		2,771		11,321
Increase (decrease) in valuation allowance	1,814		(3,428)		(11,219)
	1,853		(657)		102
Total income tax expense	$	1,801	$	1,799	$	2,603

Schedule of Cash Flow, Supplemental Disclosures

Total cash paid for income taxes was as follows:


	For the Year Ended December 31, 2025
Federal	$	—
State:
Utah	(100)
Other	74
	(26)
Foreign:
Canada	2,539
United Kingdom	(672)
	1,867

Total cash paid for income taxes (net of refunds) (1)	$	1,841

(1) Total cash paid for income taxes during the year ended December 31, 2024 was $1.8 million. The Company received income tax refunds of $4.9 million for year ended December 31, 2023 (prior to adoption of ASU 2023-09).

Reconciliation of Statutory United States Federal Income Tax Rate to Domestic Effective Tax Rate

The reconciliation of the statutory United States federal income tax rate to the Company's effective tax rate is as follows:


	For the Years Ended December 31,
	2025		2024		2023
Statutory U.S. federal income tax rate	21.0	%	21.0	%	21.0	%
Nondeductible executive compensation	(1.1)		(8.5)		0.5
Impact of stock-based payment awards	(1.8)		(2.3)		(0.3)
Tax effect of foreign items	(0.6)		(1.9)		(0.4)
State income taxes, net of federal benefit	1.3		(9.1)		2.0
U.S. and foreign tax credits	1.3		1.2		1.3
Uncertain tax positions	(2.9)		—		—
Nondeductible expenses and other	1.2		(2.4)		0.9
Nondeductible transaction costs	(0.2)		(2.1)		—
NOL adjustment, domestic	(2.2)		—		—
NOL adjustment, foreign	25.5		(31.4)		—
Change in the estimated fair value of acquisition-related contingent consideration	(1.4)		—		—
Acquisition adjustments	(8.7)		—		—
Non-controlling interests	(0.7)		2.2		—
Change in valuation allowance, federal and state	(14.4)		(10.0)		—
Change in valuation allowance, foreign	(19.0)		32.1		(20.4)
Effective tax rate	(2.7)	%	(11.2)	%	4.6	%

The reconciliation of the statutory United States federal income tax rate to the Company's effective tax rate is as follows:


	For the Year Ended December 31, 2025
	Dollars		Percentage
Statutory U.S. federal income tax rate	$	(14,055)	21.0	%
State and local income taxes, net of federal income tax effect (1)	325		(0.5)	%
Foreign tax effects
United Kingdom
Change in NOL limitation	(17,062)		25.5	%
Intangible acquisition adjustment	4,524		(6.7)	%
Change in valuation allowances	12,728		(19.0)	%
Other	(195)		0.3	%
Other foreign jurisdictions	114		(0.2)	%
Effect of changes in tax laws/rates enacted in the current period	—		—	%
Effect of cross-border tax laws
Global intangible low-taxed income	523		(0.8)	%
Tax credits
Research and development tax credits	(536)		0.8	%
Changes in valuation allowances	8,700		(13.0)	%
Nontaxable or nondeductible items
Share based payment awards	773		(1.1)	%
Nondeductible officer's compensation	714		(1.1)	%
Change in the estimated fair value of acquisition-related contingent consideration	960		(1.4)	%
Other	192		(0.3)	%
Changes in unrecognized tax benefits	1,728		(2.6)	%
Acquisition adjustments	1,285		(1.9)	%
NOL adjustment	1,441		(2.2)	%
Other adjustments	(358)		0.5	%
Effective tax rate	$	1,801	(2.7)	%

(1) The tax effect in this category was primarily driven by state taxes in Pennsylvania (greater than 50%).

Components of Total Deferred Tax Assets (Liabilities)

Significant components of the Company's deferred tax assets (liabilities) are as follows:


	December 31,
	2025		2024
Deferred tax assets:
Net operating loss carryforwards	$	54,859	$	55,583
Inventories	2,108		2,344
Capitalized research and development costs	10,889		12,946
Accruals and reserves currently not deductible	1,805		2,754
Depreciation and amortization	114		—
Lease liabilities	2,254		2,497
Stock-based compensation	3,244		3,303
Tax credit carryforwards	6,628		4,184
Net deferred tax asset	81,901		83,611
Valuation allowance	(77,006)		(75,191)
Total deferred tax assets	$	4,895	$	8,420

Deferred tax liabilities:
Depreciation and amortization	—		(2,017)
Acquired intangible assets	(2,220)		(3,981)
Right-of-use assets	(2,073)		(2,266)
Deferred compensation	(331)		—
Total deferred tax liabilities	$	(4,624)	$	(8,264)
Net deferred tax asset	$	271	$	156

Summary of Operating Loss Carryforwards

The state NOL carryforwards have expirations as follows:


Year of Expiration	NOLs
2026 - 2041	$	30,419
2042 - 2055	20,023
Non-Expiring	14,350
	$	64,792

Reconciliation of Beginning and Ending Amount of Unrecognized Tax Benefits

The reconciliation of the Company's unrecognized tax benefits is as follows:


	2025		2024		2023
Balance at January 1	$	333	$	304	$	373
Additions for tax positions of prior periods	1,729		29		—
Reductions for tax positions of prior periods	—		—		(69)
Balance at December 31	$	2,062	$	333	$	304

Leases (Tables)

12 Months Ended

Dec. 31, 2025

Lessee Disclosure [Abstract]

Summary of Components of Lease Expense

The components of lease expense are as follows:


	For the Years Ended December 31,
	2025		2024		2023
Operating lease cost	$	2,285	$	1,729	$	2,407
Variable and short-term lease cost	37		549		381
Sublease income	(161)		(151)		(155)
Finance lease cost:
Amortization of right-of use assets	61		331		1,091
Interest on lease liabilities	8		22		51
Total finance lease cost	69		353		1,142
Total lease cost	$	2,230	$	2,480	$	3,775

Summary of Supplemental Cash Flow Information Related to Leases

Supplemental cash flow information related to leases is as follows:


	For the Years Ended December 31,
	2025		2024		2023
Cash paid for amounts included in the measurement of lease liabilities:
Operating cash flows from operating leases	$	2,156	$	1,901	$	1,863
Operating cash flows from financing leases	8		22		51
Financing cash flows from financing leases	61		842		1,345
Non-cash activity:
Right-of-use assets obtained in exchange for operating lease obligations	169		4,086		4,363
Right-of-use assets obtained in exchange for finance lease obligations	62		193		334

Summary of Supplemental Balance Sheet Information Related to Leases

Supplemental balance sheet information related to leases is as follows:


	December 31,
	2025		2024














Weighted Average Remaining Lease Term
Weighted-average remaining lease term — operating leases	6.70 years		7.57 years
Weighted-average remaining lease term — finance leases	2.70 years		3.74 years

Weighted Average Discount Rate
Weighted-average discount rate — operating leases	4.48	%	4.44	%
Weighted-average discount rate — finance leases	5.10	%	4.82	%

Schedule of Minimum Lease Payments by Period Expected

As of December 31, 2025, minimum lease payments by period are expected to be as follows:


	Finance		Operating
2026	$	70	$	2,548
2027	65		2,287
2028	34		2,157
2029	6		2,097
2030	—		2,106
Thereafter	—		3,778
Total minimum lease payments	175		14,973
Less: imputed interest	(12)		(1,939)
Present value of lease liabilities	$	163	$	13,034

Income Taxes - Reconciliation of Beginning and Ending Amount of Unrecognized Tax Benefits (Detail) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2025	Dec. 31, 2024	Dec. 31, 2023
Unrecognized Tax Benefits [Roll Forward]
Balance at January 1	$ 333	$ 304	$ 373
Additions for tax positions of prior periods	1,729	29	0
Reductions for tax positions of prior periods	0	0	(69)
Balance at December 31	$ 2,062	$ 333	$ 304

Summary of Significant Accounting Policies

12 Months Ended

Dec. 31, 2025

Accounting Policies [Abstract]

Summary of Significant Accounting Policies

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES:

Principles of Consolidation and Basis of Presentation

The consolidated financial statements include the accounts of OraSure Technologies, Inc. (“OraSure”) and its wholly-owned subsidiaries, DNA Genotek Inc. ("DNAG"), Diversigen, Inc. ("Diversigen"), Novosanis NV ("Novosanis"), BioMedomics, Inc. ("BioMedomics") and Sherlock Biosciences, Inc. ("Sherlock"). Novosanis was legally dissolved in June 2025. All intercompany transactions and balances have been eliminated. References herein to “we”, “us”, “our”, or the “Company” mean OraSure and its consolidated subsidiaries, unless otherwise indicated.

Change in Accounting Principle

Effective January 1, 2025, the Company changed its methodology for valuing certain inventories to the average cost method from the first-in, first-out ("FIFO") cost method. The change was applicable to all inventories. The Company concluded that the average cost basis of accounting is preferable as it results in greater precision in the calculation of acquisition cost of inventory on the balance sheet. The effect of this change in accounting principle was immaterial. Therefore, retroactive application was not determined to be necessary and a cumulative adjustment of $0.1 million was recorded in the statement of operations for the twelve months ended December 31, 2025.

Use of Estimates

The preparation of consolidated financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions about future events. These estimates and underlying assumptions affect the amounts of assets and liabilities reported, disclosures about contingent assets and liabilities, and reported amounts of revenues and expenses. Such estimates include the fair value of assets acquired and liabilities assumed for business combinations, the valuation of accounts receivable and inventories and assumptions utilized in impairment testing for property, plant and equipment, intangible assets and goodwill, as well as estimates related to accruals, taxes, contingent consideration, and performance-based compensation expense. These estimates and assumptions are based on management’s best estimates and judgment. Management evaluates its estimates and assumptions on an ongoing basis, using historical experience and other factors, which management believes to be reasonable under the circumstances, including the current economic environment. As future events and their effects cannot be determined with precision, actual results could differ significantly from these estimates. Changes in those estimates resulting from continuing changes in the economic environment and other factors will be reflected in the financial statements in those future periods.

Supplemental Cash Flow Information

The Company paid income taxes of $1.8 million and $1.8 million in 2025 and 2024, respectively, and received income tax refunds of $4.9 million in 2023.

The Company had account receivable write-offs of $0.5 million, $0.5 million, and $0.7 million in 2025, 2024, and 2023, respectively.

As of December 31, 2025, 2024 and 2023, the Company had accruals for purchases of property and equipment of $0.5 million, $0.5 million and $0.2 million, respectively.

The Company acquired BioMedomics which included contingent consideration of $0.3 million for the year ended December 31, 2025.

The Company acquired Sherlock which included contingent consideration of $22.9 million for the year ended December 31, 2024.

Cash Equivalents & Short-Term Investments

The Company considers all investments in debt securities to be available-for-sale securities. These securities consist of guaranteed investment certificates purchased with maturities greater than ninety days. Securities with maturities ninety days or less are considered cash equivalents. Available-for-sale securities are carried at fair value, based upon quoted market prices, with unrealized gains and losses, if any, reported in stockholders’ equity as a component of accumulated other comprehensive loss.

The Company records an allowance for credit loss for the Company's available-for-sale securities when a decline in investment market value is due to credit-related factors. When evaluating an investment for impairment, the Company reviews factors such as the severity of the impairment, changes in underlying credit ratings, forecasted recovery, the Company’s intent to sell or the likelihood that it would be required to sell the investment before its anticipated recovery in market value, and the probability that the scheduled cash payments will continue to be made.

The Company had no available-for-sale securities as of December 31, 2025 and December 31, 2024.

The Company maintains cash balances in the United States in excess of the federally insured limits. The Company periodically evaluates financial institutions and believes the risk of loss to be remote due to this evaluation.

Fair Value of Financial Instruments

As of December 31, 2025 and 2024, the carrying values of cash and cash equivalents, accounts receivable, accounts payable, and accrued expenses approximate their respective fair values based on their short-term nature.

Fair value measurements of all financial assets and liabilities that are being measured and reported on a fair value basis are required to be classified and disclosed in one of the following three categories:

Level 1: Unadjusted quoted prices in active markets that are accessible at the measurement date for identical, unrestricted assets or liabilities;

Level 2: Quoted prices in markets that are not active, or inputs which are observable, either directly or indirectly, for substantially the full term of the asset or liability; and

Level 3: Prices or valuation techniques that require inputs that are both significant to the fair value measurement and unobservable (i.e., supported by little or no market activity).

To the extent that valuation is based on models or inputs that are unobservable in the market, determining fair value requires more judgment. Because of the inherent uncertainty of valuation, estimated values may be materially higher or lower than the values that would have been used had a ready market for the investments existed. Therefore, the degree of judgment exercised in determining fair value is greatest for assets or liabilities categorized in Level 3.


		December 31,		December 31,
	Level	2025		2024
Guaranteed investment certificates	1	$	13,114	$	66,584
Trading securities	1	543		724
Contingent consideration:	3
Current portion		$	18,380	$	—
Long-term portion		9,333		22,910
		$	27,713	$	22,910

Included in cash and cash equivalents at December 31, 2025 and 2024 was $13.1 million and $66.6 million, respectively, invested in guaranteed investment certificates.

Included in cash and cash equivalents at December 31, 2025 and 2024, was $68.4 million and $118.5 million, respectively, invested in government money market funds. These funds have investments in U.S. government securities and are measured as Level 1 instruments.

The Company offers a nonqualified deferred compensation plan for certain eligible employees and members of the Company's Board of Directors. The assets of the plan are held in the name of the Company at a third-party financial institution. Separate accounts are maintained for each participant to reflect the amounts deferred by the participant and all earnings and losses on those deferred amounts. The assets of the plan are held in mutual funds and Company stock. The fair value of the plan assets as of December 31, 2025 and 2024 was $0.5 million and $0.7 million, respectively, and was calculated using the quoted market prices of the assets as of those dates. All investments in the plan are classified as trading securities and measured as Level 1 instruments. The fair value of plan assets is included in both current assets and other noncurrent assets with the same amounts included in accrued expenses and other noncurrent liabilities in the accompanying consolidated balance sheets.

Contingent Consideration

As discussed further in Note 13, Business Combinations, the Company has identified its contingent consideration obligations as Level 3 liabilities due to significant inputs that are required to measure the fair value of these obligations. The contingent consideration is comprised of three different tranches: milestone payments, royalty payments, and earnout payments. The significant quantitative unobservable inputs for the milestone payments are the discount rate and probability achievement of a milestone of a regulatory approval.

The fair value methodology for royalty payments is based on a discounted cash flow model. Significant quantitative unobservable inputs are internally developed future expected cash flows, discount rate and probability achievement of a milestone of a regulatory approval. The royalty payments represent a mid-single digit percentage of the net sales through 2034 associated with the acquired in-process and research and development intangible asset.

The fair value methodology for earnout payments is based on a Monte Carlo model. Significant quantitative unobservable inputs are future expected cash flows, discount rate and volatility rate.

There was an increase of $4.6 million in the fair value of the Company's contingent consideration from date of acquisition to December 31, 2025 for the milestone and royalty payments.


	Fair Value
Balance at December 31, 2024	$	22,910
Additions	233
Change in fair value	4,570
Balance at December 31, 2025	$	27,713

Equity Method Investee

In January 2024, the Company led the Series B financing and entered into wide-ranging strategic distribution agreements with KKR Sapphiros L.P. ("Sapphiros"), a privately held consumer diagnostic portfolio company, and certain of its related entities. Through this relationship, the Company expects to be able to offer a more comprehensive range of low-cost diagnostic tests and molecular sample management solutions to the Company's customers globally. As of December 31, 2025, the Company had funded $30.0 million for its interest in Sapphiros. The Company recorded the investment using the equity method in accordance with Accounting Standards Codification ("ASC") Topic 323, Investments—Equity Method and Joint Ventures—Overall. In accordance with the equity method, the Company's equity investment is presented net of its share of any gains or losses of the investee. The Company has elected as its accounting policy to recognize its share of any income or loss in Sapphiros on a three-month lag. The investment in Sapphiros of $26.0 million as of December 31, 2025 is included in the investment in equity method investee line of the Company's balance sheet. The Company has no unconditional obligations or guarantees to, or in support of, its equity method investee and its operations. In conjunction with the preparation of the Company's December 31, 2025 financial statements, the Company evaluated the investment in Sapphiros for impairment and concluded there was no such impairment. The Company's investment in Sapphiros was valued at $28.3 million as of December 31, 2024.

Related Party

The Company loaned Sapphiros $0.3 million during the year ended December 31, 2025. The loan plus interest is due in December 2026. During the year ended December 31, 2025, the Company entered into an agreement with Sapphiros to develop certain products for Sapphiros. A total of $0.2 million of revenue was recognized from this agreement.

Accounts Receivable

Accounts receivable has been reduced by an estimated allowance for amounts that may become uncollectible in the future. This estimated allowance is based primarily on management’s evaluation of specific balances as they become past due, the financial condition of the Company's customers and the Company's historical experience related to write-offs.


	December 31,
	2025		2024		2023
Accounts receivable	$	22,203	$	23,816	$	40,171
Allowance for doubtful accounts	$	188	$	774	$	1,216

Inventories

Inventories are stated at the lower of cost or net realizable value, with cost determined on an average cost method, and include the cost of raw materials, labor and overhead. The majority of the Company's inventories are subject to expiration dating, which can be extended in certain circumstances. The Company continually evaluates quantities on hand and the carrying value of the Company's inventories to determine the need for net realizable value adjustments for excess and obsolete inventories, based primarily on prior experience with consideration of expected changes in the business and estimated forecasts of product sales. The Company reserves for inventory expiring within ninety days, with the exception of inventory that will be consumed or will have expiration dates extended. The Company also considers items identified through specific identification procedures in assessing the adequacy of the Company's reserve. Although the Company makes every effort to ensure the accuracy of expected changes in the business and of its forecasts of future product demand, any significant unanticipated changes in demand could have a significant impact on the carrying value of its inventories and reported operating results

Property, Plant and Equipment

Property, plant and equipment are stated at cost. Additions or improvements are capitalized, while repairs and maintenance are charged to expense. Depreciation and amortization are provided using the straight-line method over the estimated useful lives of the related assets as follows:

•buildings twenty years;

•leasehold improvements, the lesser of the useful life of the improvement or the remaining life of the building or lease;

•computer equipment and software three years;

•machinery and equipment five years; and

•furniture and fixtures seven years

When assets are sold, retired, or discarded, the related property amounts are relieved from the accounts, and any gain or loss is recorded in the consolidated statements of operations.

Intangible Assets

Intangible assets consist of customer relationships, patents and product rights, acquired technology, in-process research and development technology and trade names. Patents and product rights consist of costs associated with the acquisition of patents, licenses and product distribution rights. Intangible assets are amortized using the straight-line method over their estimated useful lives of five to fifteen years.

Impairment of Long-Lived Assets

Long-lived assets, which include property, plant and equipment and definite-lived intangible assets, are tested for recoverability whenever events or changes in business circumstances indicate that the carrying amount of the assets may not be fully recoverable. The Company assesses the recoverability of the Company's long-lived assets by determining whether the carrying value of such assets can be recovered through the sum of the undiscounted future cash flows generated from the use and eventual disposition of the asset. If indicators of impairment exist, the Company measures the amount of such impairment by comparing the carrying value of the assets to the fair value of the assets, which is generally determined based on the present value of the expected future cash flows associated with the use of the assets. Expected future cash flows reflect the Company's assumptions about selling prices, volumes, costs and market conditions over a reasonable period of time. See Note 5 for discussion of property, plant and equipment impairments, recorded for the year ended December 31, 2024. See Note 6 for discussion of definite-lived intangible asset impairments, recorded for the year ended December 31, 2023.

Goodwill

Goodwill represents the excess of the purchase price over the fair value of the net tangible and identifiable intangible assets acquired in a business combination. Goodwill is not amortized but rather is tested annually for impairment or more frequently if the Company believes that indicators of impairment exist. Current generally accepted accounting principles permit the Company to make a qualitative evaluation about the likelihood of goodwill impairment. If the Company concludes that it is more likely than not that the carrying value of a reporting unit is greater than its fair value, then the Company would be required to recognize an impairment charge for the amount by which the carrying amount exceeds the reporting unit’s fair value, provided the impairment charge does not exceed the total amount of goodwill allocated to the reporting unit.

The Company historically performed an annual goodwill impairment assessment as of July 31. During the three months ended December 31, 2023, the Company changed the date of the annual impairment assessment to November 30, to better align with the Company's annual forecasting process. On November 30, 2025, the Company performed a quantitative goodwill impairment test which concluded that the carrying value of the Company's goodwill for both the diagnostic and collection devices reporting units was below its fair value indicating there was no impairment.

As of November 30, 2025, the diagnostic reporting unit fair value exceeded its carrying value by 13%. As of December 31, 2025, the diagnostic reporting unit had $8.2 million of goodwill. The diagnostic reporting unit goodwill impairment analysis used both an income and market approach. These two approaches were weighted and the income approach was weighed more than the market approach. Key assumptions included revenues increasing each year as products are launched and a weighted-average cost of capital based on guideline companies. The revenue and cashflows assumes products are passed by regulatory bodies on a set timeline and market competition of future products is low. The revenues assume market growth will accelerate each year. If there are delays to attaining regulatory approval or successfully launching products, this could have a negative outcome on the goodwill impairment analysis. In addition, if the Company's weighted-average cost of capital is not aligned with guideline companies, this could negatively affect the goodwill impairment outcome.

The below table illustrates the discount rate and exit multiple sensitivity to the fair value of the diagnostic reporting unit goodwill when performing the goodwill impairment analysis as of November 30, 2025. In the annual goodwill impairment analysis as of November 30, 2025, the diagnostic reporting unit utilized a 14% discount rate with an exit multiple of one.



	Exit Multiple
Discount Rate	0.80		0.90		1.00		1.10		1.20
13%	$	208,132	$	217,464	$	226,796	$	236,128	$	245,460
14%	205,252		214,254		223,256		232,258		241,259
15%	202,501		211,188		219,875		228,562		237,249
16%	199,868		208,254		216,640		225,025		233,411
17%	197,339		205,436		213,533		221,630		229,726

A more frequent evaluation is performed if an event occurs or circumstances change between annual tests that could more likely than not reduce the fair value of a reporting unit below its carrying amount.

Revenue

Product sales. Revenue from product sales is recognized upon transfer of control of a product to a customer based on an amount that reflects the consideration the Company is entitled to, net of allowances for any discounts or rebates.

The Company generally does not grant product return rights to its customers, except for warranty returns and return rights on sales of the Company's OraQuick® HIV Self-Test to retail trade customers, and InteliSwab® products to retail trade and certain other customers.

Historically, returns arising from warranty issues have been infrequent and immaterial. Accordingly, the Company expenses warranty returns as incurred.

The Company records shipping and handling charges billed to the Company's customers as product revenue and the related expense as cost of products sold.

Service revenues. Service revenues represent microbiome laboratory testing and analytical services. The Company recognizes revenues when the Company satisfies its performance obligations for services rendered. Service revenues are associated with the Diversigen business, which was discontinued in 2024. There were zero service revenues for the year ended December 31, 2025.

Arrangements with multiple performance obligations. In arrangements involving more than one performance obligation, which largely applies to the Company's service revenue stream, each required performance obligation is evaluated to determine whether it qualifies as a distinct performance obligation based on whether (i) the customer can benefit from the good or service either on its own or together with other resources that are readily available and (ii) the good or service is separately identifiable from other promises in the contract. The consideration under the arrangement is then allocated to each separate distinct performance obligation based on their respective relative stand-alone selling price. The estimated selling price of each performance obligation is determined using an observable cost plus margin approach. The consideration allocated to each distinct performance obligation is recognized as revenue when control is transferred for the related goods or services or when the performance obligation has been satisfied. Arrangements with multiple performance obligations are associated with the Diversigen business, which was discontinued in 2024.

Other revenues. Other revenues consist primarily of royalty income and funding from grants of research and development efforts. Royalties from licensees are based on third-party sales of licensed products and are recorded when the related third-party product sale occurs. The Company accounts for government grants by analogy to International Accounting Standard 20, Accounting for Government Grants and Disclosure of Government Assistance ("IAS 20"), as U.S. GAAP does not provide specific guidance. Grants are recognized when there is reasonable assurance that conditions will be met and the grant will be received, and are recognized in earnings over the periods in which the related costs are incurred. The expenses are recorded in research and development expense and the reimbursements are recorded in other revenue. Funding of research and development efforts and charitable support reimbursements are recorded as the activities are performed in accordance with the respective agreements.

Financing and payment. The Company's payment terms vary by the type and location of the customer and products or services offered. Payment terms differ by jurisdiction and customer, but payment is generally required in a term ranging from 30 to 120 days from date of shipment or satisfaction of the performance obligation.

For certain products or services and customer types, the Company may require payment before the products are delivered or services are rendered to the customer.

Practical expedients and exemptions. Taxes assessed by governmental authorities, such as sales or value-added taxes, are excluded from product revenues.

Sales commissions are expensed when incurred if the amortization period is one year or less. These costs are recorded in sales and marketing expense in the consolidated statements of operations. If the amortization period exceeds one year, the Company defers the cost of the commission and expenses it over the life of the related sales contract.

Revenues by Product Line. The following table represents total net revenues by product line:


	For the Years Ended December 31,
		2025		2024		2023
HIV		$	49,802	$	60,804	$	60,823
Sample Management Solutions (1)		38,356		51,046		54,274
HCV		13,759		14,024		12,871
Other product and services revenues (2)		4,648		3,506		2,265
Risk Assessment Testing (3)		1,866		8,354		9,736
COVID-19 (4)		624		45,172		257,779
Molecular Services		—		1,705		4,474
Net product and services revenues		$	109,055	$	184,611	$	402,222
Non-product and services revenues (5)		5,966		1,216		3,250
Net revenues		$	115,021	$	185,827	$	405,472

(1) Includes Genomics, Microbiome and Colli-Pee® product revenues.

(2) Includes Syphilis revenues.

(3) Includes substance abuse testing product revenues.

(4) Includes COVID-19 Diagnostics and COVID-19 Sample Management Solutions revenues.

(5) Includes funded research and development contracts, royalty income and grant revenues.

Revenues by Geographic Area. The following table represents total net revenues by geographic area, based on the location of the customer:


	For the Years Ended December 31,
		2025		2024		2023
United States		$	78,252	$	139,161	$	361,660
Africa		23,993		32,745		29,254
Europe		7,393		8,424		8,111
Other regions		5,383		5,497		6,447
		$	115,021	$	185,827	$	405,472

Customer Concentrations. The following table represents customer concentration risk:


	For the Years Ended December 31,
Net Revenues		2025	2024


Non-commercial customer		N/A	24%


		December 31,
Accounts Receivable		2025	2024
Commercial customer		15%	10%

Vendor Concentrations. The Company currently purchases certain products and critical components of the Company's products from sole-supply vendors. If these vendors are unable or unwilling to supply the required components and products, the Company could be subject to increased costs and substantial delays in the delivery of the Company's products to its customers. Third-party suppliers also manufacture certain products. The Company's inability to have a timely supply of any of these components and products could have a material adverse effect on the Company's business, as well as the Company's financial condition and results of operations.

Deferred Revenue. The Company records deferred revenue when funds are received prior to the recognition of the associated revenue. Deferred revenue as of December 31, 2025, 2024, and 2023 was comprised of customer prepayments of $1.2 million, $3.0 million, and $1.2 million, respectively. Deferred revenue as of December 31, 2025 was also comprised of $0.4 million of unearned grant income. Deferred revenue as of December 31, 2023 also included $0.4 million associated with a long-term contract that has variable pricing based on volume. The average price over the life of the contract was determined and revenue was recognized at that average price. The $0.4 million associated with the long-term contract at December 31, 2023 met the criteria to be recognized as revenue during the year ended December 31, 2024, and as such there was no equivalent balance remaining in deferred revenue at December 31, 2025 or 2024.


	December 31,
	2025		2024		2023
Deferred Revenue	$	1,518	$	2,961	$	1,559

The following table represents deferred revenue recognized:


	For the Years Ended December 31,
Deferred Revenue Recognized		2025		2024
Accrued at beginning of year		$	2,484	$	3,680

Research and Development

Research and development expenses consist of costs incurred in performing research and development activities, including salaries and benefits, facilities expenses, overhead expenses, clinical trial and related clinical manufacturing expenses, contract services and other outside expenses. Research and development costs are charged to expense as incurred.

Advertising Expenses

Advertising costs are charged to expense as incurred. During the years ended December 31, 2025, 2024, and 2023, the Company incurred $0.6 million, $0.5 million, and $1.6 million, respectively, in advertising expenses.

Stock-Based Compensation

The Company accounts for stock-based compensation to employees and directors using the fair value method. The Company recognizes compensation expense for stock option and restricted stock awards issued to employees and directors on a straight-line basis over the requisite service period of the award. The Company recognizes compensation expense related to performance-based restricted stock units based on assumptions as to what percentage of each performance target will be achieved. The Company evaluates these target assumptions on a quarterly basis and adjusts compensation expense related to these awards, as appropriate. To satisfy the exercise of stock options, issuance of restricted stock, or redemption of performance-based restricted stock units, the Company issues new shares rather than purchase shares in the open market.

Income Taxes

The Company follows the asset and liability method for accounting for income taxes. Under this method, deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and the respective tax basis of assets and liabilities, as well as operating loss and credit carryforwards. Deferred tax assets and liabilities are measured using enacted tax rates for the respective taxing jurisdiction that are expected to apply to taxable income in the years in which those temporary differences and operating loss and credit carryforwards are expected to be recovered, settled or utilized. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period that includes the enactment date.

The Company assesses the realizability of its net deferred tax assets on a quarterly basis. If, after considering all relevant positive and negative evidence, it is more likely than not that some portion or all of the net deferred tax assets will not be realized, the Company reduces its net deferred tax assets by a valuation allowance. The realization of the net deferred tax assets is dependent on several factors, including the generation of sufficient taxable income prior to the expiration of the Company's net operating loss carryforwards.

Uncertain Tax Positions

Assets and liabilities are established for uncertain tax positions taken or positions expected to be taken in income tax returns when such positions fail to meet the "more likely than not" threshold based on the technical merits of the positions. The Company assesses whether previously unrecognized tax benefits may be recognized when tax positions are (1) more likely than not of being sustained based on their technical merits, (2) effectively settled through examination, negotiation or litigation, or (3) settled through actual expiration of the relevant tax statutes. The assessment of an uncertain tax position requires significant judgment.

Foreign Currency Translation

The assets and liabilities of the Company's foreign operations are translated into U.S. dollars at current exchange rates as of the balance sheet date, and revenues and expenses are translated at average exchange rates for the period. Resulting translation adjustments are reflected in accumulated other comprehensive loss, which is a separate component of stockholders’ equity.

Transaction gains and losses resulting from exchange rate changes on transactions denominated in currencies other than functional currency are included in the Company's consolidated statements of operations in the period in which the change occurs. Net foreign exchange gains (losses) resulting from foreign currency transactions included in other income in the Company's consolidated statements of operations were $(0.9) million, $1.2 million, and $(0.1) million for the years ended December 31, 2025, 2024, and 2023, respectively.

Earnings (Loss) Per Share

Basic earnings (loss) per share is computed by dividing net income (loss) by the weighted-average number of shares of common stock outstanding during the period. Diluted earnings (loss) per share is computed in a manner similar to basic earnings (loss) per share except that the weighted-average number of shares outstanding is increased to include incremental shares from the assumed vesting or exercise of dilutive securities, such as common stock options, unvested restricted stock or performance stock units, unless the impact is anti-dilutive. The number of incremental shares is calculated by assuming that outstanding stock options were exercised and unvested restricted shares and performance stock units were vested, and the proceeds from such exercises or vesting were used to acquire shares of common stock at the average market price during the reporting period. Basic and dilutive computations of net loss per share are the same in periods in which a net loss exists as the dilutive effects of excluded items would be anti-dilutive.


	For the Years Ended December 31,
	2025		2024		2023
Net (loss) income	$	(68,731)	$	(19,500)	$	53,655
Weighted average shares of common stock outstanding:
Basic	73,485		74,434		73,348
Dilutive effect of stock options, restricted stock, and performance stock units	—		—		1,041
Diluted	73,485		74,434		74,389
Loss (earnings) per share:
Basic	$	(0.94)	$	(0.26)	$	0.73
Diluted	$	(0.94)	$	(0.26)	$	0.72

For the years ended December 31, 2025 and 2024, outstanding common stock options, unvested restricted stock, and unvested performance stock units representing 572 and 896 shares, respectively, were excluded from the computation of diluted loss per share. For the year ended December 31, 2023, outstanding common stock options, unvested restricted stock, and unvested performance stock units representing 1,778 shares were excluded from the computation of diluted earnings per share as their inclusion would have been antidilutive.

Accumulated Other Comprehensive Loss

The Company classifies items of other comprehensive income (loss) by their nature and discloses the accumulated balance of other comprehensive income (loss) separately from accumulated deficit and additional paid-in capital in the stockholders’ equity section of the Company's consolidated balance sheets.

The Company has defined the Canadian dollar as the functional currency of the Company's Canadian subsidiary, DNAG, and the Company has defined the Euro as the functional currency of the Company's Belgian subsidiary, Novosanis. The results of operations are translated into U.S. dollars, which is the reporting currency of the Company.

Change in accumulated other comprehensive loss by component is listed below:


	Foreign Currency		Total
Balance at December 31, 2024	$	(24,360)	$	(24,360)
Other comprehensive gain	5,956		5,956
Balance at December 31, 2025	$	(18,404)	$	(18,404)

Recent Accounting Pronouncements

In December 2023, the FASB issued ASU No. 2023-09, Income Taxes (Topic 740), Improvements to Income Tax Disclosures. The purpose of the update was to address investor requests for more transparency about income tax information through improvements to income tax disclosures primarily related to the rate reconciliation and incomes taxes paid information. The amendments in this ASU are effective for annual periods beginning after December 15, 2024. The amendments may be applied prospectively or retrospectively, and early adoption is permitted. Management has implemented on a prospective basis for the year ended December 31, 2025.

In November 2024, the Financial Accounting Standards Board ("FASB") issued Accounting Standard Update ("ASU") No. 2024-03, Income Statement—Reporting Comprehensive Income—Expense Disaggregation Disclosures (Subtopic 220-40), Disaggregation of Income Statement Expenses. The purpose of this update was to require disclosure, in the notes to financial statements, of specified information about certain costs and expenses on a disaggregated basis. The amendments in the ASU are effective for all public business entities for annual periods beginning after December 15, 2026, and interim periods beginning after December 15, 2027, with early adoption permitted. The amendments are to be applied either prospectively to financial statements issued for reporting periods after the effective date of the update or retrospectively to any or all prior periods presented in the financial statements. Management is evaluating the impact on the Company's consolidated financial statements.

In March 2024, the FASB issued ASU No. 2024-01, Compensation—Stock Compensation (Topic 718), Measurement of Credit Losses for Accounts Receivable and Contract Assets. The purpose of this update was to provide illustrative examples to demonstrate how an entity should apply guidance to determine whether profits interests and similar awards should be accounted for in accordance with Topic 718. For public business entities, the amendments in this ASU are effective for fiscal years beginning after December 15, 2024, and interim periods within those fiscal periods. The amendments may be applied prospectively or retrospectively, and early adoption is permitted. Management does not expect an impact on the Company's consolidated financial statements.

In July 2025, the FASB issued ASU No. 2025-05, Financial Instruments—Credit Losses (Topic 326), Scope Application of Profits Interest and Similar Awards. The purpose of this update was to address challenges encountered when applying the guidance in Topic 326, Financial Instruments—Credit Losses, to current accounts receivable and current contract assets arising from transactions accounted for under Topic 606, Revenue from Contracts with Customers illustrative examples to demonstrate how an entity should apply guidance to determine whether profits interests and similar awards should be accounted for in accordance with Topic 718. For all business entities, the amendments in this ASU are effective for fiscal years beginning after December 15, 2025, and interim periods within those fiscal periods. The amendments are applied prospectively, and early adoption is permitted. Management does not expect an impact on the Company's consolidated financial statements.

In September 2025, the FASB issued ASU No. 2025-06, Intangibles—Goodwill and Other—Internal-Use Software (Subtopic 350-40), Targeted Improvements to the Accounting for Internal-Use Software. The purpose of this update was to modernize the accounting for software costs. For all business entities, the amendments in this ASU are effective for fiscal years beginning after December 15, 2027, and interim periods within those fiscal periods. The amendments can be applied prospectively, a modified transition or retrospectively. Early adoption is permitted as of the beginning of an annual reporting period. Management does not expect an impact on the Company's consolidated financial statements.

In December 2025, the FASB issued ASU No. 2025-10, Government Grants (Topic 832), Accounting for Government Grants Received by Business Entities. The purpose of this update was to improve US GAAP by establishing authoritative guidance on the accounting for government grants received by business entities. For public business entities, the amendments in this ASU are effective for annual reporting periods beginning after December 15, 2028, and interim reporting periods within those annual reporting periods. Early adoption is permitted in both interim and annual reporting periods in which financial statements have not yet been issued or made available for issuance. The amendments can be applied under a modified prospective approach, a modified retrospective approach, or a retrospective approach. Management is evaluating the impact on the Company's consolidated financial statements.

In December 2025, the FASB issued ASU No. 2025-11, Interim Reporting (Topic 270), Narrow-Scope Improvements. The purpose of this update was to improve the navigability of the required interim disclosures and clarifying when that guidance is applicable. The update also provides additional guidance on what disclosures should be provided in interim periods and adds a principal that requires entities to disclose events since the end of the last annual reporting period that have a material impact on the entity. For public business entities, the amendments in this ASU are effective for interim

reporting periods within annual reporting periods beginning after December 15, 2027. Early adoption is permitted. The amendments in this update can be applied either prospectively or retrospectively to any or all prior periods presented in the financial statements. Management is evaluating the impact on the Company's consolidated financial statements.

Property, Plant and Equipment (Tables)

12 Months Ended

Dec. 31, 2025

Property, Plant and Equipment [Abstract]

Schedule of Property, Plant and Equipment


	December 31,		December 31,
	2025		2024
Land	$	1,118	$	1,118
Buildings and improvements	39,071		36,152
Machinery and equipment	46,202		51,015
Computer equipment and software	11,101		11,502
Furniture and fixtures	1,632		1,621
Construction in progress	2,931		9,615
	102,055		111,023
Accumulated depreciation	(62,876)		(65,918)
	$	39,179	$	45,105

The Company - Additional Information (Detail)	12 Months Ended
The Company - Additional Information (Detail)	Dec. 31, 2025 segment
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Number of operating segments	2
Number of reportable segments	1

Summary of Significant Accounting Policies - Goodwill Sensitivity Analysis (Details)	12 Months Ended
	Dec. 31, 2025 USD ($)
Discount Rate, 13% Analysis \| Exit Multiple 0.80
Goodwill [Line Items]
Reporting unit, annual impairment, amount	$ 208,132
Discount Rate, 13% Analysis \| Exit Multiple 0.90
Goodwill [Line Items]
Reporting unit, annual impairment, amount	217,464
Discount Rate, 13% Analysis \| Exit Multiple 1.00
Goodwill [Line Items]
Reporting unit, annual impairment, amount	226,796
Discount Rate, 13% Analysis \| Exit Multiple 1.10
Goodwill [Line Items]
Reporting unit, annual impairment, amount	236,128
Discount Rate, 13% Analysis \| Exit Multiple 1.20
Goodwill [Line Items]
Reporting unit, annual impairment, amount	245,460
Discount Rate, 14% Analysis \| Exit Multiple 0.80
Goodwill [Line Items]
Reporting unit, annual impairment, amount	205,252
Discount Rate, 14% Analysis \| Exit Multiple 0.90
Goodwill [Line Items]
Reporting unit, annual impairment, amount	214,254
Discount Rate, 14% Analysis \| Exit Multiple 1.00
Goodwill [Line Items]
Reporting unit, annual impairment, amount	223,256
Discount Rate, 14% Analysis \| Exit Multiple 1.10
Goodwill [Line Items]
Reporting unit, annual impairment, amount	232,258
Discount Rate, 14% Analysis \| Exit Multiple 1.20
Goodwill [Line Items]
Reporting unit, annual impairment, amount	241,259
Discount Rate, 15% Analysis \| Exit Multiple 0.80
Goodwill [Line Items]
Reporting unit, annual impairment, amount	202,501
Discount Rate, 15% Analysis \| Exit Multiple 0.90
Goodwill [Line Items]
Reporting unit, annual impairment, amount	211,188
Discount Rate, 15% Analysis \| Exit Multiple 1.00
Goodwill [Line Items]
Reporting unit, annual impairment, amount	219,875
Discount Rate, 15% Analysis \| Exit Multiple 1.10
Goodwill [Line Items]
Reporting unit, annual impairment, amount	228,562
Discount Rate, 15% Analysis \| Exit Multiple 1.20
Goodwill [Line Items]
Reporting unit, annual impairment, amount	237,249
Discount Rate, 16% Analysis \| Exit Multiple 0.80
Goodwill [Line Items]
Reporting unit, annual impairment, amount	199,868
Discount Rate, 16% Analysis \| Exit Multiple 0.90
Goodwill [Line Items]
Reporting unit, annual impairment, amount	208,254
Discount Rate, 16% Analysis \| Exit Multiple 1.00
Goodwill [Line Items]
Reporting unit, annual impairment, amount	216,640
Discount Rate, 16% Analysis \| Exit Multiple 1.10
Goodwill [Line Items]
Reporting unit, annual impairment, amount	225,025
Discount Rate, 16% Analysis \| Exit Multiple 1.20
Goodwill [Line Items]
Reporting unit, annual impairment, amount	233,411
Discount Rate, 17% Analysis \| Exit Multiple 0.80
Goodwill [Line Items]
Reporting unit, annual impairment, amount	197,339
Discount Rate, 17% Analysis \| Exit Multiple 0.90
Goodwill [Line Items]
Reporting unit, annual impairment, amount	205,436
Discount Rate, 17% Analysis \| Exit Multiple 1.00
Goodwill [Line Items]
Reporting unit, annual impairment, amount	213,533
Discount Rate, 17% Analysis \| Exit Multiple 1.10
Goodwill [Line Items]
Reporting unit, annual impairment, amount	221,630
Discount Rate, 17% Analysis \| Exit Multiple 1.20
Goodwill [Line Items]
Reporting unit, annual impairment, amount	$ 229,726

Summary of Significant Accounting Policies (Tables)

12 Months Ended

Dec. 31, 2025

Accounting Policies [Abstract]

Schedule of Fair Value, Assets and Liabilities


		December 31,		December 31,
	Level	2025		2024
Guaranteed investment certificates	1	$	13,114	$	66,584
Trading securities	1	543		724
Contingent consideration:	3
Current portion		$	18,380	$	—
Long-term portion		9,333		22,910
		$	27,713	$	22,910

Business Combination, Contingent Consideration


	Fair Value
Balance at December 31, 2024	$	22,910
Additions	233
Change in fair value	4,570
Balance at December 31, 2025	$	27,713

Schedule of Accounts Receivable


	December 31,
	2025		2024		2023
Accounts receivable	$	22,203	$	23,816	$	40,171
Allowance for doubtful accounts	$	188	$	774	$	1,216

Goodwill, Sensitivity of Fair Value



	Exit Multiple
Discount Rate	0.80		0.90		1.00		1.10		1.20
13%	$	208,132	$	217,464	$	226,796	$	236,128	$	245,460
14%	205,252		214,254		223,256		232,258		241,259
15%	202,501		211,188		219,875		228,562		237,249
16%	199,868		208,254		216,640		225,025		233,411
17%	197,339		205,436		213,533		221,630		229,726

Disaggregation of Revenue by Product and Geographic Area

The following table represents total net revenues by product line:


	For the Years Ended December 31,
		2025		2024		2023
HIV		$	49,802	$	60,804	$	60,823
Sample Management Solutions (1)		38,356		51,046		54,274
HCV		13,759		14,024		12,871
Other product and services revenues (2)		4,648		3,506		2,265
Risk Assessment Testing (3)		1,866		8,354		9,736
COVID-19 (4)		624		45,172		257,779
Molecular Services		—		1,705		4,474
Net product and services revenues		$	109,055	$	184,611	$	402,222
Non-product and services revenues (5)		5,966		1,216		3,250
Net revenues		$	115,021	$	185,827	$	405,472

(1) Includes Genomics, Microbiome and Colli-Pee® product revenues.

(2) Includes Syphilis revenues.

(3) Includes substance abuse testing product revenues.

(4) Includes COVID-19 Diagnostics and COVID-19 Sample Management Solutions revenues.

(5) Includes funded research and development contracts, royalty income and grant revenues.

The following table represents total net revenues by geographic area, based on the location of the customer:


	For the Years Ended December 31,
		2025		2024		2023
United States		$	78,252	$	139,161	$	361,660
Africa		23,993		32,745		29,254
Europe		7,393		8,424		8,111
Other regions		5,383		5,497		6,447
		$	115,021	$	185,827	$	405,472

Schedules of Concentration of Risk, by Risk Factor

The following table represents customer concentration risk:


	For the Years Ended December 31,
Net Revenues		2025	2024


Non-commercial customer		N/A	24%


		December 31,
Accounts Receivable		2025	2024
Commercial customer		15%	10%

Schedule of Deferred Revenue

The following table represents deferred revenue recognized:


	For the Years Ended December 31,
Deferred Revenue Recognized		2025		2024
Accrued at beginning of year		$	2,484	$	3,680

Schedule of Earnings Per Share, Basic and Diluted


	For the Years Ended December 31,
	2025		2024		2023
Net (loss) income	$	(68,731)	$	(19,500)	$	53,655
Weighted average shares of common stock outstanding:
Basic	73,485		74,434		73,348
Dilutive effect of stock options, restricted stock, and performance stock units	—		—		1,041
Diluted	73,485		74,434		74,389
Loss (earnings) per share:
Basic	$	(0.94)	$	(0.26)	$	0.73
Diluted	$	(0.94)	$	(0.26)	$	0.72

Schedule of Accumulated Other Comprehensive Income (Loss)

Change in accumulated other comprehensive loss by component is listed below:


	Foreign Currency		Total
Balance at December 31, 2024	$	(24,360)	$	(24,360)
Other comprehensive gain	5,956		5,956
Balance at December 31, 2025	$	(18,404)	$	(18,404)

Business Segment Information - Schedule of Additional Significant Segment Expense (Detail) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2025	Dec. 31, 2024	Dec. 31, 2023
Segment Reporting, Revenue Reconciling Item [Line Items]
Share-based compensation	$ 10,147	$ 11,920	$ 10,729
Depreciation and amortization	10,192	10,872	20,936
Cost of products and services sold
Segment Reporting, Revenue Reconciling Item [Line Items]
Share-based compensation	707	734	564
Depreciation and amortization	4,527	6,343	15,311
Research and development
Segment Reporting, Revenue Reconciling Item [Line Items]
Share-based compensation	1,046	839	1,159
Depreciation and amortization	2,081	1,029	1,208
Sales and marketing
Segment Reporting, Revenue Reconciling Item [Line Items]
Share-based compensation	863	1,129	1,181
Depreciation and amortization	80	189	571
General and administrative
Segment Reporting, Revenue Reconciling Item [Line Items]
Share-based compensation	7,531	9,218	7,826
Depreciation and amortization	$ 3,504	$ 3,311	$ 3,846

- Definition

The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.

+ References + Details

Leases - Summary of Supplemental Cash Flow Information Related to Leases (Detail) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2025	Dec. 31, 2024	Dec. 31, 2023
Cash paid for amounts included in the measurement of lease liabilities:
Operating cash flows from operating leases	$ 2,156	$ 1,901	$ 1,863
Operating cash flows from financing leases		22	51
Financing cash flows from financing leases	61	842	1,345
Non-cash activity:
Right-of-use assets obtained in exchange for operating lease obligations	169	4,086	4,363
Right-of-use assets obtained in exchange for finance lease obligations	$ 62	$ 193	$ 334

Subsequent Events	12 Months Ended
Subsequent Events	Dec. 31, 2025
Subsequent Events [Abstract]
Subsequent Events	SUBSEQUENT EVENTS: In February 2026, the Company terminated certain non-production employees, which was less than 10% of its work force. The termination was to align the Company's cost structure.

Business Combinations - Schedule of Pro Forma Financial Information (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2024	Dec. 31, 2023
BioMedomics, Inc
Business Combination [Line Items]
Net revenues	$ 115,797	$ 187,041
Net income loss	(68,964)	(20,889)
Sherlock Biosciences
Business Combination [Line Items]
Net revenues	188,126	406,381
Net income loss	$ (41,459)	$ 7,992

- Definition

Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 350
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 4
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482573/350-20-50-4

Reference 2: http://www.xbrl.org/2003/role/exampleRef
-Topic 805
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 8
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479328/805-10-50-8

Reference 3: http://www.xbrl.org/2003/role/exampleRef
-Topic 805
-SubTopic 10
-Name Accounting Standards Codification
-Section 55
-Paragraph 47
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479303/805-10-55-47

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Topic 805
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 5
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479907/805-20-50-5

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Topic 805
-SubTopic 30
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (f)(1)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479581/805-30-50-1

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Topic 805
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (d)(1)(i)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479907/805-20-50-1

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Topic 805
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (d)(1)(ii)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479907/805-20-50-1

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Topic 805
-SubTopic 30
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (b)(3)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479581/805-30-50-1

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Topic 805
-SubTopic 30
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (b)(1)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479581/805-30-50-1

Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 805
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (d)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479907/805-20-50-1

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Topic 805
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (d)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479328/805-10-50-2

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Topic 805
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479328/805-10-50-2

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Topic 805
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479907/805-20-50-2

Reference 14: http://www.xbrl.org/2003/role/disclosureRef
-Topic 805
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (c)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479328/805-10-50-2

Reference 15: http://www.xbrl.org/2003/role/disclosureRef
-Topic 805
-SubTopic 30
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479581/805-30-50-2

Reference 16: http://www.xbrl.org/2003/role/disclosureRef
-Topic 805
-SubTopic 30
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479581/805-30-50-1

Reference 17: http://www.xbrl.org/2003/role/disclosureRef
-Topic 805
-SubTopic 30
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (f)(2)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479581/805-30-50-1

Reference 18: http://www.xbrl.org/2003/role/disclosureRef
-Topic 805
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (e)(1)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479907/805-20-50-1

Reference 19: http://www.xbrl.org/2003/role/disclosureRef
-Topic 805
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 3
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479328/805-10-50-3

Reference 20: http://www.xbrl.org/2003/role/disclosureRef
-Topic 805
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 4A
-Subparagraph (c)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479907/805-20-50-4A

Reference 21: http://www.xbrl.org/2003/role/disclosureRef
-Topic 805
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 4
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479907/805-20-50-4

Reference 22: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 805
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479907/805-20-50-1

Reference 23: http://www.xbrl.org/2003/role/disclosureRef
-Topic 805
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (b)(1)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479907/805-20-50-1

Reference 24: http://www.xbrl.org/2003/role/disclosureRef
-Topic 805
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (b)(3)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479907/805-20-50-1

Reference 25: http://www.xbrl.org/2003/role/disclosureRef
-Topic 805
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 4A
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479907/805-20-50-4A

Reference 26: http://www.xbrl.org/2003/role/disclosureRef
-Topic 805
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (a)(3)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479907/805-20-50-1

Reference 27: http://www.xbrl.org/2003/role/disclosureRef
-Topic 805
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (a)(2)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479907/805-20-50-1

Reference 28: http://www.xbrl.org/2003/role/disclosureRef
-Topic 805
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 4A
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479907/805-20-50-4A

Reference 29: http://www.xbrl.org/2003/role/disclosureRef
-Topic 805
-SubTopic 30
-Name Accounting Standards Codification
-Section 50
-Paragraph 4
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479581/805-30-50-4

Reference 30: http://www.xbrl.org/2003/role/disclosureRef
-Topic 805
-SubTopic 30
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (b)(4)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479581/805-30-50-1

Reference 31: http://www.xbrl.org/2003/role/disclosureRef
-Topic 805
-SubTopic 30
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (b)(2)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479581/805-30-50-1

Reference 32: http://www.xbrl.org/2003/role/disclosureRef
-Topic 805
-SubTopic 30
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479581/805-30-50-1

Reference 33: http://www.xbrl.org/2003/role/disclosureRef
-Topic 805
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (e)(2)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479907/805-20-50-1

Reference 34: http://www.xbrl.org/2003/role/disclosureRef
-Topic 805
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (c)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479907/805-20-50-1

Reference 35: http://www.xbrl.org/2003/role/disclosureRef
-Topic 805
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (b)(2)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479907/805-20-50-1

Reference 36: http://www.xbrl.org/2003/role/disclosureRef
-Topic 805
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (a)(1)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479907/805-20-50-1

Reference 37: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 805
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (g)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479328/805-10-50-2

Reference 38: http://www.xbrl.org/2003/role/disclosureRef
-Topic 805
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (g)(4)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479328/805-10-50-2

Reference 39: http://www.xbrl.org/2003/role/disclosureRef
-Topic 805
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (g)(3)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479328/805-10-50-2

Reference 40: http://www.xbrl.org/2003/role/disclosureRef
-Topic 805
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (g)(2)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479328/805-10-50-2

Reference 41: http://www.xbrl.org/2003/role/disclosureRef
-Topic 805
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (g)(1)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479328/805-10-50-2

Reference 42: http://www.xbrl.org/2003/role/disclosureRef
-Topic 805
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479328/805-10-50-2

+ Details

Business Segment Information (Tables)

12 Months Ended

Dec. 31, 2025

Segment Reporting [Abstract]

Schedule of Disclosure on Geographic Areas, Long-Lived Assets in Individual Foreign Countries by Country

The following table represents total long-lived assets by geographic area:


	December 31,
	2025		2024
United States	$	36,254	$	40,286
United Kingdom	10,061		12,849
Canada	4,642		5,468
Other regions	364		89
	$	51,321	$	58,692

Schedule of Segment Reporting Information, by Segment

The following table represents reported segment revenues, segment profit (loss), and significant segment expenses:


	For the Years Ended December 31,
		2025		2024		2023
Net revenues		$	115,021	$	185,827	405,472
Cost of products and services sold (3)		66,823		106,437		233,820
Gross profit		48,198		79,390		171,652
Research and development (3)		42,528		26,047		33,728
Sales and marketing (3)		26,117		30,986		36,319
General and administrative (3)		47,677		46,215		58,191
Loss on impairments		—		4,392		10,829
Change in the estimated fair value of acquisition-related contingent consideration		4,570		—		(99)
Gain on sale of assets		(725)		—		—
Operating (loss) income		(71,969)		(28,250)		32,684
Other income (expense) (1)		229		(380)		17,836
Interest revenue		8,078		11,469		5,862
Other segment items (2)		(924)		1,160		(124)
(Loss) income before income taxes and equity investment		(64,586)		(16,001)		56,258
Income tax expense		1,801		1,799		2,603
Loss on equity investment		(2,344)		(1,700)		—
Net (loss) income		$	(68,731)	$	(19,500)	$	53,655

(1) Includes $12.8 million of excess profits recognized on government contracts in 2023.

(2) Includes interest expense and foreign currency gains (losses).

(3) The following tables represent additional significant segment expense categories:


	For the Years Ended December 31,
		2025		2024		2023
Stock-based Compensation
Cost of products and services sold		$	707	734		564
Research and development		1,046		839		1,159
Sales and marketing		863		1,129		1,181
General and administrative		7,531		9,218		7,826
		$	10,147	$	11,920	$	10,729


	For the Years Ended December 31,
		2025		2024		2023
Depreciation and Amortization
Cost of products and services sold		$	4,527	$	6,343	$	15,311
Research and development		2,081		1,029		1,208
Sales and marketing		80		189		571
General and administrative		3,504		3,311		3,846
		$	10,192	$	10,872	$	20,936

Leases - Additional Information (Detail) $ in Millions	3 Months Ended		12 Months Ended
Leases - Additional Information (Detail) $ in Millions	Dec. 31, 2025	Sep. 30, 2025 lease	Dec. 31, 2025	Dec. 31, 2024 USD ($)
Lessee Lease Description [Line Items]
Lessee operating and financing leases, period of options to terminate			1 year
Number of subleases \| lease		2
Sublease, remaining term	1 year
Operating lease, impairment loss				$ 1.2
Finance lease, impairment loss				$ 0.3
Minimum
Lessee Lease Description [Line Items]
Operating and financing leases, remaining lease terms			1 year
Maximum
Lessee Lease Description [Line Items]
Operating and financing leases, remaining lease terms			8 years

Summary of Significant Accounting Policies - Summary Earnings Per Share (Detail) - USD ($) $ / shares in Units, shares in Thousands, $ in Thousands	12 Months Ended
	Dec. 31, 2025	Dec. 31, 2024	Dec. 31, 2023
Net Income (Loss) Available to Common Stockholders, Diluted [Abstract]
Net (loss) income	$ (68,731)	$ (19,500)	$ 53,655
Weighted average shares of common stock outstanding:
Basic	73,485	74,434	73,348
Dilutive effect of stock options, restricted stock, and performance stock units	0	0	1,041
Diluted	73,485	74,434	74,389
Loss (earnings) per share:
Basic earnings per share (in US dollars per share)	$ (0.94)	$ (0.26)	$ 0.73
Diluted earnings per share (in US dollars per share)	$ (0.94)	$ (0.26)	$ 0.72

- Definition

The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 260
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482662/260-10-50-1

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (c)(2)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483443/250-10-50-1

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (c)(1)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483443/250-10-50-1

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 4
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483443/250-10-50-4

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Topic 105
-SubTopic 10
-Name Accounting Standards Codification
-Section 65
-Paragraph 9
-Subparagraph (e)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479343/105-10-65-9

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 65
-Paragraph 17
-Subparagraph (d)(1)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480336/718-10-65-17

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 6
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483443/250-10-50-6

Reference 8: http://www.xbrl.org/2003/role/exampleRef
-Topic 260
-SubTopic 10
-Name Accounting Standards Codification
-Section 55
-Paragraph 52
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482635/260-10-55-52

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Topic 805
-SubTopic 60
-Name Accounting Standards Codification
-Section 65
-Paragraph 1
-Subparagraph (g)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147476176/805-60-65-1

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Topic 740
-SubTopic 323
-Name Accounting Standards Codification
-Section 65
-Paragraph 2
-Subparagraph (g)(3)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147478666/740-323-65-2

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 3
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483443/250-10-50-3

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Topic 260
-SubTopic 10
-Name Accounting Standards Codification
-Section 55
-Paragraph 15
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482635/260-10-55-15

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Topic 815
-SubTopic 40
-Name Accounting Standards Codification
-Section 65
-Paragraph 1
-Subparagraph (e)(4)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480175/815-40-65-1

Reference 14: http://www.xbrl.org/2003/role/disclosureRef
-Topic 815
-SubTopic 40
-Name Accounting Standards Codification
-Section 65
-Paragraph 1
-Subparagraph (f)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480175/815-40-65-1

Reference 15: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 11
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483443/250-10-50-11

Reference 16: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 11
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483443/250-10-50-11

Reference 17: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 7
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483443/250-10-50-7

Reference 18: http://www.xbrl.org/2003/role/disclosureRef
-Topic 260
-SubTopic 10
-Name Accounting Standards Codification
-Section 45
-Paragraph 2
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482689/260-10-45-2

Reference 19: http://www.xbrl.org/2003/role/disclosureRef
-Topic 260
-SubTopic 10
-Name Accounting Standards Codification
-Section 45
-Paragraph 60B
-Subparagraph (d)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B

Reference 20: http://www.xbrl.org/2003/role/disclosureRef
-Topic 260
-SubTopic 10
-Name Accounting Standards Codification
-Section 45
-Paragraph 10
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482689/260-10-45-10

Reference 21: http://www.xbrl.org/2003/role/disclosureRef
-Topic 220
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03(25))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2

Reference 22: http://www.xbrl.org/2003/role/disclosureRef
-Topic 942
-SubTopic 220
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-04(27))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1

Reference 23: http://www.xbrl.org/2003/role/disclosureRef
-Topic 944
-SubTopic 220
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-04(23))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1

Reference 24: http://www.xbrl.org/2003/role/disclosureRef
-Topic 260
-SubTopic 10
-Name Accounting Standards Codification
-Section 45
-Paragraph 7
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482689/260-10-45-7

Reference 25: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 20
-Name Accounting Standards Codification
-Section 65
-Paragraph 4
-Subparagraph (f)(4)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481538/470-20-65-4

+ Details

- Definition

The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 260
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482662/260-10-50-1

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (c)(2)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483443/250-10-50-1

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (c)(1)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483443/250-10-50-1

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 4
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483443/250-10-50-4

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Topic 105
-SubTopic 10
-Name Accounting Standards Codification
-Section 65
-Paragraph 9
-Subparagraph (e)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479343/105-10-65-9

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 65
-Paragraph 17
-Subparagraph (d)(1)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480336/718-10-65-17

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 6
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483443/250-10-50-6

Reference 8: http://www.xbrl.org/2003/role/exampleRef
-Topic 260
-SubTopic 10
-Name Accounting Standards Codification
-Section 55
-Paragraph 52
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482635/260-10-55-52

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Topic 805
-SubTopic 60
-Name Accounting Standards Codification
-Section 65
-Paragraph 1
-Subparagraph (g)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147476176/805-60-65-1

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Topic 740
-SubTopic 323
-Name Accounting Standards Codification
-Section 65
-Paragraph 2
-Subparagraph (g)(3)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147478666/740-323-65-2

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 3
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483443/250-10-50-3

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Topic 260
-SubTopic 10
-Name Accounting Standards Codification
-Section 55
-Paragraph 15
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482635/260-10-55-15

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Topic 815
-SubTopic 40
-Name Accounting Standards Codification
-Section 65
-Paragraph 1
-Subparagraph (e)(4)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480175/815-40-65-1

Reference 14: http://www.xbrl.org/2003/role/disclosureRef
-Topic 815
-SubTopic 40
-Name Accounting Standards Codification
-Section 65
-Paragraph 1
-Subparagraph (f)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480175/815-40-65-1

Reference 15: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 11
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483443/250-10-50-11

Reference 16: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 11
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483443/250-10-50-11

Reference 17: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 7
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483443/250-10-50-7

Reference 18: http://www.xbrl.org/2003/role/disclosureRef
-Topic 260
-SubTopic 10
-Name Accounting Standards Codification
-Section 45
-Paragraph 2
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482689/260-10-45-2

Reference 19: http://www.xbrl.org/2003/role/disclosureRef
-Topic 260
-SubTopic 10
-Name Accounting Standards Codification
-Section 45
-Paragraph 60B
-Subparagraph (d)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B

Reference 20: http://www.xbrl.org/2003/role/disclosureRef
-Topic 220
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03(25))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2

Reference 21: http://www.xbrl.org/2003/role/disclosureRef
-Topic 942
-SubTopic 220
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-04(27))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1

Reference 22: http://www.xbrl.org/2003/role/disclosureRef
-Topic 944
-SubTopic 220
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-04(23))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1

Reference 23: http://www.xbrl.org/2003/role/disclosureRef
-Topic 260
-SubTopic 10
-Name Accounting Standards Codification
-Section 45
-Paragraph 7
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482689/260-10-45-7

Reference 24: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 20
-Name Accounting Standards Codification
-Section 65
-Paragraph 4
-Subparagraph (f)(4)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481538/470-20-65-4

+ Details

- Definition

The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.

+ References

Reference 1: http://www.xbrl.org/2003/role/exampleRef
-Topic 946
-SubTopic 830
-Name Accounting Standards Codification
-Section 55
-Paragraph 10
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479168/946-830-55-10

Reference 2: http://www.xbrl.org/2003/role/exampleRef
-Topic 220
-SubTopic 40
-Name Accounting Standards Codification
-Section 55
-Paragraph 4
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147476153/220-40-55-4

Reference 3: http://www.xbrl.org/2003/role/exampleRef
-Topic 220
-SubTopic 40
-Name Accounting Standards Codification
-Section 55
-Paragraph 21
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147476153/220-40-55-21

Reference 4: http://www.xbrl.org/2003/role/exampleRef
-Topic 220
-SubTopic 40
-Name Accounting Standards Codification
-Section 55
-Paragraph 14
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147476153/220-40-55-14

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Topic 235
-SubTopic 10
-Name Accounting Standards Codification
-Section S50
-Paragraph 1
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Topic 235
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(g)(1)(i))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Topic 235
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(k)(2))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Topic 825
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 28
-Subparagraph (f)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482907/825-10-50-28

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 4
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483443/250-10-50-4

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Topic 480
-SubTopic 10
-Name Accounting Standards Codification
-Section S50
-Paragraph 3
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479857/480-10-S50-3

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Topic 480
-SubTopic 10
-Name Accounting Standards Codification
-Section S45
-Paragraph 3
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479887/480-10-S45-3

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Topic 480
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 3A
-Subparagraph (24)(d)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480244/480-10-S99-3A

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Topic 105
-SubTopic 10
-Name Accounting Standards Codification
-Section 65
-Paragraph 9
-Subparagraph (e)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479343/105-10-65-9

Reference 14: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 65
-Paragraph 17
-Subparagraph (d)(1)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480336/718-10-65-17

Reference 15: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 6
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483443/250-10-50-6

Reference 16: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 9
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483443/250-10-50-9

Reference 17: http://www.xbrl.org/2003/role/disclosureRef
-Topic 805
-SubTopic 60
-Name Accounting Standards Codification
-Section 65
-Paragraph 1
-Subparagraph (g)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147476176/805-60-65-1

Reference 18: http://www.xbrl.org/2003/role/disclosureRef
-Topic 740
-SubTopic 323
-Name Accounting Standards Codification
-Section 65
-Paragraph 2
-Subparagraph (g)(3)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147478666/740-323-65-2

Reference 19: http://fasb.org/us-gaap/role/ref/legacyRef
-Topic 220
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03(20))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2

Reference 20: http://www.xbrl.org/2003/role/disclosureRef
-Topic 235
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(g)(1)(ii))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1

Reference 21: http://www.xbrl.org/2003/role/disclosureRef
-Topic 323
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 3
-Subparagraph (c)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481687/323-10-50-3

Reference 22: http://www.xbrl.org/2003/role/disclosureRef
-Topic 220
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 6
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482765/220-10-50-6

Reference 23: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 3
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483443/250-10-50-3

Reference 24: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (b)(2)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483443/250-10-50-1

Reference 25: http://www.xbrl.org/2003/role/disclosureRef
-Topic 815
-SubTopic 40
-Name Accounting Standards Codification
-Section 65
-Paragraph 1
-Subparagraph (f)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480175/815-40-65-1

Reference 26: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 8
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483443/250-10-50-8

Reference 27: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 11
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483443/250-10-50-11

Reference 28: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 11
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483443/250-10-50-11

Reference 29: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 220
-Name Accounting Standards Codification
-Section 45
-Paragraph 7
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479105/946-220-45-7

Reference 30: http://www.xbrl.org/2003/role/disclosureRef
-Topic 944
-SubTopic 220
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-04(18))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1

Reference 31: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 220
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.6-07(9))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1

Reference 32: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 220
-Name Accounting Standards Codification
-Section S99
-Paragraph 3
-Subparagraph (SX 210.6-09(1)(d))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3

Reference 33: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(i))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A

Reference 34: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(ii))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A

Reference 35: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(iii)(A))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A

Reference 36: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(iv))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A

Reference 37: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(5))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A

Reference 38: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(i))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B

Reference 39: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(iii)(A))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B

Reference 40: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(iii)(B))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B

Reference 41: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(iv))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B

Reference 42: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(5))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B

Reference 43: http://www.xbrl.org/2003/role/disclosureRef
-Topic 260
-SubTopic 10
-Name Accounting Standards Codification
-Section 45
-Paragraph 60B
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B

Reference 44: http://www.xbrl.org/2003/role/disclosureRef
-Topic 205
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 7
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483499/205-20-50-7

Reference 45: http://fasb.org/us-gaap/role/ref/legacyRef
-Topic 230
-SubTopic 10
-Name Accounting Standards Codification
-Section 45
-Paragraph 28
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482740/230-10-45-28

Reference 46: http://www.xbrl.org/2003/role/disclosureRef
-Topic 220
-SubTopic 10
-Name Accounting Standards Codification
-Section 45
-Paragraph 1A
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A

Reference 47: http://www.xbrl.org/2003/role/disclosureRef
-Topic 220
-SubTopic 10
-Name Accounting Standards Codification
-Section 45
-Paragraph 1B
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B

Reference 48: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 20
-Name Accounting Standards Codification
-Section 65
-Paragraph 4
-Subparagraph (f)(4)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481538/470-20-65-4

Reference 49: http://fasb.org/us-gaap/role/ref/legacyRef
-Topic 942
-SubTopic 220
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-04(22))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1

+ Details

Leases

12 Months Ended

Dec. 31, 2025

Lessee Disclosure [Abstract]

Leases

LEASES:

The Company determines whether an arrangement is a lease at inception. The Company has operating and finance leases for corporate offices, warehouse space and equipment (including vehicles). As of December 31, 2025, the Company is the lessee in all lease agreements. The Company's leases have remaining lease terms of one to eight years, some of which include options to extend the leases based on agreed upon terms, and some of which include options to terminate the leases within one year.

The Company also subleased two of its leased corporate offices. One of the subleases was terminated during the third quarter of 2025 as the Company exited the head lease agreement. The Company's remaining sublease has a remaining term of approximately one year. The Company presents the operating right-of-use asset amortization and the change in operating lease liabilities on the other non-cash amortization line item of the consolidated statements of cash flows.

As most of the Company's leases do not provide an implicit rate, the Company uses its incremental borrowing rate based on the information available at the lease commencement date in determining the present value of lease payments.

The Company has lease agreements that contain both lease and non-lease components (e.g., common-area maintenance). For these agreements, the Company accounts for lease components separately from non-lease components.

During the first quarter of 2024, the Company identified a triggering event to test for the recoverability of all the ROU assets of both the Diversigen and Novosanis subsidiaries, given the Company's decision to initiate a strategic plan to transition away from the microbiome molecular sequencing services business and close its Belgian operations. The Company performed an undiscounted cash flow analysis and determined the carrying values of the ROU assets could not be recovered through the sum of the undiscounted future cash flows and were impaired. During the year ended December 31, 2024 the Company recognized aggregate pre-tax impairment charges of $1.2 million and $0.3 million to its operating and finance ROU assets, respectively. These charges are reported in the Company's consolidated statement of operations.

The components of lease expense are as follows:


	For the Years Ended December 31,
	2025		2024		2023
Operating lease cost	$	2,285	$	1,729	$	2,407
Variable and short-term lease cost	37		549		381
Sublease income	(161)		(151)		(155)
Finance lease cost:
Amortization of right-of use assets	61		331		1,091
Interest on lease liabilities	8		22		51
Total finance lease cost	69		353		1,142
Total lease cost	$	2,230	$	2,480	$	3,775

Supplemental cash flow information related to leases is as follows:


	For the Years Ended December 31,
	2025		2024		2023
Cash paid for amounts included in the measurement of lease liabilities:
Operating cash flows from operating leases	$	2,156	$	1,901	$	1,863
Operating cash flows from financing leases	8		22		51
Financing cash flows from financing leases	61		842		1,345
Non-cash activity:
Right-of-use assets obtained in exchange for operating lease obligations	169		4,086		4,363
Right-of-use assets obtained in exchange for finance lease obligations	62		193		334

Supplemental balance sheet information related to leases is as follows:


	December 31,
	2025		2024














Weighted Average Remaining Lease Term
Weighted-average remaining lease term — operating leases	6.70 years		7.57 years
Weighted-average remaining lease term — finance leases	2.70 years		3.74 years

Weighted Average Discount Rate
Weighted-average discount rate — operating leases	4.48	%	4.44	%
Weighted-average discount rate — finance leases	5.10	%	4.82	%

As of December 31, 2025, minimum lease payments by period are expected to be as follows:


	Finance		Operating
2026	$	70	$	2,548
2027	65		2,287
2028	34		2,157
2029	6		2,097
2030	—		2,106
Thereafter	—		3,778
Total minimum lease payments	175		14,973
Less: imputed interest	(12)		(1,939)
Present value of lease liabilities	$	163	$	13,034

Summary of Significant Accounting Policies - Contingent Consideration (Details) - USD ($) $ in Thousands	9 Months Ended	12 Months Ended
	Sep. 30, 2025	Dec. 31, 2025	Dec. 31, 2024	Dec. 31, 2023
Business Combination, Contingent Consideration [Line Items]
Change in the estimated fair value of acquisition-related contingent consideration		$ 4,570	$ 0	$ (99)
Sherlock Biosciences
Business Combination, Contingent Consideration [Line Items]
Beginning balance		22,910
Additions		233
Change in the estimated fair value of acquisition-related contingent consideration	$ 4,600	4,570
Ending balance		$ 27,713	$ 22,910

- Definition

Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.

+ References + Details

Goodwill and Other Intangible Assets - Summary of Intangible Assets (Detail) - USD ($) $ in Thousands	Dec. 31, 2025	Dec. 31, 2024
Finite-Lived Intangible Assets [Line Items]
Gross	$ 29,226	$ 32,848
Accumulated Amortization	(27,180)	(32,413)
Net	2,046	435
Gross	46,226	49,848
Net	19,046	17,435
IPR&D Technology
Finite-Lived Intangible Assets [Line Items]
Indefinite-lived intangible assets	$ 17,000	$ 17,000
Minimum
Finite-Lived Intangible Assets [Line Items]
Amortization Period (Years)	5 years
Maximum
Finite-Lived Intangible Assets [Line Items]
Amortization Period (Years)	15 years
Customer relationships
Finite-Lived Intangible Assets [Line Items]
Amortization Period (Years)	10 years	10 years
Gross	$ 9,134	$ 10,858
Accumulated Amortization	(9,134)	(10,858)
Net	$ 0	$ 0
Patents and product rights
Finite-Lived Intangible Assets [Line Items]
Amortization Period (Years)	5 years	5 years
Gross	$ 7,596	$ 7,495
Accumulated Amortization	(7,596)	(7,399)
Net	0	96
Developed technology
Finite-Lived Intangible Assets [Line Items]
Gross	8,995	10,169
Accumulated Amortization	(7,095)	(10,169)
Net	$ 1,900	$ 0
Developed technology \| Minimum
Finite-Lived Intangible Assets [Line Items]
Amortization Period (Years)	7 years	7 years
Developed technology \| Maximum
Finite-Lived Intangible Assets [Line Items]
Amortization Period (Years)	15 years	10 years
Trade names
Finite-Lived Intangible Assets [Line Items]
Gross	$ 3,501	$ 4,327
Accumulated Amortization	(3,355)	(3,988)
Net	$ 146	$ 339
Trade names \| Minimum
Finite-Lived Intangible Assets [Line Items]
Amortization Period (Years)	5 years	5 years
Trade names \| Maximum
Finite-Lived Intangible Assets [Line Items]
Amortization Period (Years)	15 years	15 years

Inventories - Schedule of Inventories (Detail) - USD ($) $ in Thousands	Dec. 31, 2025	Dec. 31, 2024
Inventory Disclosure [Abstract]
Raw materials	$ 14,831	$ 17,002
Work in process	56	420
Semi-finished goods	1,965	2,890
Finished goods	14,208	13,885
Total	$ 31,060	$ 34,197

Goodwill and Other Intangible Assets - Schedule of Changes in Goodwill (Detail) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2025	Dec. 31, 2024
Goodwill [Roll Forward]
Beginning balance	$ 40,330	$ 35,696
Acquisition	1,775	6,388
Change related to foreign currency translation	1,258	(1,754)
Ending balance	43,363	40,330
Diagnostics
Goodwill [Roll Forward]
Beginning balance	6,388	0
Acquisition	1,775	6,388
Change related to foreign currency translation	0	0
Ending balance	8,163	6,388
Collection Device
Goodwill [Roll Forward]
Beginning balance	33,942	35,696
Acquisition	0	0
Change related to foreign currency translation	1,258	(1,754)
Ending balance	$ 35,200	$ 33,942

- Definition

Amount, after accumulated impairment loss, of asset representing future economic benefit arising from other asset acquired in business combination or from joint venture formation or both, that is not individually identified and separately recognized.

+ References

Reference 1: http://www.xbrl.org/2003/role/exampleRef
-Topic 350
-SubTopic 20
-Name Accounting Standards Codification
-Section 55
-Paragraph 24
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482548/350-20-55-24

Reference 2: http://www.xbrl.org/2003/role/exampleRef
-Topic 805
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 8
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479328/805-10-50-8

Reference 3: http://www.xbrl.org/2003/role/exampleRef
-Topic 805
-SubTopic 10
-Name Accounting Standards Codification
-Section 55
-Paragraph 41
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479303/805-10-55-41

Reference 4: http://www.xbrl.org/2003/role/exampleRef
-Topic 805
-SubTopic 740
-Name Accounting Standards Codification
-Section 55
-Paragraph 13
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147478064/805-740-55-13

Reference 5: http://www.xbrl.org/2003/role/exampleRef
-Topic 805
-SubTopic 10
-Name Accounting Standards Codification
-Section 55
-Paragraph 39
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479303/805-10-55-39

Reference 6: http://www.xbrl.org/2003/role/exampleRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 55
-Paragraph 49
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482785/280-10-55-49

Reference 7: http://www.xbrl.org/2003/role/exampleRef
-Topic 820
-SubTopic 10
-Name Accounting Standards Codification
-Section 55
-Paragraph 100
-Subparagraph (d)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482078/820-10-55-100

Reference 8: http://www.xbrl.org/2003/role/exampleRef
-Topic 852
-SubTopic 10
-Name Accounting Standards Codification
-Section 55
-Paragraph 10
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481372/852-10-55-10

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Topic 210
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(15))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Topic 350
-SubTopic 20
-Name Accounting Standards Codification
-Section 45
-Paragraph 1
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482598/350-20-45-1

Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 350
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482573/350-20-50-1

Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 350
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (h)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482573/350-20-50-1

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Topic 942
-SubTopic 210
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-03(10)(1))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1

Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 805
-SubTopic 30
-Name Accounting Standards Codification
-Section 50
-Paragraph 4
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479581/805-30-50-4

+ Details

Government Capital Contracts - Additional Information (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2025	Dec. 31, 2024	Dec. 31, 2023	Oct. 31, 2023	Sep. 30, 2022
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Government capital contracts funding amount		$ 109,000			$ 109,000
Percentage withheld under government contracts subject to validation testing				15.00%
Net revenues	$ 115,021	185,827	$ 405,472
Other Income
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Net revenues	$ 115,021	185,827	$ 405,472
Revenue in excess of guaranteed profit		12,800
Other Income \| Government Contract
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Net revenues		2,800
Research and Development Expenses and Other Income \| Government Contract
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Reimbursement of engineering cost		$ 2,000

- Definition

+ References

Reference 1: http://www.xbrl.org/2003/role/exampleRef
-Topic 220
-SubTopic 40
-Name Accounting Standards Codification
-Section 55
-Paragraph 4
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147476153/220-40-55-4

Reference 2: http://www.xbrl.org/2003/role/exampleRef
-Topic 220
-SubTopic 40
-Name Accounting Standards Codification
-Section 55
-Paragraph 14
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147476153/220-40-55-14

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 41
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-41

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 42
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-42

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Topic 606
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 7
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479806/606-10-50-7

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Topic 270
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (i)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482964/270-10-50-1

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 32
-Subparagraph (ee)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-32

Reference 8: http://fasb.org/us-gaap/role/ref/otherTransitionRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 32
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-32

Reference 9: http://fasb.org/us-gaap/role/ref/otherTransitionRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 32
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-32

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Topic 924
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SAB Topic 11.L)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479941/924-10-S99-1

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Topic 606
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 5
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479806/606-10-50-5

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 30
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-30

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 22
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-22

Reference 14: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 40
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-40

Reference 15: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 22
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-22

Reference 16: http://www.xbrl.org/2003/role/disclosureRef
-Topic 606
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 4
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479806/606-10-50-4

+ Details

Termination Benefits

12 Months Ended

Dec. 31, 2025

Termination Benefits [Abstract]

Termination Benefits

TERMINATION BENEFITS:

2023 Reduction in Workforce

During the first and second quarters of 2023, the Company executed a reduction in workforce. This was accounted for pursuant to ASC 420, Exit or Disposal Cost Obligations. The charges for termination benefits included in the Company's consolidated statements of operations are as follows:


	For the Year Ended December 31,
	2023
Cost of products and services sold	$	369
Research and development	566
Sales and marketing	1,543
General and administrative	787
	$	3,265

As of December 31, 2024 the Company had fully paid the $3.3 million related to the reduction in workforce. This reduction in workforce was completed by June 30, 2024.

Q1 2024 Reduction in Workforce

During the first quarter of 2024, the Company executed a reduction in workforce largely affecting its COVID-19 manufacturing workforce. The charges for termination benefits included in the Company's consolidated statement of operations are as follows:


	For the Year Ended December 31,
	2024
Cost of products and services sold	$	231
Research and development	87
Sales and marketing	69
General and administrative	17
	$	404

As of December 31, 2024, the Company had fully paid the $0.4 million related to the reduction in workforce. This reduction in workforce was completed by December 31, 2024.

Q2 2024 Reduction in Workforce

During the second quarter of 2024, the Company executed an additional reduction in workforce as the Company notified employees of its intention to consolidate its Novosanis site in Belgium into other locations by the end of December 31, 2024, discontinue the Diversigen molecular services line of business by the end of June 30, 2024, and consolidate facilities by bringing third-party manufacturing activities into its Pennsylvania facilities by the end of the third quarter of 2025. The charges for termination benefits included in the Company's consolidated statements of operations are as follows:


	For the Year Ended December 31,
	2024
Cost of products and services sold	$	889
Research and development	478
Sales and marketing	125
General and administrative	160
	$	1,652

As of December 31, 2025 the Company had $0.1 million accrued and had paid $1.5 million related to the reduction in workforce. No additional expenses were incurred during the year ended December 31, 2025. The Company expects this reduction in workforce to be completed by March 2026.

Q3 2024 Reduction in Workforce

During the third quarter of 2024, the Company executed a reduction in workforce largely as the Company notified certain employees of its intention to discontinue its risk assessment business. Additional employees were notified in the fourth quarter of 2024. The charges for termination benefits included in the Company's consolidated statements of operations are as follows:


	For the Year Ended December 31,
	2024
Cost of products and services sold	$	246
Research and development	33
Sales and marketing	782
General and administrative	141
	$	1,202

As of December 31, 2025 the Company had $0.1 million accrued and had paid $1.1 million related to the reduction in workforce. No additional expense was incurred during the year ended December 31, 2025. The Company expects this reduction in workforce to be completed by September 2026.

Business Combinations - Schedule of Purchase Price (Detail) - USD ($) $ in Thousands	Nov. 12, 2025	Dec. 19, 2024	Dec. 31, 2025	Dec. 31, 2024
BioMedomics, Inc
Business Combination [Line Items]
Purchase price	$ 2,865
Transaction expenses	403
Debt paid off	330
Earnout contingent consideration	325
Expense fund	40
Estimated fair value of contingent consideration	233
Initial aggregate purchase price	3,963
BioMedomics, Inc \| Milestone Payments
Business Combination [Line Items]
Estimated fair value of contingent consideration	$ 300
Sherlock Biosciences
Business Combination [Line Items]
Purchase price		$ 5,000
Earnout contingent consideration			$ 27,713	$ 22,910
Estimated fair value of contingent consideration		22,910
Fair value of the royalty fee acquisition-related contingent consideration		7,000
Legal Fees		389
Insurance Policy Expense		50
Initial aggregate purchase price		28,349
Sherlock Biosciences \| Milestone Payments
Business Combination [Line Items]
Estimated fair value of contingent consideration		$ 15,910

Document and Entity Information - USD ($)	12 Months Ended
Document and Entity Information - USD ($)	Dec. 31, 2025	Feb. 28, 2026	Jun. 30, 2025
Cover [Abstract]
Document Type	10-K
Document Annual Report	true
Current Fiscal Year End Date	--12-31
Document Period End Date	Dec. 31, 2025
Document Transition Report	false
Entity File Number	001-16537
Entity Registrant Name	ORASURE TECHNOLOGIES, INC
Entity Incorporation, State or Country Code	DE
Entity Tax Identification Number	36-4370966
Entity Address, Address Line One	220 East First Street
Entity Address, City or Town	Bethlehem
Entity Address, State or Province	PA
Entity Address, Postal Zip Code	18015
City Area Code	610
Local Phone Number	882-1820
Title of 12(b) Security	Common Stock, $0.000001 par value per share
Trading Symbol	OSUR
Security Exchange Name	NASDAQ
Entity Well-known Seasoned Issuer	No
Entity Voluntary Filers	No
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Accelerated Filer
Entity Small Business	false
Entity Emerging Growth Company	false
ICFR Auditor Attestation Flag	true
Document Financial Statement Error Correction [Flag]	false
Entity Shell Company	false
Entity Public Float			$ 218,472,693
Entity Common Stock, Shares Outstanding		69,126,173
Documents Incorporated by Reference	Part III of this Annual Report on Form 10-K will be incorporated by reference from certain portions of the Registrant's Definitive Proxy Statement for its 2026 Annual Meeting of Shareholders, or will be included in an amendment hereto, to be filed not later than 120 days after the close of the fiscal year ended December 31, 2025. Except with respect to information specifically incorporated by reference in the Annual Report on Form 10-K, the Definitive Proxy Statement is not deemed to be filed as part hereof.
Amendment Flag	false
Entity Central Index Key	0001116463
Document Fiscal Year Focus	2025
Document Fiscal Period Focus	FY

Summary of Significant Accounting Policies - Contraction Risk (Details) - Customer Concentration Risk	3 Months Ended	12 Months Ended
	Mar. 31, 2025	Dec. 31, 2025
Net Consolidated Revenue \| Non-commercial customer
Product Information [Line Items]
Percentage of concentration risk		24.00%
Accounts Receivable \| Commercial customer
Product Information [Line Items]
Percentage of concentration risk	10.00%	15.00%

- Definition

For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the "benchmark" (or denominator) in the equation, this concept represents the concentration percentage derived from the division.

+ References + Details

Stockholders' Equity

12 Months Ended

Dec. 31, 2025

Share-Based Payment Arrangement [Abstract]

Stockholders' Equity

STOCKHOLDERS' EQUITY:

Stock-Based Awards

The Company grants stock-based awards under the OraSure Technologies, Inc. Stock Award Plan, as amended (the “Stock Plan”). The Stock Plan permits stock-based awards to employees, outside directors and consultants or other third-party advisors. Awards which may be granted under the Stock Plan include qualified incentive stock options, nonqualified stock options, stock appreciation rights, restricted awards, performance awards and other stock-based awards.

As of December 31, 2025, 5,959 shares were available for future grants under the Stock Plan.

Under the terms of the Stock Plan, nonqualified stock options may be granted to eligible employees, including the Company's officers at a price not less than 75 percent of the fair market value of a share of common stock on the date of grant. The option term and vesting schedule of such awards may be either unlimited or have a specified period in which to vest and be exercised. To date, options generally have been granted with ten-year exercise periods and an exercise price not less than the fair market value on the date of grant. Options generally vest over four years, with one quarter of the options vesting one year after grant and the remainder vesting on a monthly basis over the next three years.

The fair value of each stock option was estimated on the date of the grant using the Black-Scholes option-pricing model using the following weighted-average assumptions:


	For the Years Ended December 31,
Black-Scholes Option Valuation Assumptions	2025		2024		2023
Risk-free interest rate (1)	4.04	%	4.14	%	4.23	%
Expected dividend yield	—		—		—
Expected stock price volatility (2)	53	%	53	%	51	%
Expected life of stock options (in years) (2)	6		5		5

(1)Based on the constant maturity interest rate of U.S. Treasury securities whose term is consistent with the expected life of the Company's stock options.

(2)Based upon historical experience.

The weighted-average grant date fair value of stock options granted during the years ended December 31, 2025, 2024, and 2023 was $3.43, $3.68 and $3.24, respectively.

Compensation expense recognized in the financial statements related to stock options was $1.6 million, $1.4 million, and $1.3 million for the years ended December 31, 2025, 2024, and 2023, respectively.

The aggregate intrinsic value of options exercised during the years ended December 31, 2025, 2024, and 2023 (the amount by which the market price of the stock on the date of exercise exceeded the exercise price) was $0.0 thousand, $38.4 thousand, and $43.0 thousand, respectively.

The following table summarizes the stock option activity under the Stock Plan:


	Options	Weighted- Average Exercise Price Per Share		Weighted- Average Remaining Contractual Term (in years)	Aggregate Intrinsic Value
Outstanding on January 1, 2025	2,237	$	8.73
Granted	1,393	3.43
Exercised	—	—
Expired	(132)	9.02
Forfeited	(119)	4.72
Outstanding on December 31, 2025	3,379	$	6.68	6.97	$	—
Vested or expected to vest as of December 31, 2025	3,376	$	6.67	5.00	$	—
Exercisable on December 31, 2025	1,655	$	9.24	5.00	$	—

As of December 31, 2025, there was $3.2 million of unrecognized compensation expense related to unvested option awards that is expected to be recognized over a weighted-average period of 2.6 years.

Net cash proceeds from the exercise of stock options were $— million, $0.2 million and $0.3 million for the years ended December 31, 2025, 2024, and 2023, respectively. As a result of the Company's net operating loss carryforward position, no actual income tax benefit was realized from stock option exercises for these periods.

The following table summarizes information about stock options outstanding as of December 31, 2025:


Options Outstanding					Options Exercisable
Range of Exercise Prices	Number Outstanding	Weighted- Average Remaining Contractual Term (in years)	Weighted- Average Exercise Price Per Share		Number Exercisable	Weighted- Average Exercise Price Per Share
$2.46 - $6.56	1,855	8.40	$	4.17	382	$	6.00
$7.13 - $10.69	1,157	5.86	7.84		907	8.00
$12.90 - $19.35	324	3.42	14.89		324	14.89
$21.64 - $32.46	43	2.03	$	21.65	43	$	21.65
	3,379	6.97	$	6.67	1,656	$	9.24

The Stock Plan also permits the Company to grant restricted shares and restricted units of the Company's common stock to eligible employees, including officers, and the Company's outside directors. Generally, these shares or units are nontransferable until vested and are subject to vesting requirements and/or forfeiture, as determined by the Company's Compensation Committee or Board of Directors. The market value of these shares and units at the date of grant is recognized on a straight-line basis over the period during which the vesting restrictions lapse. Compensation cost of $6.1 million, $6.9 million and $7.6 million related to restricted shares was recognized during the years ended December 31, 2025, 2024, and 2023, respectively.

The following table summarizes restricted stock award and restricted stock units activity under the Stock Plan:


	Units	Weighted- Average Grant Date Fair Value
Issued and unvested, January 1, 2025	1,694	$	6.60
Granted	2,226	3.25
Vested	(1,128)	6.05
Forfeited	(182)	4.55
Issued and unvested, December 31, 2025	2,610	$	4.13
Issued and expected to vest, December 31, 2025	2,610	$	4.13

As of December 31, 2025, there was $6.3 million of unrecognized compensation expense related to unvested restricted stock awards and unvested restricted stock units that is expected to be recognized over a weighted average period of 1.7 years.

In connection with the vesting of restricted shares during the years ended December 31, 2025, 2024, and 2023, the Company purchased and immediately retired 363, 617 and 262 shares with aggregate values of $1.2 million, $3.4 million and $1.4 million, respectively, in satisfaction of minimum tax withholding and exercise obligations.

The Company grants performance-based restricted stock units (“PSUs”) to certain executives. Vesting of these PSUs is dependent upon achievement of certain performance-based metrics during a three-year period, from the date of grant. Assuming achievement of each performance-based metric, the executive must also generally remain in the Company's service for three years from the grant date. Performance shares were granted based on the achievement of three-year cumulative revenue metrics with a market-based condition, or a total shareholder return modifier. PSUs are converted into shares of the Company's common stock once vested and the number of shares actually earned at the end of the performance period will vary, based on actual performance, from 0% to 150% of the target number of performance share units granted. Upon grant of the PSUs, the Company recognizes compensation expense related to these awards based on assumptions as to what percentage of each target will be achieved. The Company evaluates these target assumptions on a quarterly basis and adjusts compensation expense related to these awards, as appropriate.

Compensation cost of $2.4 million, $3.6 million and $1.8 million related to the PSUs was recognized during the years ended December 31, 2025, 2024, and 2023, respectively.

The following table summarizes PSU activity under the Stock Plan:


	Units	Weighted- Average Grant Date Fair Value
Issued and unvested, January 1, 2025	1,454	$	7.19
Granted (1)	1,009	4.30
Performance adjustment (2)	12	N/A
Vested	(513)	5.18
Forfeited	(181)	5.93
Issued and unvested, December 31, 2025	1,781	$	6.24
Issued and expected to vest, December 31, 2025	1,781	$	6.24

(1)Grant activity for all PSUs disclosed at target.

(2)Reflects the performance adjustment based on actual performance measured at the end of the performance period.

As of December 31, 2025, there was $3.7 million of unrecognized compensation expense related to unvested performance stock units that is expected to be recognized over a weighted average period of 1.9 years.

In connection with the vesting of performance stock units during the year ended December 31, 2025, 2024 and 2023, the Company purchased and immediately retired 201, 23, and 86 shares with aggregate values of $0.6 million, $0.2 million and $0.5 million, respectively.

Stock Repurchase Program

In March 2025, the Company's Board of Directors approved a stock repurchase program effective March 21, 2025, whereby the Company may purchase up to $40.0 million in shares of its common stock over a period of up to two years. The amount and timing of share repurchases under the program may be carried out at the discretion of the Company's management through various methods in compliance with applicable state and federal laws. For the year ended December 31, 2025, 5.3 million shares, totaling $15.0 million, were purchased and retired.

- Definition

The entire disclosure for equity.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 815
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 8A
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480434/815-10-50-8A

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 13
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481112/505-10-50-13

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 13
-Subparagraph (h)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481112/505-10-50-13

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 14
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481112/505-10-50-14

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 235
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147477968/946-235-50-2

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 235
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (d)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147477968/946-235-50-2

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 505
-Name Accounting Standards Codification
-Section 50
-Paragraph 6
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147478448/946-505-50-6

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Topic 815
-SubTopic 40
-Name Accounting Standards Codification
-Section 50
-Paragraph 6
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480237/815-40-50-6

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.3-04)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1

Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef
-Topic 505
-Name Accounting Standards Codification
-Publisher FASB
-URI https://asc.fasb.org/505/tableOfContent

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 13
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481112/505-10-50-13

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 13
-Subparagraph (g)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481112/505-10-50-13

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 13
-Subparagraph (i)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481112/505-10-50-13

Reference 14: http://www.xbrl.org/2003/role/disclosureRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 14
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481112/505-10-50-14

Reference 15: http://www.xbrl.org/2003/role/disclosureRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 14
-Subparagraph (c)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481112/505-10-50-14

Reference 16: http://www.xbrl.org/2003/role/disclosureRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 16
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481112/505-10-50-16

Reference 17: http://www.xbrl.org/2003/role/disclosureRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 18
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481112/505-10-50-18

Reference 18: http://www.xbrl.org/2003/role/disclosureRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 18
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481112/505-10-50-18

Reference 19: http://www.xbrl.org/2003/role/disclosureRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 18
-Subparagraph (d)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481112/505-10-50-18

+ Details

Stockholders' Equity - Summary of Company's Stock Option Activity (Detail) $ / shares in Units, shares in Thousands, $ in Thousands	12 Months Ended
	Dec. 31, 2025 USD ($) $ / shares shares
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding [Roll Forward]
Beginning balance (in shares) \| shares	2,237
Granted (in shares) \| shares	1,393
Exercised (in shares) \| shares	0
Expired (in shares) \| shares	(132)
Forfeited (in shares) \| shares	(119)
Ending balance (in shares) \| shares	3,379
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]
Vested or expected to vest (in shares) \| shares	3,376
Exercisable (in shares) \| shares	1,655
Beginning balance (in US dollars per share) \| $ / shares	$ 8.73
Granted (in US dollars per share) \| $ / shares	3.43
Exercised (in US dollars per share) \| $ / shares	0
Expired (in US dollars per share) \| $ / shares	9.02
Forfeited (in US dollars per share) \| $ / shares	4.72
Ending balance (in US dollars per share) \| $ / shares	6.68
Vested or expected to vest (in US dollars per share) \| $ / shares	6.67
Exercisable (in US dollars per share) \| $ / shares	$ 9.24
Weighted-average remaining contractual term, outstanding	6 years 11 months 19 days
Weighted-average remaining contractual term, vested or expected to vest	5 years
Weighted-average remaining contractual term, exercisable	5 years
Aggregate intrinsic value, outstanding \| $	$ 0
Aggregate intrinsic value, vested or expected to vest \| $	0
Aggregate intrinsic value, exercisable \| $	$ 0

Summary of Significant Accounting Policies - Summary of Changes in Accumulated Other Comprehensive Loss by Component (Detail) $ in Thousands	12 Months Ended
	Dec. 31, 2025 USD ($)
AOCI Attributable to Parent, Net of Tax [Roll Forward]
Beginning balance	$ 410,338
Other comprehensive gain	5,956
Ending balance	340,827
Accumulated Other Comprehensive Loss
AOCI Attributable to Parent, Net of Tax [Roll Forward]
Beginning balance	(24,360)
Ending balance	(18,404)
Foreign Currency
AOCI Attributable to Parent, Net of Tax [Roll Forward]
Beginning balance	(24,360)
Other comprehensive gain	5,956
Ending balance	$ (18,404)

- Definition

Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest.

+ References

Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 235
-SubTopic 10
-Name Accounting Standards Codification
-Section S50
-Paragraph 1
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1

Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 235
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(g)(1)(i))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1

Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 825
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 28
-Subparagraph (f)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482907/825-10-50-28

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Topic 210
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(29))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1

Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef
-Topic 210
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(30))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1

Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef
-Topic 210
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(31))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1

Reference 7: http://www.xbrl.org/2003/role/exampleRef
-Topic 852
-SubTopic 10
-Name Accounting Standards Codification
-Section 55
-Paragraph 10
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481372/852-10-55-10

Reference 8: http://www.xbrl.org/2003/role/exampleRef
-Topic 946
-SubTopic 830
-Name Accounting Standards Codification
-Section 55
-Paragraph 12
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479168/946-830-55-12

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 210
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.6-04(19))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 210
-Name Accounting Standards Codification
-Section S99
-Paragraph 2
-Subparagraph (SX 210.6-05(4))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2

Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 946
-SubTopic 220
-Name Accounting Standards Codification
-Section S99
-Paragraph 3
-Subparagraph (SX 210.6-09(4)(b))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 220
-Name Accounting Standards Codification
-Section S99
-Paragraph 3
-Subparagraph (SX 210.6-09(6))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 220
-Name Accounting Standards Codification
-Section S99
-Paragraph 3
-Subparagraph (SX 210.6-09(7))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3

Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 235
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(g)(1)(ii))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1

Reference 15: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 323
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 3
-Subparagraph (c)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481687/323-10-50-3

Reference 16: http://fasb.org/us-gaap/role/ref/legacyRef
-Topic 310
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 2
-Subparagraph (SAB Topic 4.E)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480418/310-10-S99-2

+ Details

Retirement Plans	12 Months Ended
Retirement Plans	Dec. 31, 2025
Retirement Benefits [Abstract]
Retirement Plans	RETIREMENT PLANS: Substantially all of the Company's U.S. employees are eligible to participate in the OraSure Technologies, Inc. 401(k) Plan (the “401(k) Plan”). The 401(k) Plan permits voluntary employee contributions to be excluded from an employee’s current taxable income under provisions of Internal Revenue Code Section 401(k) and the regulations thereunder. The 401(k) Plan also provides for the Company to match employee contributions up to $4.0 thousand per year. The Company contributed $1.1 million, $1.2 million and $1.6 million to the 401(k) Plan, net of forfeitures, in 2025, 2024, and 2023, respectively. In addition to the Company's 401(k) plan, the Company offers a nonqualified deferred compensation plan to permit eligible directors and highly compensated employees of the Company to defer receipt and taxation of their compensation each year. The Company also may make discretionary contributions to the accounts of the participating employees in any amount either in cash or stock. Participants in the plan may not purchase OraSure stock as an investment vehicle. As of December 31, 2025 and 2024, the value of the assets associated with this plan was $0.5 million and $0.7 million, respectively, and is included in other current assets and other noncurrent assets in the Company's consolidated balance sheets. The Company's obligation related to the deferred compensation plan is included in accrued expenses and other noncurrent liabilities in the Company's consolidated balance sheets. As of December 31, 2025 and 2024, the Company's total obligation under this plan was $0.5 million and $0.7 million, respectively. Substantially all regular full-time Canadian employees are eligible to participate in the DNA Genotek Registered Retirement Savings Plan (the “RRSP”). The RRSP permits voluntary employee contributions to be excluded from an employee’s current taxable income and receive tax-preferred treatment with Canada Revenue Agency. The RRSP also provides for DNAG to match employee contributions up to $4.0 thousand CAD per year. The Company contributed $0.3 million, $0.4 million and $0.4 million to the RRSP in 2025, 2024, and 2023, respectively. Substantially all British employees are eligible to participate in the People's Pension Plan (the “PPP”). The PPP permits voluntary employee contributions which may be excluded from an employee’s current taxable income and receive tax-preferred treatment with HM Revenue and Customs. The PPP also provides for the Company to match employee contributions. The Company contributed $0.1 million to the PPP in 2025.

- Definition

The entire disclosure for retirement benefits.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 715
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (o)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480506/715-20-50-1

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Topic 715
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (p)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480506/715-20-50-1

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Topic 715
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (q)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480506/715-20-50-1

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Topic 715
-SubTopic 60
-Name Accounting Standards Codification
-Section 50
-Paragraph 3
-Subparagraph (c)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480266/715-60-50-3

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Topic 715
-SubTopic 20
-Name Accounting Standards Codification
-Section S99
-Paragraph 2
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480126/715-20-S99-2

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Topic 715
-SubTopic 70
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480794/715-70-50-1

Reference 7: http://www.xbrl.org/2003/role/exampleRef
-Topic 715
-SubTopic 20
-Name Accounting Standards Codification
-Section 55
-Paragraph 17
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480482/715-20-55-17

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Topic 715
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (d)(iv)(03)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480506/715-20-50-1

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Topic 715
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (d)(i)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480506/715-20-50-1

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Topic 715
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (l)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480506/715-20-50-1

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Topic 715
-Name Accounting Standards Codification
-Publisher FASB
-URI https://asc.fasb.org/715/tableOfContent

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Topic 715
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (d)(iii)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480506/715-20-50-1

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Topic 715
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (r)(1)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480506/715-20-50-1

Reference 14: http://www.xbrl.org/2003/role/disclosureRef
-Topic 715
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (r)(2)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480506/715-20-50-1

+ Details

Summary of Significant Accounting Policies - Additional Information (Detail) - USD ($)	2 Months Ended	9 Months Ended	12 Months Ended			21 Months Ended
	Dec. 31, 2025	Sep. 30, 2025	Dec. 31, 2025	Dec. 31, 2024	Dec. 31, 2023	Sep. 30, 2025	Nov. 30, 2025	Nov. 12, 2025	Dec. 19, 2024	Dec. 31, 2022
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Inventory, period charge			$ 100,000
Income taxes paid			1,800,000	$ 1,800,000
Proceeds from income tax refunds					$ 4,900,000
Write-offs against allowance for doubtful accounts			500,000	500,000	700,000
Accruals for purchases of property and equipment			500,000	500,000	200,000
Long-term portion	$ 9,333,000		9,333,000	22,910,000
Fair Value	0		0	0
Cash and cash equivalents	199,278,000		199,278,000	267,763,000
Fair value of plan assets	500,000		500,000	700,000
Change in the estimated fair value of acquisition-related contingent consideration			4,570,000	0	(99,000)
Payments to acquire equity method investment			0	30,000,000	0	$ 30,000,000.0
Investment in equity method investee	25,956,000		25,956,000	28,300,000
Loan to related party	300,000		300,000
Net revenues			115,021,000	185,827,000	405,472,000
Goodwill	43,363,000		$ 43,363,000	40,330,000	35,696,000
Sales commissions amortization period			1 year
Customer prepayments, deferred revenue	1,200,000		$ 1,200,000	3,000,000.0	1,200,000
Unearned grant income	400,000		400,000
Deferred revenue, noncurrent					400,000
Deferred revenue	1,518,000		1,518,000	2,961,000	1,559,000
Deferred Revenue Recognized			2,484,000	3,680,000
Advertising expenses			600,000	500,000	1,600,000
Net foreign exchange (losses) gains			(900,000)	1,200,000	(100,000)
Stockholders' equity	340,827,000		340,827,000	410,338,000	$ 430,671,000					$ 364,425,000
Diagnostic Reporting Unit
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Percentage of fair value in excess of carrying amount							13.00%
Goodwill	8,200,000		8,200,000
Related Party
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Net revenues			200,000
BioMedomics, Inc
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Long-term portion	300,000		300,000
Net revenues	$ 100,000
Goodwill								$ 1,775,000
Sherlock Biosciences
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Long-term portion				22,900,000
Change in the estimated fair value of acquisition-related contingent consideration		$ 4,600,000	$ 4,570,000
Goodwill									$ 6,382,000
Buildings
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Estimated useful lives of assets	20 years		20 years
Computer Equipment
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Estimated useful lives of assets	3 years		3 years
Machinery and equipment
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Estimated useful lives of assets	5 years		5 years
Furniture and fixtures
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Estimated useful lives of assets	7 years		7 years
Level I Instruments
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Cash and cash equivalents	$ 13,114,000		$ 13,114,000	66,584,000
Money Market Fund
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Cash and cash equivalents	$ 68,400,000		$ 68,400,000	$ 118,500,000
Common Stock Options Unvested Restricted Stock and Unvested Performance Units
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Number of anti-dilutive securities excluded from EPS computation (in shares)			572,000	896,000	1,778,000
Minimum
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Amortization Period (Years)	5 years		5 years
Contract with customer payment terms			30 days
Maximum
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Amortization Period (Years)	15 years		15 years
Contract with customer payment terms			120 days

Summary of Significant Accounting Policies - Schedule of Accounts Receivable (Details) - USD ($) $ in Thousands	Dec. 31, 2025	Dec. 31, 2024	Dec. 31, 2023
Accounting Policies [Abstract]
Accounts receivable	$ 22,203	$ 23,816	$ 40,171
Allowance for doubtful accounts	$ 188	$ 774	$ 1,216

Business Combinations - Additional Information (Detail) - USD ($)			2 Months Ended	3 Months Ended	12 Months Ended
	Nov. 12, 2025	Dec. 19, 2024	Dec. 31, 2025	Mar. 31, 2025	Dec. 31, 2025	Dec. 31, 2024	Dec. 31, 2023
Business Combination [Line Items]
Net revenues					$ 115,021,000	$ 185,827,000	$ 405,472,000
Net (loss) income					(68,731,000)	$ (19,500,000)	$ 53,655,000
BioMedomics, Inc
Business Combination [Line Items]
Contingent consideration, liability, value, high	$ 5,000,000.0
Estimated fair value of contingent consideration	233,000
Contingent consideration, liability, value, Low	$ 0
Acquisition-related costs					$ 500,000
Net revenues			$ 100,000
Net (loss) income			$ 1,100
BioMedomics, Inc \| Technology-Based Intangible Assets
Business Combination [Line Items]
Acquired Finite-Lived Intangible Assets, Weighted Average Useful Life	10 years
BioMedomics, Inc \| Milestone Payments
Business Combination [Line Items]
Estimated fair value of contingent consideration	$ 300,000
Sherlock Biosciences
Business Combination [Line Items]
Contingent consideration, liability, value, high		$ 20,000,000.0
Estimated fair value of contingent consideration		22,910,000
Contingent consideration, liability, value, Low		0
Fair value of the royalty fee acquisition-related contingent consideration		7,000,000
Acquisition-related costs				$ 1,000,000.0
Sherlock Biosciences \| Milestone Payments
Business Combination [Line Items]
Estimated fair value of contingent consideration		$ 15,910,000

Business Segment Information

12 Months Ended

Dec. 31, 2025

Segment Reporting [Abstract]

Business Segment Information

BUSINESS SEGMENT INFORMATION:

The Company is organized on the basis of products and services into a single reportable segment. All products and services reside under the same reporting hierarchy. The Company's reportable segment derives its revenues from the sale of diagnostics products and sample management solutions, as described in Note 2 Summary of Significant Accounting Policies. As the Company has only one reportable segment, there are no inter-segment sales or transfers.

The Company's Chief Operating Decision Maker ("CODM") is its Chief Executive Officer. The CODM uses consolidated net income (loss) as reported in the consolidated statement of operations as the primary measure of the reportable segment's profit or loss. The CODM uses consolidated net income (loss) to assess the performance of the segment and make decisions about resource allocation. Consolidated gross profit and consolidated operating income (loss), as reported in the consolidated statement of operations, are also used by the CODM as measures of segment profit or loss. The CODM uses gross profit to assess the impact of the Company's efforts to achieve manufacturing efficiencies and consolidate its production activities. The CODM uses operating income (loss) to assess the impact of the Company's recent restructurings, reduction in workforce, and efforts to streamline its operations to achieve cost savings. The CODM uses consolidated total assets as the measure of segment assets, as reported on the consolidated balance sheet.

The accounting policies of the Company's reportable segment are the same as those described in Note 2 Summary of Significant Accounting Policies.

The following table represents total long-lived assets by geographic area:


	December 31,
	2025		2024
United States	$	36,254	$	40,286
United Kingdom	10,061		12,849
Canada	4,642		5,468
Other regions	364		89
	$	51,321	$	58,692

The following table represents reported segment revenues, segment profit (loss), and significant segment expenses:


	For the Years Ended December 31,
		2025		2024		2023
Net revenues		$	115,021	$	185,827	405,472
Cost of products and services sold (3)		66,823		106,437		233,820
Gross profit		48,198		79,390		171,652
Research and development (3)		42,528		26,047		33,728
Sales and marketing (3)		26,117		30,986		36,319
General and administrative (3)		47,677		46,215		58,191
Loss on impairments		—		4,392		10,829
Change in the estimated fair value of acquisition-related contingent consideration		4,570		—		(99)
Gain on sale of assets		(725)		—		—
Operating (loss) income		(71,969)		(28,250)		32,684
Other income (expense) (1)		229		(380)		17,836
Interest revenue		8,078		11,469		5,862
Other segment items (2)		(924)		1,160		(124)
(Loss) income before income taxes and equity investment		(64,586)		(16,001)		56,258
Income tax expense		1,801		1,799		2,603
Loss on equity investment		(2,344)		(1,700)		—
Net (loss) income		$	(68,731)	$	(19,500)	$	53,655

(1) Includes $12.8 million of excess profits recognized on government contracts in 2023.

(2) Includes interest expense and foreign currency gains (losses).

(3) The following tables represent additional significant segment expense categories:


	For the Years Ended December 31,
		2025		2024		2023
Stock-based Compensation
Cost of products and services sold		$	707	734		564
Research and development		1,046		839		1,159
Sales and marketing		863		1,129		1,181
General and administrative		7,531		9,218		7,826
		$	10,147	$	11,920	$	10,729


	For the Years Ended December 31,
		2025		2024		2023
Depreciation and Amortization
Cost of products and services sold		$	4,527	$	6,343	$	15,311
Research and development		2,081		1,029		1,208
Sales and marketing		80		189		571
General and administrative		3,504		3,311		3,846
		$	10,192	$	10,872	$	20,936

- Definition

The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 21
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-21

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 21
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-21

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 32
-Subparagraph (e)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-32

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 31
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-31

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 15
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-15

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 42
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-42

Reference 7: http://www.xbrl.org/2003/role/exampleRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 55
-Paragraph 48
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482785/280-10-55-48

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 32
-Subparagraph (f)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-32

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Topic 270
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (i)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482964/270-10-50-1

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 32
-Subparagraph (ee)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-32

Reference 11: http://fasb.org/us-gaap/role/ref/otherTransitionRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 32
-Subparagraph (d)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-32

Reference 12: http://www.xbrl.org/2003/role/exampleRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 55
-Paragraph 54
-Subparagraph (d)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482785/280-10-55-54

Reference 13: http://www.xbrl.org/2003/role/exampleRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 55
-Paragraph 47
-Subparagraph (c)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482785/280-10-55-47

Reference 14: http://www.xbrl.org/2003/role/exampleRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 55
-Paragraph 54
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482785/280-10-55-54

Reference 15: http://www.xbrl.org/2003/role/exampleRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 55
-Paragraph 47
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482785/280-10-55-47

Reference 16: http://www.xbrl.org/2003/role/exampleRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 55
-Paragraph 54
-Subparagraph (e)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482785/280-10-55-54

Reference 17: http://www.xbrl.org/2003/role/exampleRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 55
-Paragraph 47
-Subparagraph (d)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482785/280-10-55-47

Reference 18: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 22
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-22

Reference 19: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 34
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-34

Reference 20: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 26C
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-26C

Reference 21: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 26B
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-26B

Reference 22: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 40
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-40

Reference 23: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-Name Accounting Standards Codification
-Publisher FASB
-URI https://asc.fasb.org/280/tableOfContent

Reference 24: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 26
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-26

Reference 25: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 41
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-41

+ Details

Inventories (Tables)

12 Months Ended

Dec. 31, 2025

Inventory Disclosure [Abstract]

Schedule of Inventories


	December 31,		December 31,
	2025		2024
Raw materials	$	14,831	$	17,002
Work in process	56		420
Semi-finished goods	1,965		2,890
Finished goods	14,208		13,885
	$	31,060	$	34,197

Retirement Plans - Additional Information (Detail)	12 Months Ended
Retirement Plans - Additional Information (Detail)	Dec. 31, 2025 USD ($)	Dec. 31, 2025 CAD ($)	Dec. 31, 2024 USD ($)	Dec. 31, 2023 USD ($)
Defined Benefit Plan Disclosure [Line Items]
Employee contributions (up to)	$ 4,000.0
Contributed to plan, net of forfeitures	1,100,000		$ 1,200,000	$ 1,600,000
Value of the assets associated with the plan	500,000		700,000
Total obligation under plan	500,000		700,000
RRSP \| DNA Genotek
Defined Benefit Plan Disclosure [Line Items]
Employee contributions (up to)		$ 4,000.0
Contributed to plan, net of forfeitures	300,000		$ 400,000	$ 400,000
People's Pension Plan
Defined Benefit Plan Disclosure [Line Items]
Contributed to plan, net of forfeitures	$ 100,000

- Definition

Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 715
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 5
-Subparagraph (k)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480506/715-20-50-5

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Topic 715
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 5
-Subparagraph (d)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480506/715-20-50-5

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Topic 715
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 5
-Subparagraph (i)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480506/715-20-50-5

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Topic 715
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 5
-Subparagraph (l)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480506/715-20-50-5

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Topic 715
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 5
-Subparagraph (g)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480506/715-20-50-5

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Topic 715
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 5
-Subparagraph (j)(1)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480506/715-20-50-5

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Topic 715
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 5
-Subparagraph (j)(2)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480506/715-20-50-5

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Topic 715
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 5
-Subparagraph (j)(4)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480506/715-20-50-5

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Topic 715
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 5
-Subparagraph (j)(3)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480506/715-20-50-5

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Topic 715
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 5
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480506/715-20-50-5

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Topic 715
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 5
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480506/715-20-50-5

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Topic 715
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 5
-Subparagraph (c)(iv)(02)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480506/715-20-50-5

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Topic 715
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 5
-Subparagraph (c)(ii)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480506/715-20-50-5

Reference 14: http://www.xbrl.org/2003/role/disclosureRef
-Topic 715
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 7
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480506/715-20-50-7

Reference 15: http://www.xbrl.org/2003/role/disclosureRef
-Topic 715
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 5
-Subparagraph (q)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480506/715-20-50-5

Reference 16: http://www.xbrl.org/2003/role/disclosureRef
-Topic 715
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 5
-Subparagraph (m)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480506/715-20-50-5

Reference 17: http://www.xbrl.org/2003/role/disclosureRef
-Topic 715
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 5
-Subparagraph (h)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480506/715-20-50-5

Reference 18: http://www.xbrl.org/2003/role/disclosureRef
-Topic 715
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 5
-Subparagraph (f)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480506/715-20-50-5

Reference 19: http://www.xbrl.org/2003/role/disclosureRef
-Topic 715
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 5
-Subparagraph (e)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480506/715-20-50-5

Reference 20: http://www.xbrl.org/2003/role/disclosureRef
-Topic 715
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 5
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480506/715-20-50-5

+ Details

Inventories

12 Months Ended

Dec. 31, 2025

Inventory Disclosure [Abstract]

Inventories

INVENTORIES:


	December 31,		December 31,
	2025		2024
Raw materials	$	14,831	$	17,002
Work in process	56		420
Semi-finished goods	1,965		2,890
Finished goods	14,208		13,885
	$	31,060	$	34,197

During the years ended December 31, 2025, 2024, and 2023, the Company recorded writedowns to inventory which had a cost of $2.9 million, $2.6 million, and $8.9 million, respectively. Adjustments for the year ended December 31, 2025 were primarily driven by the write down of COVID-19 inventory and normal operating scrap. Adjustments for the year ended December 31, 2024 were primarily driven by the write down of inventory associated with the Company's exit of the Risk Assessment Testing business and normal operating scrap. Adjustments for the year ended December 31, 2023 were primarily related to reduction in COVID-19 demand and the need to reserve for excess inventory levels.

Leases - Summary of Components of Lease Expense (Detail) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2025	Dec. 31, 2024	Dec. 31, 2023
Lessee Disclosure [Abstract]
Operating lease cost	$ 2,285	$ 1,729	$ 2,407
Variable and short-term lease cost	37	549	381
Sublease income	(161)	(151)	(155)
Finance lease cost:
Amortization of right-of use assets	61	331	1,091
Interest on lease liabilities	8	22	51
Total finance lease cost	69	353	1,142
Total lease cost	$ 2,230	$ 2,480	$ 3,775

Stockholders' Equity - Schedule of Currently Outstanding and Exercisable Stock Options (Detail) shares in Thousands	12 Months Ended
	Dec. 31, 2025 $ / shares shares
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Shares outstanding (in shares) \| shares	3,379
Weighted- Average Remaining Contractual Term (in years)	6 years 11 months 19 days
Weighted average exercise price (in US dollars per share)	$ 6.67
Shares exercisable (in shares) \| shares	1,656
Weighted average exercise price (in US dollars per share)	$ 9.24
Range One
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Lower range limit (in US dollars per share)	2.46
Upper range limit (in US dollars per share)	$ 6.56
Shares outstanding (in shares) \| shares	1,855
Weighted- Average Remaining Contractual Term (in years)	8 years 4 months 24 days
Weighted average exercise price (in US dollars per share)	$ 4.17
Shares exercisable (in shares) \| shares	382
Weighted average exercise price (in US dollars per share)	$ 6.00
Range Two
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Lower range limit (in US dollars per share)	7.13
Upper range limit (in US dollars per share)	$ 10.69
Shares outstanding (in shares) \| shares	1,157
Weighted- Average Remaining Contractual Term (in years)	5 years 10 months 9 days
Weighted average exercise price (in US dollars per share)	$ 7.84
Shares exercisable (in shares) \| shares	907
Weighted average exercise price (in US dollars per share)	$ 8.00
Range Three
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Lower range limit (in US dollars per share)	12.90
Upper range limit (in US dollars per share)	$ 19.35
Shares outstanding (in shares) \| shares	324
Weighted- Average Remaining Contractual Term (in years)	3 years 5 months 1 day
Weighted average exercise price (in US dollars per share)	$ 14.89
Shares exercisable (in shares) \| shares	324
Weighted average exercise price (in US dollars per share)	$ 14.89
Range Four
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Lower range limit (in US dollars per share)	21.64
Upper range limit (in US dollars per share)	$ 32.46
Shares outstanding (in shares) \| shares	43
Weighted- Average Remaining Contractual Term (in years)	2 years 10 days
Weighted average exercise price (in US dollars per share)	$ 21.65
Shares exercisable (in shares) \| shares	43
Weighted average exercise price (in US dollars per share)	$ 21.65

Business Segment Information - Additional Information (Detail) $ in Thousands	12 Months Ended
	Dec. 31, 2025 USD ($) segment	Dec. 31, 2024 USD ($)	Dec. 31, 2023 USD ($)
Segment Reporting [Abstract]
Number of reportable segments \| segment	1
Segment Reporting, Revenue Reconciling Item [Line Items]
Operating (loss) income	$ 229	$ (380)	$ 17,836
Government Contract
Segment Reporting, Revenue Reconciling Item [Line Items]
Operating (loss) income			$ 12,800

Government Capital Contracts - Summary of Government Contracts Included in Statements of Cash Flows (Details) - USD ($) $ in Thousands	Dec. 31, 2025	Dec. 31, 2024
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Cost of assets, cumulative	$ 102,055	$ 111,023
Total property, plant and equipment, net	$ 39,179	45,105
Government Contract
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Cost of assets, cumulative		86,993
Reduction for funding earned to date, not yet received		0
Reduction for funding received to date		(86,993)
Total property, plant and equipment, net		$ 0

Leases - Summary of Supplemental Balance Sheet Information Related to Leases (Detail)	Dec. 31, 2025	Dec. 31, 2024
Lessee Disclosure [Abstract]
Weighted-average remaining lease term — operating leases	6 years 8 months 12 days	7 years 6 months 25 days
Weighted-average remaining lease term — finance leases	2 years 8 months 12 days	3 years 8 months 26 days
Weighted-average discount rate — operating leases	4.48%	4.44%
Weighted-average discount rate — finance leases	5.10%	4.82%

Inventories - Additional Information (Details) - USD ($) $ in Millions	Dec. 31, 2025	Dec. 31, 2024	Dec. 31, 2023
Inventory Disclosure [Abstract]
Inventory adjustments	$ 2.9	$ 2.6	$ 8.9

Property, Plant and Equipment - Schedule of Property, Plant and Equipment (Detail) - USD ($) $ in Thousands	Dec. 31, 2025	Dec. 31, 2024
Property, Plant and Equipment [Line Items]
Property, plant and equipment, gross	$ 102,055	$ 111,023
Accumulated depreciation	(62,876)	(65,918)
Total property, plant and equipment, net	39,179	45,105
Land
Property, Plant and Equipment [Line Items]
Property, plant and equipment, gross	1,118	1,118
Buildings and improvements
Property, Plant and Equipment [Line Items]
Property, plant and equipment, gross	39,071	36,152
Machinery and equipment
Property, Plant and Equipment [Line Items]
Property, plant and equipment, gross	46,202	51,015
Computer equipment and software
Property, Plant and Equipment [Line Items]
Property, plant and equipment, gross	11,101	11,502
Furniture and fixtures
Property, Plant and Equipment [Line Items]
Property, plant and equipment, gross	1,632	1,621
Construction in progress
Property, Plant and Equipment [Line Items]
Property, plant and equipment, gross	$ 2,931	$ 9,615

Audit Information	12 Months Ended
Audit Information	Dec. 31, 2025
Audit Information [Abstract]
Auditor Name	GRANT THORNTON LLP
Auditor Location	Philadelphia, PA
Auditor Firm ID	248

Goodwill and Other Intangible Assets - Additional Information (Detail) $ in Millions	12 Months Ended
	Dec. 31, 2025 USD ($) unit	Dec. 31, 2024 USD ($)	Dec. 31, 2023 USD ($)
Goodwill [Line Items]
Number of reporting units \| unit	2
Amortization expense	$ 0.3	$ 0.7	$ 2.0
Developed Technology, Trade Names And Customer Relationships
Goodwill [Line Items]
Impairment of intangible assets (excluding goodwill)			$ 6.2
Impairment, Intangible Asset, Statement of Income or Comprehensive Income [Extensible Enumeration]			Loss on impairments
Developed technology
Goodwill [Line Items]
Impairment of intangible assets (excluding goodwill)			$ 2.4

- Definition

The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Name Accounting Standards Codification
-Section 45
-Paragraph 28
-Subparagraph (b)
-SubTopic 10
-Topic 230
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482740/230-10-45-28

Reference 2: http://www.xbrl.org/2003/role/exampleRef
-Topic 220
-SubTopic 40
-Name Accounting Standards Codification
-Section 55
-Paragraph 18
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147476153/220-40-55-18

Reference 3: http://www.xbrl.org/2003/role/exampleRef
-Topic 220
-SubTopic 40
-Name Accounting Standards Codification
-Section 55
-Paragraph 11
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147476153/220-40-55-11

Reference 4: http://www.xbrl.org/2003/role/exampleRef
-Topic 220
-SubTopic 40
-Name Accounting Standards Codification
-Section 55
-Paragraph 24
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147476153/220-40-55-24

Reference 5: http://www.xbrl.org/2003/role/exampleRef
-Topic 220
-SubTopic 40
-Name Accounting Standards Codification
-Section 50
-Paragraph 12
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147476148/220-40-50-12

Reference 6: http://www.xbrl.org/2003/role/exampleRef
-Name Accounting Standards Codification
-Section 55
-Paragraph 40
-SubTopic 30
-Topic 350
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482640/350-30-55-40

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Topic 350
-SubTopic 30
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (a)(2)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482665/350-30-50-2

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Topic 350
-SubTopic 30
-Name Accounting Standards Codification
-Section 45
-Paragraph 2
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482686/350-30-45-2

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Topic 220
-SubTopic 40
-Name Accounting Standards Codification
-Section 50
-Paragraph 6
-Subparagraph (d)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147476148/220-40-50-6

+ Details

- Definition

Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.

+ References

Reference 1: http://www.xbrl.org/2003/role/exampleRef
-Topic 350
-SubTopic 20
-Name Accounting Standards Codification
-Section 55
-Paragraph 24
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482548/350-20-55-24

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Topic 350
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482573/350-20-50-2

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Topic 350
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482573/350-20-50-1

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Topic 350
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482573/350-20-50-1

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Topic 350
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482573/350-20-50-1

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Topic 350
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (c)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482573/350-20-50-1

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Topic 350
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (d)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482573/350-20-50-1

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Topic 350
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (e)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482573/350-20-50-1

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Topic 350
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (f)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482573/350-20-50-1

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Topic 350
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (g)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482573/350-20-50-1

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Topic 350
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (h)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482573/350-20-50-1

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Topic 350
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1A
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482573/350-20-50-1A

+ Details

Leases - Schedule of Minimum Lease Payments by Period Expected (Detail) $ in Thousands	Dec. 31, 2025 USD ($)
Finance Lease Liabilities, Payments, Due [Abstract]
2026	$ 70
2027	65
2028	34
2029	6
2030	0
Thereafter	0
Total minimum lease payments	175
Less: imputed interest	(12)
Present value of lease liabilities	163
Operating Lease Liabilities, Payments Due [Abstract]
2026	2,548
2027	2,287
2028	2,157
2029	2,097
2030	2,106
Thereafter	3,778
Total minimum lease payments	14,973
Less: imputed interest	(1,939)
Present value of lease liabilities	$ 13,034

Consolidated Balance Sheets (Parenthetical) - USD ($) $ in Thousands	Dec. 31, 2025	Dec. 31, 2024
Statement of Financial Position [Abstract]
Allowance for doubtful accounts	$ 188	$ 774
Preferred stock, par value (in US dollars per share)	$ 0.000001	$ 0.000001
Preferred stock, shares authorized (in shares)	25,000,000	25,000,000
Preferred stock, shares issued (in shares)	0	0
Common stock, par value (in US dollars per share)	$ 0.000001	$ 0.000001
Common stock, shares authorized (in shares)	120,000,000	120,000,000
Common stock, shares issued (in shares)	70,391,000	74,598,000
Common stock, shares outstanding (in shares)	70,391,000	74,598,000

Accrued Expenses And Other Current Liabilities

12 Months Ended

Dec. 31, 2025

Payables and Accruals [Abstract]

Accrued Expenses and Other Current Liabilities

ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES:


	December 31,		December 31,
	2025		2024
Payroll and related benefits	$	5,255	$	11,147
Professional fees	1,938		2,469
Sales tax payable	1,152		1,339
Other	2,804		5,224
	$	11,149	$	20,179

Income Taxes - Reconciliation of Statutory United States Federal Income Tax Rate Percentage to Domestic Effective Tax Rate (Detail)	12 Months Ended
	Dec. 31, 2025	Dec. 31, 2024	Dec. 31, 2023
Income Tax Contingency [Line Items]
Statutory U.S. federal income tax rate	21.00%
NOL adjustment, domestic	(2.20%)
Change in the estimated fair value of acquisition-related contingent consideration	(1.40%)
Effective tax rate	(2.70%)
Pro Forma
Income Tax Contingency [Line Items]
Statutory U.S. federal income tax rate	21.00%	21.00%	21.00%
Nondeductible executive compensation	(1.10%)	(8.50%)	0.50%
Impact of stock-based payment awards	(1.80%)	(2.30%)	(0.30%)
Tax effect of foreign items	(0.60%)	(1.90%)	(0.40%)
State income taxes, net of federal benefit	1.30%	(9.10%)	2.00%
U.S. and foreign tax credits	1.30%	1.20%	1.30%
Uncertain tax positions	(2.90%)	0.00%	0.00%
Nondeductible expenses and other	1.20%	(2.40%)	0.90%
Nondeductible transaction costs	(0.20%)	(2.10%)	0.00%
NOL adjustment, domestic	(2.20%)	0.00%	0.00%
NOL adjustment, foreign	25.50%	(31.40%)	0.00%
Change in the estimated fair value of acquisition-related contingent consideration	(1.40%)	0.00%	0.00%
Acquisition adjustments	(8.70%)	0.00%	0.00%
Non-controlling interests	0.70%	(2.20%)	0.00%
Change in valuation allowance, federal and state	(14.40%)	(10.00%)	0.00%
Change in valuation allowance, foreign	(19.00%)	32.10%	(20.40%)
Effective tax rate	(2.70%)	(11.20%)	4.60%

Stockholders' Equity - Additional Information (Detail) - USD ($)	12 Months Ended
	Dec. 31, 2025	Dec. 31, 2024	Dec. 31, 2023	Mar. 21, 2025
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Shares available for future grants under the Stock Plan	5,959,000
Award requisite service period	3 years
Achievement period	3 years
Total compensation cost	$ 10,147,000	$ 11,920,000	$ 10,729,000
Proceeds from exercise of stock options	0	214,000	269,000
Income tax benefit realized from stock option exercises during period	0	0	0
Total cost of common stock purchased and retired	1,843,000	3,548,000	1,901,000
Amount share repurchase program of common shares				$ 40,000,000.0
Shares repurchased and retired in connection with share repurchase program	15,040,000
Additional Paid-in Capital
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Total cost of common stock purchased and retired	1,843,000	$ 3,548,000	$ 1,901,000
Shares repurchased and retired in connection with share repurchase program	$ 15,040,000
Share Repurchase Program
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of shares purchased and retired	5,300,000
Stock Options
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Percent of the fair market value of a share granted as Stock plan price	75.00%
Granted exercise period	10 years
Vesting period	4 years
Weighted-average grant date fair value of stock options granted (in US dollars per share)	$ 3.43	$ 3.68	$ 3.24
Total compensation cost	$ 1,600,000	$ 1,400,000	$ 1,300,000
Aggregate intrinsic value of options exercised	0.0	38,400	43,000.0
Unrecognized compensation expense related to unvested option awards	$ 3,200,000
Expected weighted-average period for recognition of compensation expense related to unvested awards	2 years 7 months 6 days
Restricted Stock
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Total compensation cost	$ 6,100,000	$ 6,900,000	$ 7,600,000
Expected weighted-average period for recognition of compensation expense related to unvested awards	1 year 8 months 12 days
Unrecognized compensation expense related to unvested restricted stock awards	$ 6,300,000
Vesting of restricted shares, withholding and exercise obligations	363,000	617,000	262,000
Restricted shares of common stock, aggregate values	$ 1,200,000	$ 3,400,000	$ 1,400,000
Performance Based Restricted Stock \| Share-based Compensation Award, Tranche Two
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Vesting period	3 years
Performance Based Restricted Stock Unit
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Total compensation cost	$ 2,400,000	$ 3,600,000	$ 1,800,000
Expected weighted-average period for recognition of compensation expense related to unvested awards	1 year 10 months 24 days
Unrecognized compensation expense related to unvested restricted stock awards	$ 3,700,000
Number of shares purchased and retired	201,000	23,000	86,000
Total cost of common stock purchased and retired	$ 600,000	$ 200,000	$ 500,000
Maximum \| Performance Based Restricted Stock \| Share-based Compensation Award, Tranche One
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Percentage of actual performance share units granted	150.00%
Minimum \| Performance Based Restricted Stock \| Share-based Compensation Award, Tranche One
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Percentage of actual performance share units granted	0.00%

Property, Plant and Equipment

12 Months Ended

Dec. 31, 2025

Property, Plant and Equipment [Abstract]

Property, Plant and Equipment

PROPERTY, PLANT, AND EQUIPMENT, NET:


	December 31,		December 31,
	2025		2024
Land	$	1,118	$	1,118
Buildings and improvements	39,071		36,152
Machinery and equipment	46,202		51,015
Computer equipment and software	11,101		11,502
Furniture and fixtures	1,632		1,621
Construction in progress	2,931		9,615
	102,055		111,023
Accumulated depreciation	(62,876)		(65,918)
	$	39,179	$	45,105

During the first quarter of 2024, the Company initiated a strategic plan to transition away from the microbiome molecular sequencing services business and to cease operations at its Belgium location. As a result of these decisions, the Company determined that the carrying values of all of associated property, plant, and equipment were not recoverable and recorded an aggregate pre-tax asset impairment charge of $1.8 million during the year ended December 31, 2024. All of these assets were disposed of as of December 31, 2024.

During the second quarter of 2024, the Company determined a manufacturing line will no longer be utilized. As a result of this decision, the Company determined that the carrying value of the equipment was not recoverable and recorded an aggregate pre-tax impairment charge of $1.1 million during the year ended December 31, 2024.

During the year ended December 31, 2023 the Company determined several manufacturing lines would not be utilized due to changes in forecasted demand for the products the lines are intended to produce. Additionally, the Company elected not to proceed with certain leasehold improvements to its research and development laboratories. As a result of these decisions, the Company determined that the carrying values of the equipment and leasehold improvements were not recoverable and recorded aggregate pre-tax asset impairment charges of $2.3 million for the year ended December 31, 2023.

During the year ended December 31, 2023, the Company shortened the useful lives of machinery and equipment utilized for InteliSwab® production in Thailand. This reduction in useful lives resulted in $6.9 million of accelerated depreciation during 2023, recorded in cost of products and services sold. Also during 2023, the Company shortened the useful lives of leasehold improvements and equipment due a lease termination. This reduction in useful lives resulted in an additional $0.5 million of accelerated depreciation recorded in cost of products and services sold.

Depreciation expense for 2025, 2024, and 2023 was $9.9 million, $9.8 million, and $17.9 million, respectively.

Contingencies - Additional Information (Detail) $ in Millions	Dec. 31, 2025 USD ($)
Commitments and Contingencies Disclosure [Abstract]
Contractual obligation	$ 3.8

Contingencies	12 Months Ended
Contingencies	Dec. 31, 2025
Commitments and Contingencies Disclosure [Abstract]
Contingencies	CONTINGENCIES: Collaborations Sherlock has active third-party license agreements entered into in order to advance and obtain technologies and services related to the business. Under these licenses, the Company is required to make up to $3.8 million of cash payments upon the achievement of certain scientific and commercial milestones as well as low single digit royalty payments on product sales. The Company has the right to terminate the licenses. Litigation From time to time, the Company is involved in certain legal actions arising in the ordinary course of business. In management’s opinion, based upon the advice of counsel, the outcomes of such actions are not expected, individually or in the aggregate, to have a material adverse effect on the Company's future financial position or results of operations. On November 14, 2024 the Company filed a complaint against NowDiagnostics, Inc. ("NowDx"), Jody Berry ("Berry") and Janean Young ("Young") in the United States District Court for the Eastern District of Pennsylvania alleging misappropriation and misuse of the Company's proprietary information and trade secrets by NowDx, Berry and Young in violation of the Federal Defend Trade Secrets Act and the Pennsylvania Uniform Trade Secrets Act. The complaint also alleges breach of contract and duty of loyalty by Young, unfair competition by NowDx, and tortious interference with contractual relations by Berry and NowDx. NowDx filed Counterclaims against the Company on January 13, 2025 and the Company filed its Answer to the Counterclaims on February 3, 2025. Young filed a Motion to Dismiss the claims against her, which was denied by the court on February 4, 2025. NowDx, Berry, and Young agreed to a preliminary injunction which the Court entered on February 27, 2025. The case is currently in the discovery phase and the schedule for any further proceedings is currently pending.

Accrued Expenses and Other Current Liabilities - Schedule of Accrued Expenses and Other Current Liabilities (Detail) - USD ($) $ in Thousands	Dec. 31, 2025	Dec. 31, 2024
Payables and Accruals [Abstract]
Payroll and related benefits	$ 5,255	$ 11,147
Professional fees	1,938	2,469
Sales tax payable	1,152	1,339
Other	2,804	5,224
Total	$ 11,149	$ 20,179

Stockholders' Equity (Tables)

12 Months Ended

Dec. 31, 2025

Share-Based Payment Arrangement [Abstract]

Weighted-Average Assumptions for Fair Value Measurement

The fair value of each stock option was estimated on the date of the grant using the Black-Scholes option-pricing model using the following weighted-average assumptions:


	For the Years Ended December 31,
Black-Scholes Option Valuation Assumptions	2025		2024		2023
Risk-free interest rate (1)	4.04	%	4.14	%	4.23	%
Expected dividend yield	—		—		—
Expected stock price volatility (2)	53	%	53	%	51	%
Expected life of stock options (in years) (2)	6		5		5

(1)Based on the constant maturity interest rate of U.S. Treasury securities whose term is consistent with the expected life of the Company's stock options.

(2)Based upon historical experience.

Summary of Company's Stock Option Activity

The following table summarizes the stock option activity under the Stock Plan:


	Options	Weighted- Average Exercise Price Per Share		Weighted- Average Remaining Contractual Term (in years)	Aggregate Intrinsic Value
Outstanding on January 1, 2025	2,237	$	8.73
Granted	1,393	3.43
Exercised	—	—
Expired	(132)	9.02
Forfeited	(119)	4.72
Outstanding on December 31, 2025	3,379	$	6.68	6.97	$	—
Vested or expected to vest as of December 31, 2025	3,376	$	6.67	5.00	$	—
Exercisable on December 31, 2025	1,655	$	9.24	5.00	$	—

Schedule of Currently Outstanding and Exercisable Stock Options

The following table summarizes information about stock options outstanding as of December 31, 2025:


Options Outstanding					Options Exercisable
Range of Exercise Prices	Number Outstanding	Weighted- Average Remaining Contractual Term (in years)	Weighted- Average Exercise Price Per Share		Number Exercisable	Weighted- Average Exercise Price Per Share
$2.46 - $6.56	1,855	8.40	$	4.17	382	$	6.00
$7.13 - $10.69	1,157	5.86	7.84		907	8.00
$12.90 - $19.35	324	3.42	14.89		324	14.89
$21.64 - $32.46	43	2.03	$	21.65	43	$	21.65
	3,379	6.97	$	6.67	1,656	$	9.24

Summary of Restricted Stock Award and Restricted Stock Units Activity Under Stock Plan

The following table summarizes restricted stock award and restricted stock units activity under the Stock Plan:


	Units	Weighted- Average Grant Date Fair Value
Issued and unvested, January 1, 2025	1,694	$	6.60
Granted	2,226	3.25
Vested	(1,128)	6.05
Forfeited	(182)	4.55
Issued and unvested, December 31, 2025	2,610	$	4.13
Issued and expected to vest, December 31, 2025	2,610	$	4.13

Summary of Performance Based Restricted Stock Unit Award Activity Under Stock Plan

The following table summarizes PSU activity under the Stock Plan:


	Units	Weighted- Average Grant Date Fair Value
Issued and unvested, January 1, 2025	1,454	$	7.19
Granted (1)	1,009	4.30
Performance adjustment (2)	12	N/A
Vested	(513)	5.18
Forfeited	(181)	5.93
Issued and unvested, December 31, 2025	1,781	$	6.24
Issued and expected to vest, December 31, 2025	1,781	$	6.24

(1)Grant activity for all PSUs disclosed at target.

(2)Reflects the performance adjustment based on actual performance measured at the end of the performance period.

Accrued Expenses and Other Current Liabilities (Tables)

12 Months Ended

Dec. 31, 2025

Payables and Accruals [Abstract]

Schedule of Accrued Expenses and Other Current Liabilities


	December 31,		December 31,
	2025		2024
Payroll and related benefits	$	5,255	$	11,147
Professional fees	1,938		2,469
Sales tax payable	1,152		1,339
Other	2,804		5,224
	$	11,149	$	20,179

Income Taxes - Reconciliation of Statutory United States Federal Income Tax Rate to Domestic Effective Tax Rate (Detail) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2025	Dec. 31, 2024	Dec. 31, 2023
Income Tax Expense (Benefit), Effective Income Tax Rate Reconciliation, Amount [Abstract]
Statutory U.S. federal income tax rate	$ (14,055)
State and local income taxes, net of federal income tax effect (1)	325
Effect of changes in tax laws/rates enacted in the current period	0
Global intangible low-taxed income	523
Research and development tax credits	(536)
Nontaxable or nondeductible items
Share based payment awards	773
Nondeductible officer's compensation	714
Change in the estimated fair value of acquisition-related contingent consideration	960
Other	192
Changes in unrecognized tax benefits	1,728
Acquisition adjustments	1,285
NOL adjustment	1,441
Other adjustments	(358)
Total income tax expense	$ 1,801	$ 1,799	$ 2,603
Effective Income Tax Rate Reconciliation, Percent [Abstract]
Statutory U.S. federal income tax rate	21.00%
State income taxes, net of federal benefit	(0.50%)
Change in the estimated fair value of acquisition-related contingent consideration	(1.40%)
Effect of changes in tax laws/rates enacted in the current period	0.00%
Global intangible low-taxed income	(0.80%)
Research and development tax credits	0.80%
Nontaxable or nondeductible items
Impact of stock-based payment awards	(1.10%)
Nondeductible officer's compensation	(1.10%)
Other	(0.30%)
Changes in unrecognized tax benefits	(2.60%)
Acquisition adjustments	(1.90%)
NOL adjustment, domestic	(2.20%)
Other adjustments	0.50%
Effective tax rate	(2.70%)
United Kingdom
Income Tax Expense (Benefit), Effective Income Tax Rate Reconciliation, Amount [Abstract]
Change in NOL limitation	$ (17,062)
Intangible acquisition adjustment	4,524
Change in valuation allowances	12,728
Other	$ (195)
Effective Income Tax Rate Reconciliation, Percent [Abstract]
Change in NOL limitation	25.50%
Intangible acquisition adjustment	(6.70%)
Change in valuation allowance, foreign	(19.00%)
Tax effect of foreign items	0.30%
Foreign Tax Jurisdiction, Other
Income Tax Expense (Benefit), Effective Income Tax Rate Reconciliation, Amount [Abstract]
Other	$ 114
Effective Income Tax Rate Reconciliation, Percent [Abstract]
Tax effect of foreign items	(0.20%)
United States
Income Tax Expense (Benefit), Effective Income Tax Rate Reconciliation, Amount [Abstract]
Change in valuation allowances	$ 8,700
Effective Income Tax Rate Reconciliation, Percent [Abstract]
Change in valuation allowance, foreign	(13.00%)

Goodwill and Other Intangible Assets - Summary of Amortization Expense (Detail) - USD ($) $ in Thousands	Dec. 31, 2025	Dec. 31, 2024
Goodwill and Intangible Assets Disclosure [Abstract]
2026	$ 336
2027	190
2028	190
2029	190
2030	190
Beyond	950
Net	$ 2,046	$ 435

Stockholders' Equity - Weighted-Average Assumptions for Fair Value Measurement (Detail)

12 Months Ended

Dec. 31, 2025

Dec. 31, 2024

Dec. 31, 2023

Share-Based Payment Arrangement [Abstract]

Risk-free interest rate

^[1]

4.04%

4.14%

4.23%

Expected dividend yield

0.00%

Expected stock price volatility

^[2]

53.00%

51.00%

Expected life of stock options (in years)

^[2]

6 years

5 years

[1]	Based on the constant maturity interest rate of U.S. Treasury securities whose term is consistent with the expected life of the Company's stock options.
[2]	Based upon historical experience.

Government Capital Contracts

12 Months Ended

Dec. 31, 2025

Organization, Consolidation and Presentation of Financial Statements [Abstract]

Government Capital Contracts

GOVERNMENT CAPITAL CONTRACTS:

In September 2021, the Company entered into an agreement for $109.0 million in funding from the U.S. Department of Defense (the "DOD"), in coordination with the Department of Health and Human Services, to build additional manufacturing capacity in the United States for its InteliSwab® COVID-19 Rapid Tests as part of the nation’s pandemic preparedness plan. In accordance with the milestone payment schedule, 15% of the total was not billed and funded until the completion of the final validation testing, which occurred in October 2023. The Company began receiving funds from the DOD in January 2022 and received $109.0 million as of December 31, 2023. In connection with the completion of the contract in the fourth quarter of 2023, all funds were received.

Activity for these capital contracts is accounted for pursuant to International Accounting Standards ("IAS") 20, Accounting for Government Grants and Disclosure of Government Assistance. Funding received in relation to capital-related costs incurred for government contracts is recorded as a reduction to the cost of property, plant and equipment and reflected within investing activities in the consolidated statements of cash flows and associated unpaid liabilities and government proceeds receivable are considered non-cash changes in such balances within the operating section of the consolidated statements of cash flows.

Amounts earned for the Company's guaranteed profit which covered project management costs were recognized straight-line in other income over the term of the government contract. The Company recognized no such income during the years ended December 31, 2025 and 2024. The Company recognized $2.8 million of such income during the year ended December 31, 2023. Additionally, in connection with the completion of the contract, the Company recognized $12.8 million in excess of the guaranteed profit in other income in the Company's consolidated statement of operations during the year ended December 31, 2023, which reflects the difference in overall spend compared to the firm fixed price contract amount of $109.0 million.

The DOD also reimbursed the Company for certain engineering consulting costs. These expenses are reflected in research and development expenses as incurred with the corresponding amount presented in other income. The Company recognized no such costs during the years ended December 31, 2025 and 2024. The Company recognized $2.0 million of such costs during the year ended December 31, 2023.

The activity corresponding to the government contracts included in the Company's consolidated statements of cash flows is as follows:


	December 31,
	2023
Cost of assets, cumulative	$	86,993
Reduction for funding earned to date, not yet received	—
Reduction for funding received to date	(86,993)
Total property, plant and equipment, net	$	—

Consolidated Statements of Stockholders' Equity - USD ($) shares in Thousands, $ in Thousands	Total	Common Stock	Additional Paid-in Capital	Accumulated Other Comprehensive Loss	Accumulated Deficit
Beginning balance (in shares) at Dec. 31, 2022		72,734
Beginning balance at Dec. 31, 2022	$ 364,425	$ 0	$ 520,446	$ (18,435)	$ (137,586)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Common stock issued upon exercise of options (in shares)		44
Common stock issued upon exercise of options	269		269
Vesting of restricted stock and performance stock units (in shares)		1,098
Purchase and retirement of common shares (in shares)		(348)
Purchase and retirement of common shares	(1,901)		(1,901)
Stock-based compensation	10,729		10,729
Net (loss) income	53,655				53,655
Currency translation adjustments	3,274			3,274
Unrealized gain on marketable securities	220			220
Ending balance (in shares) at Dec. 31, 2023		73,528
Ending balance at Dec. 31, 2023	430,671	$ 0	529,543	(14,941)	(83,931)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Common stock issued upon exercise of options (in shares)		32
Common stock issued upon exercise of options	214		214
Vesting of restricted stock and performance stock units (in shares)		1,678
Purchase and retirement of common shares (in shares)		(640)
Purchase and retirement of common shares	(3,548)		(3,548)
Stock-based compensation	11,920		11,920
Net (loss) income	(19,500)				(19,500)
Currency translation adjustments	(9,419)			(9,419)
Unrealized gain on marketable securities	0
Ending balance (in shares) at Dec. 31, 2024		74,598
Ending balance at Dec. 31, 2024	$ 410,338	$ 0	538,129	(24,360)	(103,431)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Common stock issued upon exercise of options (in shares)	0
Shares repurchased and retired in satisfaction of minimum tax withholding for vested restricted stock and performance stock units (in shares)		1,640
Purchase and retirement of common shares (in shares)		(564)
Purchase and retirement of common shares	$ (1,843)		(1,843)
Stock-based compensation	10,147		10,147
Shares repurchased and retired in connection with share repurchase program (in shares)		(5,283)
Shares repurchased and retired in connection with share repurchase program	(15,040)		(15,040)
Net (loss) income	(68,731)				(68,731)
Currency translation adjustments	5,956			5,956
Unrealized gain on marketable securities	0
Ending balance (in shares) at Dec. 31, 2025		70,391
Ending balance at Dec. 31, 2025	$ 340,827	$ 0	$ 531,393	$ (18,404)	$ (172,162)

Business Combinations - Summary of Preliminary Estimated Fair Values of Assets Acquired and Liabilities Assumed (Detail) - USD ($) $ in Thousands	Dec. 31, 2025	Nov. 12, 2025	Dec. 31, 2024	Dec. 19, 2024	Dec. 31, 2023
Assets Acquired
Goodwill	$ 43,363		$ 40,330		$ 35,696
BioMedomics, Inc
Assets Acquired
Other current and non current assets		$ 10
Inventory		284
Operating right-of-use assets		120
In-process research and development technology intangible asset		1,900
Goodwill		1,775
Total assets acquired		4,089
Liabilities Assumed
Accounts payable		34
Current liabilities		17
Deferred revenue		72
Operating lease liability		120
Total liabilities assumed		243
Net Assets Acquired		3,846
Estimated fair value of contingent consideration		(233)
Net Cash Paid		3,613
Cash acquired in excess of payments to acquire business		$ 25
Sherlock Biosciences
Assets Acquired
Other current assets				$ 2,570
Property, plant, and equipment, net				9,244
Other noncurrent assets				462
Operating right-of-use assets				4,080
In-process research and development technology intangible asset				17,000
Goodwill				6,382
Total assets acquired				39,738
Liabilities Assumed
Accounts payable				2,449
Current liabilities				3,621
Deferred revenue				1,641
Operating lease liability				4,080
Total liabilities assumed				11,791
Net Assets Acquired				27,947
Estimated fair value of contingent consideration				(22,910)
Net Cash Paid				5,037
Cash acquired in excess of payments to acquire business				$ 402

Consolidated Statements of Comprehensive (Loss) Income - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2025	Dec. 31, 2024	Dec. 31, 2023
Statement of Comprehensive Income [Abstract]
Net (loss) income	$ (68,731)	$ (19,500)	$ 53,655
OTHER COMPREHENSIVE LOSS
Currency translation adjustments	5,956	(9,419)	3,274
Unrealized gain on marketable securities	0	0	220
COMPREHENSIVE (LOSS) INCOME	$ (62,775)	$ (28,919)	$ 57,149

- Definition

Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.

+ References + Details

- Definition

The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.

+ References

+ Details

Income Taxes - Additional Information (Detail) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2025	Dec. 31, 2024	Dec. 31, 2023	Dec. 31, 2022
Income Tax Contingency [Line Items]
Foreign income tax expense (benefit)	$ (300)	$ 1,400	$ 700
Federal income tax expense	200	200	0
State income tax expense (benefit)	1,900	100	1,900
Operating loss carryforwards	64,792
Gross unrecognized tax benefits	2,062	333	$ 304	$ 373
Unrecognized tax benefits that would impact effective tax rate	1,700
Income tax penalties and interest expense	200
Domestic Tax Jurisdiction
Income Tax Contingency [Line Items]
Operating loss carryforwards	232,900
Operating loss carryforwards, acquired	12,900
Foreign Tax Jurisdiction
Income Tax Contingency [Line Items]
Operating loss carryforwards		63,000
State and Local Jurisdiction
Income Tax Contingency [Line Items]
Operating loss carryforwards		$ 57,600
Operating loss carryforwards, acquired	$ 7,200

Consolidated Balance Sheets - USD ($)	Dec. 31, 2025	Dec. 31, 2024
Current Assets:
Cash and cash equivalents	$ 199,278,000	$ 267,763,000
Accounts receivable, net of allowance for doubtful accounts of $188 and $774	22,203,000	23,816,000
Inventories	31,060,000	34,197,000
Prepaid expenses	5,221,000	3,956,000
Other current assets	4,146,000	3,488,000
Total current assets	261,908,000	333,220,000
Noncurrent Assets:
Property, plant and equipment, net of accumulated depreciation	39,179,000	45,105,000
Operating right-of-use assets, net	11,996,000	13,442,000
Finance right-of-use assets, net	146,000	145,000
Net	19,046,000	17,435,000
Goodwill	43,363,000	40,330,000
Investment in equity method investee	25,956,000	28,300,000
Deferred tax asset	271,000	156,000
Other noncurrent assets	1,303,000	1,526,000
Total noncurrent assets	141,260,000	146,439,000
TOTAL ASSETS	403,168,000	479,659,000
Current Liabilities:
Accounts payable	6,521,000	8,173,000
Deferred revenue	1,518,000	2,961,000
Accrued expenses and other current liabilities	11,149,000	20,179,000
Finance lease liability	63,000	41,000
Operating lease liability	2,164,000	2,129,000
Current portion	18,380,000	0
Total current liabilities	39,795,000	33,483,000
Noncurrent Liabilities:
Finance lease liability	100,000	113,000
Operating lease liability	10,870,000	12,321,000
Long-term portion	9,333,000	22,910,000
Other noncurrent liabilities	2,243,000	494,000
Total noncurrent liabilities	22,546,000	35,838,000
TOTAL LIABILITIES	62,341,000	69,321,000
Commitments and Contingencies
STOCKHOLDERS' EQUITY
Preferred stock, par value $0.000001, 25,000 shares authorized, none issued	0	0
Common stock, par value $0.000001, 120,000 shares authorized, 70,391 and 74,598 shares issued and outstanding	0	0
Additional paid-in capital	531,393,000	538,129,000
Accumulated other comprehensive loss	(18,404,000)	(24,360,000)
Accumulated deficit	(172,162,000)	(103,431,000)
Total stockholders' equity	340,827,000	410,338,000
TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY	$ 403,168,000	$ 479,659,000

Summary of Significant Accounting Policies (Policies)

12 Months Ended

Dec. 31, 2025

Accounting Policies [Abstract]

Principles of Consolidation and Basis of Presentation

Inventories

Change in Accounting Principle

Inventories

Use of Estimates

Supplemental Cash Flow Information

The Company paid income taxes of $1.8 million and $1.8 million in 2025 and 2024, respectively, and received income tax refunds of $4.9 million in 2023.

The Company had account receivable write-offs of $0.5 million, $0.5 million, and $0.7 million in 2025, 2024, and 2023, respectively.

As of December 31, 2025, 2024 and 2023, the Company had accruals for purchases of property and equipment of $0.5 million, $0.5 million and $0.2 million, respectively.

The Company acquired BioMedomics which included contingent consideration of $0.3 million for the year ended December 31, 2025.

The Company acquired Sherlock which included contingent consideration of $22.9 million for the year ended December 31, 2024.

Cash Equivalents & Short-Term Investments

Fair Value of Financial Instruments

Level 1: Unadjusted quoted prices in active markets that are accessible at the measurement date for identical, unrestricted assets or liabilities;

Level 2: Quoted prices in markets that are not active, or inputs which are observable, either directly or indirectly, for substantially the full term of the asset or liability; and

Level 3: Prices or valuation techniques that require inputs that are both significant to the fair value measurement and unobservable (i.e., supported by little or no market activity).


		December 31,		December 31,
	Level	2025		2024
Guaranteed investment certificates	1	$	13,114	$	66,584
Trading securities	1	543		724
Contingent consideration:	3
Current portion		$	18,380	$	—
Long-term portion		9,333		22,910
		$	27,713	$	22,910

Included in cash and cash equivalents at December 31, 2025 and 2024 was $13.1 million and $66.6 million, respectively, invested in guaranteed investment certificates.

Contingent Consideration

The fair value methodology for earnout payments is based on a Monte Carlo model. Significant quantitative unobservable inputs are future expected cash flows, discount rate and volatility rate.

There was an increase of $4.6 million in the fair value of the Company's contingent consideration from date of acquisition to December 31, 2025 for the milestone and royalty payments.


	Fair Value
Balance at December 31, 2024	$	22,910
Additions	233
Change in fair value	4,570
Balance at December 31, 2025	$	27,713

Equity Method Investee

Accounts Receivable

Property, Plant and Equipment

•buildings twenty years;

•leasehold improvements, the lesser of the useful life of the improvement or the remaining life of the building or lease;

•computer equipment and software three years;

•machinery and equipment five years; and

•furniture and fixtures seven years

When assets are sold, retired, or discarded, the related property amounts are relieved from the accounts, and any gain or loss is recorded in the consolidated statements of operations.

Intangible Assets

Impairment of Long-Lived Assets

Goodwill



	Exit Multiple
Discount Rate	0.80		0.90		1.00		1.10		1.20
13%	$	208,132	$	217,464	$	226,796	$	236,128	$	245,460
14%	205,252		214,254		223,256		232,258		241,259
15%	202,501		211,188		219,875		228,562		237,249
16%	199,868		208,254		216,640		225,025		233,411
17%	197,339		205,436		213,533		221,630		229,726

Revenues

Revenue

Historically, returns arising from warranty issues have been infrequent and immaterial. Accordingly, the Company expenses warranty returns as incurred.

The Company records shipping and handling charges billed to the Company's customers as product revenue and the related expense as cost of products sold.

For certain products or services and customer types, the Company may require payment before the products are delivered or services are rendered to the customer.

Practical expedients and exemptions. Taxes assessed by governmental authorities, such as sales or value-added taxes, are excluded from product revenues.


	December 31,
	2025		2024		2023
Deferred Revenue	$	1,518	$	2,961	$	1,559

Vendor Concentrations

Research and Development

Advertising Expenses

Advertising costs are charged to expense as incurred.

Stock-Based Compensation

Income Taxes

Uncertain Tax Positions

Foreign Currency Translation

Earnings (Loss) Per Share

Accumulated Other Comprehensive Loss

Recent Accounting Pronouncements

Insider Trading Policies and Procedures	12 Months Ended
Insider Trading Policies and Procedures	Dec. 31, 2025
Insider Trading Policies and Procedures [Line Items]
Insider Trading Policies and Procedures Adopted	true

Income Taxes

12 Months Ended

Dec. 31, 2025

Income Tax Disclosure [Abstract]

Income Taxes

INCOME TAXES:

Income (loss) before income tax expense consists of the following:


	For the Years Ended December 31,
	2025		2024		2023
United States	$	(62,742)	$	(21,523)	$	61,671
Foreign	(1,844)		5,522		(5,413)
	$	(64,586)	$	(16,001)	$	56,258

In July of 2025, the One Big Beautiful Bill Act of 2025 (the “OBBBA”) was enacted in the U.S. The OBBBA includes several significant tax provisions, including the reinstatement of full expensing of domestic research and development costs among other domestic and international changes. The OBBBA is not expected to have a significant impact on the Company’s tax expense or cash paid for taxes. Our results for the year ended December 31, 2025 include the impact of the OBBBA on our consolidated financial statements.

The components of income tax expense (benefit) are as follows:


	For the Years Ended December 31,
	2025		2024		2023
Current
Federal	$	—	$	229	$	—
State	124		111		1,896
Foreign	(176)		2,116		605
	(52)		2,456		2,501
Deferred
Federal	(11,186)		(2,962)		13,570
State	870		1,368		(382)
Foreign	10,355		4,365		(1,867)
	39		2,771		11,321
Increase (decrease) in valuation allowance	1,814		(3,428)		(11,219)
	1,853		(657)		102
Total income tax expense	$	1,801	$	1,799	$	2,603

For the year ended December 31, 2025, the Company recorded net foreign tax benefit of $0.3 million. For the years ended December 31, 2024, and 2023 the Company recorded net foreign income tax expense of $1.4 million, and $0.7 million, respectively. For the years ended December 31, 2025, 2024, and 2023 the Company recorded U.S. federal tax expense of

$0.2 million, $0.2 million, and $0.0 million, respectively and state tax expense of $1.9 million, $0.1 million, and $1.9 million respectively.

Total cash paid for income taxes was as follows:


	For the Year Ended December 31, 2025
Federal	$	—
State:
Utah	(100)
Other	74
	(26)
Foreign:
Canada	2,539
United Kingdom	(672)
	1,867

Total cash paid for income taxes (net of refunds) (1)	$	1,841

(1) Total cash paid for income taxes during the year ended December 31, 2024 was $1.8 million. The Company received income tax refunds of $4.9 million for year ended December 31, 2023 (prior to adoption of ASU 2023-09).

The reconciliation of the statutory United States federal income tax rate to the Company's effective tax rate is as follows:


	For the Years Ended December 31,
	2025		2024		2023
Statutory U.S. federal income tax rate	21.0	%	21.0	%	21.0	%
Nondeductible executive compensation	(1.1)		(8.5)		0.5
Impact of stock-based payment awards	(1.8)		(2.3)		(0.3)
Tax effect of foreign items	(0.6)		(1.9)		(0.4)
State income taxes, net of federal benefit	1.3		(9.1)		2.0
U.S. and foreign tax credits	1.3		1.2		1.3
Uncertain tax positions	(2.9)		—		—
Nondeductible expenses and other	1.2		(2.4)		0.9
Nondeductible transaction costs	(0.2)		(2.1)		—
NOL adjustment, domestic	(2.2)		—		—
NOL adjustment, foreign	25.5		(31.4)		—
Change in the estimated fair value of acquisition-related contingent consideration	(1.4)		—		—
Acquisition adjustments	(8.7)		—		—
Non-controlling interests	(0.7)		2.2		—
Change in valuation allowance, federal and state	(14.4)		(10.0)		—
Change in valuation allowance, foreign	(19.0)		32.1		(20.4)
Effective tax rate	(2.7)	%	(11.2)	%	4.6	%

The reconciliation of the statutory United States federal income tax rate to the Company's effective tax rate is as follows:


	For the Year Ended December 31, 2025
	Dollars		Percentage
Statutory U.S. federal income tax rate	$	(14,055)	21.0	%
State and local income taxes, net of federal income tax effect (1)	325		(0.5)	%
Foreign tax effects
United Kingdom
Change in NOL limitation	(17,062)		25.5	%
Intangible acquisition adjustment	4,524		(6.7)	%
Change in valuation allowances	12,728		(19.0)	%
Other	(195)		0.3	%
Other foreign jurisdictions	114		(0.2)	%
Effect of changes in tax laws/rates enacted in the current period	—		—	%
Effect of cross-border tax laws
Global intangible low-taxed income	523		(0.8)	%
Tax credits
Research and development tax credits	(536)		0.8	%
Changes in valuation allowances	8,700		(13.0)	%
Nontaxable or nondeductible items
Share based payment awards	773		(1.1)	%
Nondeductible officer's compensation	714		(1.1)	%
Change in the estimated fair value of acquisition-related contingent consideration	960		(1.4)	%
Other	192		(0.3)	%
Changes in unrecognized tax benefits	1,728		(2.6)	%
Acquisition adjustments	1,285		(1.9)	%
NOL adjustment	1,441		(2.2)	%
Other adjustments	(358)		0.5	%
Effective tax rate	$	1,801	(2.7)	%

(1) The tax effect in this category was primarily driven by state taxes in Pennsylvania (greater than 50%).

Deferred income taxes reflect the tax effects of temporary differences between the basis of assets and liabilities recognized for financial reporting purposes and tax purposes, and net operating loss and tax credit carryforwards. Significant components of the Company's deferred tax assets (liabilities) are as follows:


	December 31,
	2025		2024
Deferred tax assets:
Net operating loss carryforwards	$	54,859	$	55,583
Inventories	2,108		2,344
Capitalized research and development costs	10,889		12,946
Accruals and reserves currently not deductible	1,805		2,754
Depreciation and amortization	114		—
Lease liabilities	2,254		2,497
Stock-based compensation	3,244		3,303
Tax credit carryforwards	6,628		4,184
Net deferred tax asset	81,901		83,611
Valuation allowance	(77,006)		(75,191)
Total deferred tax assets	$	4,895	$	8,420

Deferred tax liabilities:
Depreciation and amortization	—		(2,017)
Acquired intangible assets	(2,220)		(3,981)
Right-of-use assets	(2,073)		(2,266)
Deferred compensation	(331)		—
Total deferred tax liabilities	$	(4,624)	$	(8,264)
Net deferred tax asset	$	271	$	156

In assessing the realizability of the Company's deferred tax asset, the Company considers all relevant positive and negative evidence in determining whether it is more likely than not that some portion or all of the deferred income tax assets will not be realized. The realization of the gross deferred tax assets is dependent upon several factors, including the generation of sufficient taxable income, to realize the NOL carryforwards. In 2008, the Company established a full valuation allowance against the Company's U.S. deferred tax asset. The Company has not achieved a level of sustained profitability that would, in the Company's judgment, support the release of the valuation allowance. Management believes the full valuation allowance is still appropriate as of December 31, 2025 and 2024. As a result, no U.S. federal income tax benefit was recorded for the years ended December 31, 2025, 2024, and 2023.

The Company's federal NOL carryforwards consist of $232.9 million from existing business along with $12.9 million of acquired NOL carryforwards. None of these NOL carryforwards have an expiration date. The Company does not have any foreign NOL carryforwards as of December 31, 2025. As of December 31, 2024, the Company's foreign NOL carryforwards consisted of $63.0 million of acquired NOL carryforwards. The foreign NOLs were reduced to zero due to loss limitation rules. The Company's state NOL carryforwards consist of $57.6 million from existing business along with $7.2 million of acquired NOL carryforwards. The state NOL carryforwards have expirations as follows:


Year of Expiration	NOLs
2026 - 2041	$	30,419
2042 - 2055	20,023
Non-Expiring	14,350
	$	64,792

The Tax Reform Act of 1986 contains provisions under Internal Revenue Code (“IRC”) Section 382 and Section 383 that limit the annual amount of federal and state NOL carryforwards and tax credits that can be used in any given year in the

event a significant change in ownership. The Company does not believe that there is a Section 382 limitation that will impair the Company's future ability to utilize NOLs to offset the Company's future taxable income. The Company continues to review ownership changes on an annual basis and the Company does not believe it has had a subsequent ownership change that would impact the NOLs. The Company acquired 382 limited NOL carryforwards as part of its acquisition of BioMedomics. These NOL carryforwards have no expiration date. The Company has not undertaken any formal 382 or 383 studies that would indicate any limitations to its NOL or credit carryforwards. However, any such study could potentially limit the NOL and credit carryforwards of the Company.

It is still the Company's intention to continue to permanently reinvest the historical undistributed earnings of the Company's foreign subsidiary to the extent that the Company will not incur any additional tax expense associated with foreign withholding or other local tax expense on the future cash transfers. As such, deferred taxes have not been recorded on the unremitted earnings of the foreign subsidiary as of December 31, 2025.

As of December 31, 2025, the Company's gross unrecognized tax benefits totaled $2.1 million, and based upon the valuation allowance for the Company's U.S. operations, the recognition of any tax benefit would not impact the Company's effective tax rate. The 2025 addition of $1.7 million is not offset by the valuation allowance and its reversal would impact the Company’s effective tax rate. The Company records interest and penalties related to unrecognized tax benefits as a component of income tax expense. Interest and penalties were $0.2 million in 2025, and immaterial in 2024 and 2023. As a result of the Company's NOL carryforward position, the Company has been subject to audit by the Internal Revenue Service since the Company's inception, as well as by several jurisdictions for the years ended September 30, 1998 through December 31, 2025.

The reconciliation of the Company's unrecognized tax benefits is as follows:


	2025		2024		2023
Balance at January 1	$	333	$	304	$	373
Additions for tax positions of prior periods	1,729		29		—
Reductions for tax positions of prior periods	—		—		(69)
Balance at December 31	$	2,062	$	333	$	304

- Definition

The entire disclosure for income tax.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 942
-SubTopic 740
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147477617/942-740-50-1

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Topic 235
-SubTopic 10
-Name Accounting Standards Codification
-Section S50
-Paragraph 1
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Topic 944
-SubTopic 740
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147478822/944-740-50-1

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Topic 740
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 12
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482685/740-10-50-12

Reference 5: http://www.xbrl.org/2003/role/exampleRef
-Topic 740
-SubTopic 10
-Name Accounting Standards Codification
-Section 55
-Paragraph 231
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482663/740-10-55-231

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Topic 740
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 12C
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482685/740-10-50-12C

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Topic 740
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 12B
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482685/740-10-50-12B

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Topic 740
-SubTopic 270
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147477891/740-270-50-1

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Topic 740
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SAB Topic 6.I.5.Q1)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479360/740-10-S99-1

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 13
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480990/946-20-50-13

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Topic 235
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(h)(2))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Topic 740
-Name Accounting Standards Codification
-Publisher FASB
-URI https://asc.fasb.org/740/tableOfContent

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Topic 740
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 14
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482685/740-10-50-14

Reference 14: http://www.xbrl.org/2003/role/disclosureRef
-Topic 740
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 21
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482685/740-10-50-21

Reference 15: http://www.xbrl.org/2003/role/disclosureRef
-Topic 740
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 17
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482685/740-10-50-17

Reference 16: http://www.xbrl.org/2003/role/disclosureRef
-Topic 740
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 2
-Subparagraph (SAB Topic 11.C)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479360/740-10-S99-2

Reference 17: http://www.xbrl.org/2003/role/disclosureRef
-Topic 740
-SubTopic 30
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482603/740-30-50-2

+ Details

Cybersecurity Risk Management and Strategy Disclosure	12 Months Ended
Cybersecurity Risk Management and Strategy Disclosure	Dec. 31, 2025
Cybersecurity Risk Management, Strategy, and Governance [Line Items]
Cybersecurity Risk Management Processes for Assessing, Identifying, and Managing Threats [Text Block]	Our management recognizes the impact that cybersecurity threats could have on our business operations, our compliance with regulations, and our reputation. We have identified cybersecurity as a critical business risk as part of our overall risk management strategy, which our board of directors oversees. We have implemented an information security management system in accordance with our risk profile and business that is designed to protect the Company, our employees, and our customers from cybersecurity threats. This system, which is informed by the National Institute of Standards and Technology (NIST) Cybersecurity Framework, includes, among other things, written policies, technical controls, and employee training. We have also developed an incident response policy and procedure designed to facilitate the handling of cybersecurity incidents. Our cybersecurity risk management program, which is part of our enterprise risk management program, aims to identify risks from cybersecurity threats. Our cybersecurity risk management program includes a number of components, including informal self-assessments, penetration testing, and vulnerability assessments. Our managed security services provider helps us implement additional security controls, including malware protection and network security tools. We take a risk-based approach to the evaluation of third-party vendors, and apply mitigations and processes based on our evaluation of the sensitivity of the data accessed by the vendor and the maturity of the vendor’s programs. Where our risk-based evaluation indicates the need, we use a third-party tool to assess the degree of risk posed by the vendor and use a vendor security questionnaire as part of our assessment of third-parties. We have been subject to cybersecurity incidents in the past, including the publicly disclosed April 2024 security incident. We do not believe that risks from cybersecurity threats, including as a result of any previous cybersecurity incidents have materially affected our operations, financial systems, or financial condition. However, there is no guarantee that past security incidents and any future incidents will not have a material impact on our operations, financial systems, or financial condition in the future. For more information, see Item 1A. Risk Factors.
Cybersecurity Risk Management Processes Integrated [Flag]	true
Cybersecurity Risk Management Processes Integrated [Text Block]	We have implemented an information security management system in accordance with our risk profile and business that is designed to protect the Company, our employees, and our customers from cybersecurity threats. This system, which is informed by the National Institute of Standards and Technology (NIST) Cybersecurity Framework, includes, among other things, written policies, technical controls, and employee training. We have also developed an incident response policy and procedure designed to facilitate the handling of cybersecurity incidents. Our cybersecurity risk management program, which is part of our enterprise risk management program, aims to identify risks from cybersecurity threats. Our cybersecurity risk management program includes a number of components, including informal self-assessments, penetration testing, and vulnerability assessments. Our managed security services provider helps us implement additional security controls, including malware protection and network security tools.
Cybersecurity Risk Management Third Party Engaged [Flag]	true
Cybersecurity Risk Third Party Oversight and Identification Processes [Flag]	true
Cybersecurity Risk Materially Affected or Reasonably Likely to Materially Affect Registrant [Flag]	false
Cybersecurity Risk Board of Directors Oversight [Text Block]	Our management recognizes the impact that cybersecurity threats could have on our business operations, our compliance with regulations, and our reputation. We have identified cybersecurity as a critical business risk as part of our overall risk management strategy, which our board of directors oversees.
Cybersecurity Risk Board Committee or Subcommittee Responsible for Oversight [Text Block]	The board and Audit Committee oversee the management of risks by the Company’s executives.
Cybersecurity Risk Process for Informing Board Committee or Subcommittee Responsible for Oversight [Text Block]	The Audit Committee, pursuant to its charter, is responsible for reviewing the Company’s cybersecurity program and risks, as identified by Company management, and the steps that Company management has taken to protect against threats to the Company’s assets including information systems and data security. The VP of IT provides updates to the Audit Committee approximately annually, which include, as appropriate, a description of risks from cybersecurity threats.
Cybersecurity Risk Role of Management [Text Block]	Our vice president of information technology (“VP of IT”) is responsible for the strategic leadership and direction of the Company’s information security management system. Our VP of IT has over 25 years experience managing IT teams, including 10 years managing IT security teams. Led by the VP of IT, along with our Director of IT Security, the IT leadership team reviews the Company’s cybersecurity objectives at least annually, and more frequently as needed, and takes steps to further the suitability and effectiveness of the Company’s information security program. The output from these reviews are reported periodically to senior management. We have also established a cybersecurity management committee comprised of IT, communications, finance, legal and product personnel.
Cybersecurity Risk Management Positions or Committees Responsible [Flag]	true
Cybersecurity Risk Management Positions or Committees Responsible [Text Block]	Our vice president of information technology (“VP of IT”) is responsible for the strategic leadership and direction of the Company’s information security management system.
Cybersecurity Risk Management Expertise of Management Responsible [Text Block]	Our VP of IT has over 25 years experience managing IT teams, including 10 years managing IT security teams.
Cybersecurity Risk Process for Informing Management or Committees Responsible [Text Block]	Led by the VP of IT, along with our Director of IT Security, the IT leadership team reviews the Company’s cybersecurity objectives at least annually, and more frequently as needed, and takes steps to further the suitability and effectiveness of the Company’s information security program.
Cybersecurity Risk Management Positions or Committees Responsible Report to Board [Flag]	true

Subsequent Events - Additional Information (Detail)	1 Months Ended
Subsequent Events - Additional Information (Detail)	Feb. 28, 2026
Subsequent Event
Subsequent Event [Line Items]
Percentage of terminated workforce (less than)	10.00%

Consolidated Statements of Operations - USD ($) shares in Thousands, $ in Thousands	12 Months Ended
	Dec. 31, 2025	Dec. 31, 2024	Dec. 31, 2023
NET REVENUES:
Total revenue	$ 115,021	$ 185,827	$ 405,472
COST OF PRODUCTS AND SERVICES SOLD	66,823	106,437	233,820
Gross profit	48,198	79,390	171,652
OPERATING EXPENSES:
Research and development	42,528	26,047	33,728
Sales and marketing	26,117	30,986	36,319
General and administrative	47,677	46,215	58,191
Loss on impairments	0	4,392	10,829
Change in the estimated fair value of acquisition-related contingent consideration	4,570	0	(99)
Gain on sale of assets	(725)	0	0
Total operating expenses	120,167	107,640	138,968
Operating (loss) income	(71,969)	(28,250)	32,684
OTHER INCOME	7,383	12,249	23,574
(Loss) income before income taxes and equity investment	(64,586)	(16,001)	56,258
INCOME TAX EXPENSE	1,801	1,799	2,603
(LOSS) INCOME BEFORE EQUITY INVESTMENT	(66,387)	(17,800)	53,655
LOSS ON EQUITY INVESTMENT	(2,344)	(1,700)	0
NET (LOSS) INCOME	$ (68,731)	$ (19,500)	$ 53,655
(LOSS) INCOME PER SHARE:
Basic earnings per share (in US dollars per share)	$ (0.94)	$ (0.26)	$ 0.73
Diluted earnings per share (in US dollars per share)	$ (0.94)	$ (0.26)	$ 0.72
SHARES USED IN COMPUTING (LOSS) INCOME PER SHARE:
Basic weighted average number of shares outstanding (in shares)	73,485	74,434	73,348
Diluted weighted average number of shares outstanding (in shares)	73,485	74,434	74,389
Products and services
NET REVENUES:
Total revenue	$ 109,055	$ 184,611	$ 402,222
Other
NET REVENUES:
Total revenue	$ 5,966	$ 1,216	$ 3,250

Income Taxes - Schedule of Operating Loss Carryforward (Details) $ in Thousands	Dec. 31, 2025 USD ($)
Operating Loss Carryforwards [Line Items]
Operating loss carryforwards	$ 64,792
2026 - 2041
Operating Loss Carryforwards [Line Items]
Operating loss carryforwards	30,419
2042 - 2055
Operating Loss Carryforwards [Line Items]
Operating loss carryforwards	20,023
Non Expiring
Operating Loss Carryforwards [Line Items]
Operating loss carryforwards	$ 14,350

Stockholders' Equity - Summary of Performance Based Restricted Stock Unit Award Activity Under Stock Plan (Detail) - Performance Based Restricted Stock Unit
shares in Thousands

12 Months Ended

Dec. 31, 2025

$ / shares

Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]

Beginning balance (in shares)

1,454

Granted (in shares)

1,009

^[1]

Performance adjustment (in shares)

^[2]

Vested (in shares)

(513)

Forfeited (in shares)

(181)

Ending balance (in shares)

1,781

Issued and expected to vest (in shares)

1,781

Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value

Beginning balance (in US dollars per share) | $ / shares

$ 7.19

Granted (in US dollars per share) | $ / shares

4.30

^[1]

Vested (in US dollars per share) | $ / shares

5.18

Forfeited (in US dollars per share) | $ / shares

5.93

Ending balance (in US dollars per share) | $ / shares

6.24

Issued and expected to vest (in US dollars per share) | $ / shares

$ 6.24

[1]	Grant activity for all PSUs disclosed at target.
[2]	Reflects the performance adjustment based on actual performance measured at the end of the performance period.

Goodwill and Other Intangible Assets (Tables)

12 Months Ended

Dec. 31, 2025

Goodwill and Intangible Assets Disclosure [Abstract]

Schedule of Goodwill

Changes in goodwill are as follows:


	Reporting Unit
	Diagnostics		Collection Devices		Total
Balance at January 1, 2024	$	—	$	35,696	$	35,696
Acquisition	6,388		—		6,388
Change related to foreign currency translation	—		(1,754)		(1,754)
Balance at December 31, 2024	6,388		33,942		40,330
Acquisition	1,775		—		1,775
Change related to foreign currency translation	—		1,258		1,258
Balance at December 31, 2025	$	8,163	$	35,200	$	43,363

Summary of Intangible Assets

Intangible assets consist of the following:


		December 31, 2025
	Amortization Period (Years)	Gross		Accumulated Amortization		Net
Definite Life Intangible Assets
Customer relationships	10	$	9,134	$	(9,134)	$	—
Patents and product rights	5	7,596		(7,596)		—
Developed technology	7-15	8,995		(7,095)		1,900
Trade names	5-15	3,501		(3,355)		146
		29,226		(27,180)		2,046
Indefinite Life Intangible Assets
IPR&D technology (Note 13)	N/A	17,000		—		17,000
		$	46,226	(27,180)		19,046


		December 31, 2024
	Amortization Period (Years)	Gross		Accumulated Amortization		Net
Definite Life Intangible Assets
Customer relationships	10	$	10,858	$	(10,858)	$	—
Patents and product rights	5	7,495		(7,399)		96
Developed technology	7-10	10,169		(10,169)		—
Trade names	5-15	4,327		(3,988)		339
		32,848		(32,413)		435
Indefinite Life Intangible Assets
IPR&D technology (Note 13)	N/A	17,000		—		17,000
		$	49,848	$	(32,413)	$	17,435

Summary of Amortization Expense

Amortization expense for each of the five succeeding fiscal years and beyond is estimated as follows:


2026	$	336
2027	190
2028	190
2029	190
2030	190
Beyond	950
	$	2,046

- Definition

Tabular disclosure of goodwill by reportable segment and in total which includes a rollforward schedule.

+ References

Reference 1: http://www.xbrl.org/2003/role/exampleRef
-Topic 350
-SubTopic 20
-Name Accounting Standards Codification
-Section 55
-Paragraph 24
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482548/350-20-55-24

Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 350
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482573/350-20-50-1

Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 350
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (h)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482573/350-20-50-1

Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 350
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482573/350-20-50-1

Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 350
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482573/350-20-50-1

Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 350
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (c)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482573/350-20-50-1

Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 350
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (d)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482573/350-20-50-1

Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 350
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (e)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482573/350-20-50-1

Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 350
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (f)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482573/350-20-50-1

Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 350
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (g)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482573/350-20-50-1

Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 350
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1A
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482573/350-20-50-1A

Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 350
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482573/350-20-50-2

+ Details

Income Taxes - Components of Income Tax Expense (Benefit) (Detail) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2025	Dec. 31, 2024	Dec. 31, 2023
Current
Federal	$ 0	$ 229	$ 0
State	124	111	1,896
Foreign	(176)	2,116	605
Total current income tax expense (benefit)	(52)	2,456	2,501
Deferred
Federal	(11,186)	(2,962)	13,570
State	870	1,368	(382)
Foreign	10,355	4,365	(1,867)
Total deferred income tax expense (benefit)	39	2,771	11,321
Increase (decrease) in valuation allowance	1,814	(3,428)	(11,219)
Deferred income taxes	1,853	(657)	102
Total income tax expense	$ 1,801	$ 1,799	$ 2,603

Property, Plant and Equipment - Additional Information (Detail) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2025	Dec. 31, 2024	Dec. 31, 2023
Property, Plant and Equipment [Line Items]
Loss on impairments	$ 0	$ 4,392	$ 10,829
Depreciation expense	$ 9,900	9,800	17,900
Property, Plant and Equipment
Property, Plant and Equipment [Line Items]
Loss on impairments		1,800
Machinery and equipment
Property, Plant and Equipment [Line Items]
Loss on impairments		$ 1,100
Cost, depreciation			6,900
Equipment and Leasehold Improvements
Property, Plant and Equipment [Line Items]
Loss on impairments			2,300
Leasehold Improvements
Property, Plant and Equipment [Line Items]
Cost, depreciation			$ 500

Leases - Summary of Lease Term and Discount Rate (Detail)	Dec. 31, 2025	Dec. 31, 2024
Weighted Average Remaining Lease Term
Weighted-average remaining lease term — operating leases	6 years 8 months 12 days	7 years 6 months 25 days
Weighted-average remaining lease term — finance leases	2 years 8 months 12 days	3 years 8 months 26 days
Weighted Average Discount Rate
Weighted-average discount rate — operating leases	4.48%	4.44%
Weighted-average discount rate — finance leases	5.10%	4.82%

Business Segment Information - Presentation of Total Long-Lived Assets by Geographic Area (Detail) - USD ($) $ in Thousands	Dec. 31, 2025	Dec. 31, 2024
Segment Reporting, Revenue Reconciling Item [Line Items]
Long-lived assets	$ 51,321	$ 58,692
United States
Segment Reporting, Revenue Reconciling Item [Line Items]
Long-lived assets	36,254	40,286
United Kingdom
Segment Reporting, Revenue Reconciling Item [Line Items]
Long-lived assets	10,061	12,849
Canada
Segment Reporting, Revenue Reconciling Item [Line Items]
Long-lived assets	4,642	5,468
Other regions
Segment Reporting, Revenue Reconciling Item [Line Items]
Long-lived assets	$ 364	$ 89

Business Combinations

12 Months Ended

Dec. 31, 2025

Business Combination [Abstract]

Business Combinations

BUSINESS COMBINATIONS:

BioMedomics

On November 12, 2025, the Company acquired all of the outstanding stock of BioMedomics, pursuant to the terms of an acquisition agreement (the "Acquisition Agreement"). The Company began operating this entity as of the November 12, 2025 closing date.

The primary reason for the acquisition of BioMedomics was to expand the Company's diagnostic portfolio by adding SickleSCAN®, a rapid, point-of-need test for sickle cell disease that is sold outside of the United States.

The initial aggregate purchase price of this transaction was funded with cash on hand as shown in the table below:


Cash paid to BioMedomics	$	2,865
Transaction expenses	403
Debt paid off	330
Earnout contingent consideration	325
Expense fund	40
Initial aggregate purchase price	$	3,963

Pursuant to the Acquisition Agreement, the Company agreed to pay up to $5.0 million of contingent consideration based on the achievement of sales thresholds before December 31, 2031 as defined in Acquisition Agreement. The acquisition-date fair value of the earnout contingent consideration was $0.3 million. The range of outcome for the earnout contingent consideration is zero to $5.0 million.

During the year ended December 31, 2025, the Company incurred a total of $0.5 million of acquisition related costs, including accounting, legal, and other professional fees, all of which were expensed and reported as a component of general and administrative expenses in the consolidated statement of operations for the year ended December 31, 2025.

The following table summarizes the estimated fair values of the assets acquired and liabilities assumed as of the acquisition date:


Assets Acquired


Other current and non current assets	$	10
Inventory	284
Operating right-of-use assets	120


Developed technology intangible asset	1,900
Goodwill	1,775
Total assets acquired	4,089
Liabilities Assumed
Accounts payable	34
Current liabilities	17
Deferred revenue	72
Operating lease liability	120
Total liabilities assumed	243
Net Assets Acquired	3,846
Estimated fair value of contingent consideration	(233)
Net Cash Paid (net of cash acquired of $25)	$	3,613

The purchase price was allocated to the tangible assets and identifiable intangible asset acquired and liabilities assumed based on their acquisition-date estimate fair values. The identifiable intangible asset was developed technology. The developed technology was all assigned a ten year useful life.

The Company, with the assistance of an independent valuation specialist, assessed the fair value of the intangible asset and contingent consideration of BioMedomics. The fair values recorded as of November 12, 2025 are based on significant inputs that are not observable in the market and thus represent a fair value measurement categorized within Level 3 of the fair value hierarchy.

The fair value of the acquired developed technology was determined using the multi-period excess earnings method, which required judgment in estimating appropriate cashflows, discount rate, survival factor, and remaining useful life.

The fair value of the earnout contingent consideration was determined using the Monte Carlo simulation model, which require judgment in estimating expected revenue, volatility, expected discount rate and risk-free interest rate.

Goodwill is calculated as the difference between the acquisition date fair value of the consideration transferred and the fair value of the net assets acquired, and represents the future economic benefits that we expect to achieve as a result of the acquisition. The Company believes the goodwill related to the acquisition was a result of BioMedomics providing a product that will enable the Company to leverage the products with existing and new customers. The goodwill is not deductible for income tax purposes.

The Company continues to evaluate the fair value of assets acquired and liabilities assumed. Additional information, which existed as of the acquisition date, but was at that time unknown to the Company, may become known during the remainder of the measurement period. Changes to amounts recorded as a result of the final determination may result in a corresponding adjustment to these assets and liabilities, including goodwill. The determination of the estimated fair values of all assets acquired is expected to be completed within one year from the date of acquisition.

Revenues from BioMedomics consist of sales from the SickleSCAN® test. Effective as of November 12, 2025, the financial results of BioMedomics are included in the consolidated financial results of the Company. BioMedomics contributed $0.1 million and $1.1 thousand of revenue and net income, respectively, to the consolidated statement of operations for the year ended December 31, 2025.

Unaudited Pro Forma Financial Information


	For the Years Ended December 31,
	2025		2024
Net revenues	$	115,797	$	187,041
Net loss	$	(68,964)	$	(20,889)

Sherlock Biosciences

On December 19, 2024, the Company acquired all of the outstanding stock of Sherlock, pursuant to the terms of a merger agreement (the "Merger Agreement"). The Company began operating this entity as of the December 19, 2024 closing date.

The primary reason for the acquisition was Sherlock's first test for Chlamydia Trachomatis (CT) and Neisseria Gonorrhoeae (NG), which is in clinical studies and was submitted to the FDA in late 2025. Subject to regulatory approvals, this test is expected to expand the Company's portfolio for rapid diagnostics for sexually transmitted infections.

The initial aggregate purchase price of this transaction was funded with cash on hand as shown in the table below:


Milestone contingent consideration	$	15,910
Royalty based contingent consideration	7,000
Cash paid to Sherlock	5,000
Legal expenses	389
Insurance policy expense	50
Initial aggregate purchase price	$	28,349

Pursuant to the Merger Agreement, the Company agreed to pay up to $20.0 million of contingent consideration based on the achievement of a regulatory milestone on or before December 31, 2026 as defined in the Merger Agreement. The acquisition-date fair value of the milestone contingent consideration was $15.9 million. The range of outcome for the milestone contingent consideration is zero to $20.0 million. There is also a mid-single digits quarterly royalty fee based on future sales until 2034 as defined in the Merger Agreement, the fair value of which was determined as part of the contingent consideration. The estimated acquisition-date fair value of the royalty fee acquisition-related contingent consideration was $7.0 million. The range of outcome for the royalty payment cannot be determined due to the fact it is based on future sales associated with the acquired in-process research and development technology through 2034 and thus does not have an upper limit.

During the year ended December 31, 2024, the Company incurred a total of $1.0 million of acquisition related costs, including accounting, legal, and other professional fees, all of which were expensed and reported as a component of general and administrative expenses in the consolidated statement of operations for the year ended December 31, 2024.

The following table summarizes the estimated fair values of the assets acquired and liabilities assumed as of the acquisition date:


Assets Acquired


Other current assets	$	2,570
Property, plant, and equipment, net	9,244
Other noncurrent assets	462
Operating right-of-use assets	4,080
In-process research and development technology intangible asset	17,000
Goodwill	6,382
Total assets acquired	39,738
Liabilities Assumed
Accounts payable	2,449
Current liabilities	3,621
Deferred revenue	1,641
Operating lease liability	4,080
Total liabilities assumed	11,791
Net Assets Acquired	27,947
Estimated fair value of contingent consideration	(22,910)
Net Cash Paid (net of cash acquired of $402)	$	5,037

The purchase price was allocated to the tangible assets and identifiable intangible assets acquired and liabilities assumed based on their acquisition-date estimate fair values. The identifiable intangible assets included in-process research and development technology ("IPR&D Technology"), which is an indefinite lived asset.

The Company, with the assistance of an independent valuation specialist, assessed the fair value of the assets and contingent consideration of Sherlock. The income approach was used to value the acquired intangibles, and the fair value measurements were primarily based on significant inputs that are not observable in the market and are considered Level 3 fair value measurements. The income approach estimates fair value for an asset based on the present value of cash flows projected to be generated by the asset. Projected cash flows are discounted at a required rate of return that reflects the relative risk of achieving the cash flows and the time value of money.

The regulatory milestone scenario based model was used to value the assumed milestone contingent consideration, and the fair value measurements were primarily based on significant unobservable inputs and are considered Level 3 fair value measurements. The regulatory milestone scenario based model estimates fair value for contingent consideration based on the probability of on the achievement of a certain milestone as defined under the agreements and the discount rate.

The income approach was used to value the royalty based contingent consideration, and the fair value measurements were primarily based on significant unobservable inputs and are considered Level 3 fair value measurements. The fair value of contingent payments approach was primarily based on projected cash flows, probability of on the achievement of a regulatory milestone as defined under the agreements, and discount rate.

Goodwill is calculated as the difference between the acquisition date fair value of the consideration transferred and the fair value of the net assets acquired, and represents the future economic benefits that we expect to achieve as a result of the acquisition. The Company believes the goodwill related to the acquisition was a result of Sherlock providing a product offering that will enable the Company to leverage those products with existing and new customers. The goodwill is not deductible for income tax purposes.

The Company has completed the fair value of the assets acquired and liabilities assumed.

Revenues from Sherlock primarily consist of grant revenues for research and development purposes. Effective as of December 19, 2024, the financial results of Sherlock are included in the consolidated financial results of the Company.

Unaudited Pro Forma Financial Information

The unaudited pro forma results presented below include the results of the Sherlock acquisition as if it had been consummated as of January 1, 2023. The unaudited pro forma results include depreciation of the acquired property plant and equipment and the estimated tax effect of adjustments to income before income taxes, but do not include changes in the fair value of the Company's contingent consideration obligations. Material nonrecurring charges, directly attributable to the transactions, including direct acquisition costs, are also excluded. In addition, the unaudited pro forma results do not include any expected benefits of the acquisitions. Accordingly, the unaudited pro forma results are not necessarily indicative of either future results of operations or results that might have been achieved had the acquisitions been consummated as of January 1, 2023.


	For the Years Ended December 31,
	2024		2023
Net revenues	$	188,126	$	406,381
Net income loss	$	(41,459)	$	7,992

- Definition

The entire disclosure for business combination.

+ References

Reference 1: http://www.xbrl.org/2003/role/exampleRef
-Topic 805
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 8
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479328/805-10-50-8

Reference 2: http://www.xbrl.org/2003/role/exampleRef
-Topic 805
-SubTopic 10
-Name Accounting Standards Codification
-Section 55
-Paragraph 38
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479303/805-10-55-38

Reference 3: http://www.xbrl.org/2003/role/exampleRef
-Topic 805
-SubTopic 10
-Name Accounting Standards Codification
-Section 55
-Paragraph 46
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479303/805-10-55-46

Reference 4: http://www.xbrl.org/2003/role/exampleRef
-Topic 805
-SubTopic 10
-Name Accounting Standards Codification
-Section 55
-Paragraph 43
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479303/805-10-55-43

Reference 5: http://www.xbrl.org/2003/role/exampleRef
-Topic 805
-SubTopic 10
-Name Accounting Standards Codification
-Section 55
-Paragraph 45
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479303/805-10-55-45

Reference 6: http://www.xbrl.org/2003/role/exampleRef
-Topic 805
-SubTopic 10
-Name Accounting Standards Codification
-Section 55
-Paragraph 29
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479303/805-10-55-29

Reference 7: http://www.xbrl.org/2003/role/exampleRef
-Topic 805
-SubTopic 10
-Name Accounting Standards Codification
-Section 55
-Paragraph 29
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479303/805-10-55-29

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Topic 805
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 5
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479907/805-20-50-5

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Topic 805
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (d)(1)(ii)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479907/805-20-50-1

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Topic 805
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 3
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479907/805-20-50-3

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Topic 805
-SubTopic 30
-Name Accounting Standards Codification
-Section 50
-Paragraph 3
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479581/805-30-50-3

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Topic 805
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479328/805-10-50-2

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Topic 805
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479907/805-20-50-2

Reference 14: http://www.xbrl.org/2003/role/disclosureRef
-Topic 805
-SubTopic 30
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479581/805-30-50-2

Reference 15: http://www.xbrl.org/2003/role/disclosureRef
-Topic 805
-SubTopic 30
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479581/805-30-50-1

Reference 16: http://www.xbrl.org/2003/role/disclosureRef
-Topic 805
-SubTopic 30
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (f)(2)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479581/805-30-50-1

Reference 17: http://www.xbrl.org/2003/role/disclosureRef
-Topic 805
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 3
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479328/805-10-50-3

Reference 18: http://www.xbrl.org/2003/role/disclosureRef
-Topic 805
-SubTopic 30
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (c)(3)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479581/805-30-50-1

Reference 19: http://www.xbrl.org/2003/role/disclosureRef
-Topic 805
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (h)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479328/805-10-50-2

Reference 20: http://www.xbrl.org/2003/role/disclosureRef
-Topic 805
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 4
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479328/805-10-50-4

Reference 21: http://www.xbrl.org/2003/role/disclosureRef
-Topic 805
-SubTopic 30
-Name Accounting Standards Codification
-Section 50
-Paragraph 4
-Subparagraph (a)(2)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479581/805-30-50-4

Reference 22: http://www.xbrl.org/2003/role/disclosureRef
-Topic 805
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (a)(3)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479907/805-20-50-1

Reference 23: http://www.xbrl.org/2003/role/disclosureRef
-Topic 805
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (a)(2)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479907/805-20-50-1

Reference 24: http://www.xbrl.org/2003/role/disclosureRef
-Topic 805
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (h)(4)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479328/805-10-50-2

Reference 25: http://www.xbrl.org/2003/role/disclosureRef
-Topic 805
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (e)(1)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479328/805-10-50-2

Reference 26: http://www.xbrl.org/2003/role/disclosureRef
-Topic 805
-SubTopic 40
-Name Accounting Standards Codification
-Section 45
-Paragraph 1
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479326/805-40-45-1

Reference 27: http://www.xbrl.org/2003/role/disclosureRef
-Topic 805
-SubTopic 30
-Name Accounting Standards Codification
-Publisher FASB
-URI https://asc.fasb.org/805-30/tableOfContent

Reference 28: http://www.xbrl.org/2003/role/disclosureRef
-Topic 805
-SubTopic 20
-Name Accounting Standards Codification
-Publisher FASB
-URI https://asc.fasb.org/805-20/tableOfContent

Reference 29: http://www.xbrl.org/2003/role/disclosureRef
-Topic 805
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 7
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479328/805-10-50-7

Reference 30: http://www.xbrl.org/2003/role/disclosureRef
-Topic 805
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 5
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479328/805-10-50-5

Reference 31: http://www.xbrl.org/2003/role/disclosureRef
-Topic 805
-SubTopic 10
-Name Accounting Standards Codification
-Publisher FASB
-URI https://asc.fasb.org/805-10/tableOfContent

+ Details